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Abstract 
The vaginal microbiota of healthy women consists of a wide variety of anaerobic and aerobic 
bacteria, dominated by the genus Lactobacillus. The activity of lactobacilli is essential to protect 
women from genital infections and to maintain the natural healthy balance of the vaginal 
ecosystem. This role is particularly important during pregnancy because vaginal infection is one of 
the most important mechanisms for preterm birth. The most common vaginal disorder is bacterial 
vaginosis (BV). BV is a polymicrobial disorder, characterized by a depletion of lactobacilli and an 
increase in the concentration of other bacteria, including Gardnerella vaginalis, anaerobic Gram-
negative rods, anaerobic Gram-positive cocci, Mycoplasma hominis, and Mobiluncus spp. An 
integrated molecular approach based on real-time PCR and PCR-DGGE was used to investigate the 
effects of two different therapeutic approaches on the vaginal microbiota composition. (i) The 
impact of a dietary supplementation with the probiotic VSL#3, a mixture of Lactobacillus, 
Bifidobacterium and Streptococcus strains, on the vaginal microbial ecology and immunological 
profiles of healthy women during late pregnancy was investigated. The intake was associated to a 
slight modulation of the vaginal microbiota and cytokine secretion, with potential implications in 
preventing preterm birth. (ii) The efficacy of different doses of the antibiotic rifaximin (100 mg/day 
for 5 days, 25 mg/day for 5 days, 100 mg/day for 2 days) on the vaginal microbiota of patients with 
BV enrolled in a multicentre, double-blind, randomised, placebo-controlled study was also 
evaluated. The molecular analyses demonstrated the ability of rifaximin 25 mg/day for 5 days to 
induce an increase of lactobacilli and a decrease of the BV-associated bacteria after antibiotic 
treatment, and a reduction of the complexity of the vaginal microbial communities. Thus, 
confirming clinical results, it represents the most effective treatment to be used in future pivotal 
studies for the treatment of BV. 
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1. The vaginal microbiota 
 
1.1 Overview 
The female genital tract is composed of a sequence of cavities. The external genital tract leads 
into the vagina that connects in succession to the endocervix, the uterus and then to the Fallopian 
tubes. This passageway allows for the migration of the mature fetus and menstrual flow to the 
exterior, and for the movement of spermatozoa to the interior. This exposure of the female genital 
tract to the external environment carries with it the risk of potential infections in this area. Among 
the defense mechanisms, one of the most important is the composition of the microbial 
communities that colonize the vagina (Witkin et al, 2007-a). The microbial inhabitants of the 
human vagina constitute a finely balanced ecosystem, with the vaginal environment controlling the 
colonizing bacteria and the microbiota in turn controlling the vaginal environment. This dynamic 
microbial community plays a key role in preventing colonization by undesirable organisms. 
Historically, studies of the components of the vaginal ecosystem relied first on microscopic 
evaluation and then on identification of specific bacteria by culture techniques (Larsen and Monif, 
2001). In 1892, Professor Albert Döderlein published a monograph, Das Scheidensekret (“vaginal 
secretions”), reporting the first descriptions and images of the vaginal bacillus, subsequently called 
the “Döderlein’s bacillus”. He divided the bacterial communities of pregnant women into normal 
(dominated by the vaginal bacillus) and abnormal (containing numerous other organisms), and 
recorded that, in the normal secretions, vaginal bacilli were able to promote conditions, including 
acidity, that could inhibit the growth of pathogens in vitro and in vivo (Döderlein, 1892). In 1928, 
Stanley Thomas renamed “Döderlein’s bacillus” as Lactobacillus acidophilus, and defined it as a 
characteristic group of related species, or a species that underwent a remarkable transformation 
(Thomas, 1928). Subsequent improvements in culture techniques and in biochemical 
characterization of microorganisms led to the conclusion that L. acidophilus was not a single 
organism but a heterogeneous group of lactobacilli with distinct characteristics (Hunter et al, 1959; 
Johnson et al, 1980; Rogosa and Sharpe, 1960). The use of quantitative culture, improved transport 
media, and anaerobic incubation greatly expanded the survey of vaginal microbes. Gram-positive 
rods, staphylococci and streptococci, and Gram-negative enteric organisms, as well as a variety of 
cultivable anaerobes, such as Prevotella spp., and Fusobacteria spp., could all be found in vaginal 
samples (Larsen and Monif, 2001). 
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Much of our knowledge about the composition of the vaginal microbial communities comes 
from qualitative and semi-quantitative descriptive studies using cultivation-dependent techniques 
(Chow and Bartlett, 1898; Johnson et al, 1985; Larsen and Monif, 2001; Marrazzo et al, 2002-b; 
Stahl and Hill, 2009). However, utilization of culture media for the comprehensive identification of 
bacterial ecosystem diversity is now recognized as being incomplete and fragmentary. In most 
instances, this is because readily cultivated populations represent a small fraction of the existing 
community (McCaig et al, 1999). In recent years, the development and introduction of cultivation-
independent molecular-based techniques have revolutionized bacterial detection and provided new 
information about the phylogenetic diversity of microorganisms composing the vaginal microflora. 
The microbiota of the vagina have been revealed as considerably more dynamic and complex, 
comprising previously undetected bacterial vaginal inhabitants (Fredricks et al, 2005; Verhelst et al, 
2004; Zhou et al, 2004). 
The vaginal ecosystem of healthy women typically shows a predominance of Lactobacillus 
species, but a diverse array of other bacteria and microorganisms, such as Staphylococcus, 
Ureaplasma, Corynebacterium, Streptococcus, Peptostreptococcus, Gardnerella, Bacteroides, 
Mycoplasma, Enterococcus, Escherichia, Veillonella, Bifidobacterium and Candida (Hyman et al, 
2005; Larsen and Monif, 2001; Marrazzo et al, 2002-b; Redondo-Lopez et al, 1990) can be present 
in much lower amounts. Lactobacilli are involved in promoting a healthy vaginal environment by 
preventing overgrowth of pathogenic and opportunistic organisms, and by producing lactic acid, 
hydrogen peroxide (H2O2), and bacteriocins (Aroutcheva et al, 2001-a; Hawes et al, 1996; 
Rönnqvist et al, 2006; Skarin and Syl, 1986). On the other hand, Lactobacillus-deficient conditions 
are associated with the development of numerous infectious conditions, such as bacterial vaginosis 
(BV), candidiasis (CA) and aerobic vaginitis (AV), and promote the transmission of sexually 
transmitted diseases, such as Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, HIV, and HPV 
which may lead to cervical cancer (Donders, 2007; Fredricks et al, 2005; Myer et al, 2005; Sobel, 
2002; Watts et al, 2005; Witkin et al, 2007-a). In 1921, Schröder was the first to classify the vaginal 
microflora into three “Lactobacillary grades” (Schröder, 1921). Lactobacillary grade I, 
corresponding to a “healthy” or “normal” microflora, had predominant lactobacillary morphotypes 
of variable size (Figure 1A). Lactobacillary grade III, or “abnormal” microflora, represented a 
condition wherein the lactobacillary morphotypes were completely replaced by other bacterial 
morphotypes (Figure 1D and 1E). Lactobacillary grade II, corresponding to an “intermediate” 
microflora, was characterized by the partial replacement of the lactobacilli by other bacteria (Figure 
1B and 1C). Afterwards, Donders refined grade II and subdivided this group into slightly disturbed, 
fairly normal (IIa) and moderately disturbed, rather abnormal (IIb) lactobacillary microflora 
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(Donders, 1999). In order to diagnose such abnormal lactobacillary grades, the use of the wet mount 
was preferred to the Gram stain due to its superior accuracy (Donders et al, 2000-b) and better 
correlation with vaginal lactate (Donders et al, 1998), accepted by most as the best functional test 
for lactobacillary defense function (Forney, 2004). 
 
 
Figure 1. “Lactobacillary grades”: (A) Lactobacillary grade I, normal vaginal microflora; (B) 
Lactobacillary grade IIa, lactobacilli prominent, but mixed with some other bacteria; (C) Lactobacillary 
grade IIb, lactobacilli still present, but more bacteria of other types present; (D) Lactobacillary grade III: 
coccoid aerobic vaginitis (AV) microflora; (E) Lactobacillary grade III, bacterial vaginosis (BV) microflora. 
(Donders, 2007). 
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1.2 Normal vaginal microbiota 
As previously stated, the dominant species in the vagina of healthy premenopausal women 
was initially identified as Lactobacillus acidophilus. This turned out to be an oversimplification, 
however. There are many different strains of lactobacilli present in the vagina, the most frequent 
being Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus iners and Lactobacillus jensenii, 
and there is a wide variation in species and relative numbers of species according to the population 
studied (Pavlova et al, 2002; Tärnberg et al, 2002). Using molecular-based techniques, we now 
know that the healthy vaginal microbiota does not contain high numbers of many different species 
of Lactobacillus. Rather, a single species among the most frequent, or a group of closely related 
species are dominant, whereas other species are rare, lower in titer, and tend to be novel phylotypes 
(Biagi et al, 2009; Burton and Reid, 2002; Shi et al, 2009; Song et al, 1999; Thies et al, 2007; 
Vásquez et al, 2002; Verhelst et al, 2004; Vitali et al, 2007; Wilks et al, 2004; Yamamoto et al, 
2009; Zhou et al, 2004; Zhou et al,2007). The rare coexistence of multiple species of lactobacilli in 
vaginal communities could be caused by competitive exclusion of one species by another, pre-
emptive colonization by a particular species or host factors that strongly influence which species are 
able to colonize the environment (Zhou et al, 2004). Despite there is a wide variation in species and 
relative numbers of species according to the population studied, the principle of numerical 
dominance persists and may be an important defense mechanism. 
Interestingly, apparently healthy vaginal ecosystems are maintained in a significant proportion 
(7–33%) of women in the absence of a Lactobacillus-dominant vaginal microbiota (Anukam et al, 
2006-b; Hyman et al, 2005; Verhelst et al, 2004; Zhou et al, 2004). Lactobacilli may be replaced by 
other lactic acid-producing bacteria, such as Atopobium vaginae, Megasphaera spp., and 
Leptotrichia spp. (Ravel et al, 2011; Rodriguez et al, 1999; Zhou et al, 2004 ; Zhou et al, 2007). 
Although the structure of the vaginal communities may differ between populations, health can be 
maintained provided that the function of the microbiota is conserved, that is the production of lactic 
acid and maintenance of a low pH environment that precludes the colonization and growth of 
pathogens and other undesirable microorganisms (Schwebke, 2001; Yamamoto et al, 2009; Zhou et 
al, 2004). Consequently, the absence of lactobacilli or the presence of certain organisms such as 
Gardnerella vaginalis, or species of Peptostreptococcus, Prevotella, Pseudomonas, and/or 
Streptococcus, does not always constitute an abnormal state (Hyman et al, 2005). 
Several bacterial populations recovered using molecular-based techniques are not readily 
cultivated and may have been overlooked in culture-dependent studies. L. iners does not grow on 
the selective media commonly used for the isolation of Lactobacillus spp., namely MRS and 
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Rogosa media (Falsen et al, 1999). Likewise, A. vaginae, Megasphaera spp. and Leptotrichia spp. 
are strict anaerobes, require specialized media and often grow slowly. The finding of these 
microorganisms as members of normal vaginal microflora illustrates how culture-independent 
techniques have revolutionized bacterial detection. Their application has clarified the identification 
of the most common Lactobacillus spp., demonstrated that lactobacilli are not always the dominant 
microbial species in apparently healthy women, and has identified previously undetected bacterial 
vaginal inhabitants (Fredricks et al, 2005; Verhelst et al, 2004; Zhou et al, 2004). Although 
cultivation-independent techniques may show greater diversity, they are limited by their tendency to 
sample only the most prevalent bacteria in a community, such that low-abundance or minority 
species are likely to be missed (Hillier, 2005). This being the case, despite their limitations, 
cultivation studies remain an important part of vaginal microbiology, and should be used in 
combination with cultivation-independent techniques (Donachie et al, 2007). 
The advent of next-generation ultra-high-throughput sequencing technologies has removed an 
important quantitative barrier in molecular analysis, by increasing the number of reads from a gene 
or genome by orders of magnitude in a single run (Schellenberg et al, 2009). The recent transition 
from low-throughput clone library sequencing studies to deep sequencing of PCR amplicons has led 
to a rapid accumulation of data regarding human associated microbial communities and has been 
crucial in furthering our understanding of the microbiota colonizing the genital tract (Rampersaud et 
al, 2012). The most detailed investigation to date used pyrosequencing of barcoded 16S rRNA 
genes to probe the vaginal microbiota in women of childbearing age. The study by Ravel et al 
developed an in-depth characterization of the vaginal microbial communities in a cohort of 396 
North American women equally representing four ethnic backgrounds (Asian, White, Black, and 
Hispanic) (Ravel et al, 2011). In the study the depth of coverage for each bacterial community was 
sufficient to detect taxa that constitute ~0.1% of the community. The low-abundance or “rare” taxa 
are only rare in the context of sampling depth, but they could play major roles in the ecology of a 
community, whereas undetected members may constitute a “seed bank” of species whose numbers 
increase under conditions that favor their growth. The analysis, in which the vaginal bacterial 
communities were grouped according to community composition, revealed five major groups, 
which is reminiscent of previously published studies on microbial diversity in the human vagina 
(Zhou et al, 2009). Four of the five groups, accounting for 73% of the participants, were dominated 
by one or more species of Lactobacillus, that constituted >50% of all sequences obtained. 
Communities in group I (26.2% of the women), were dominated by L. crispatus, whereas groups II 
(6.3%), III (34.1%), and V (5.3%) were dominated by L. gasseri, L. iners, and L. jensenii, 
respectively (Fig 2). The remaining community (group IV), found in 27% of the women, formed a 
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Figure 2. Heat map showing the distribution of microbial taxa found in the vaginal microbial communities 
of 394 reproductive-age women: (A) Complete linkage clustering of samples based on species composition 
and abundance in communities. (B) Nugent scores and pH measurements for each of the 394 samples. (C) 
Shannon diversity indices calculated for each of the 394 vaginal communities (two singletons were 
excluded) (Ravel et al, 2011). Adapted with permission from Proceedings of the National Academy of 
Sciences of the United States of America (Brotman, 2011). 
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large heterogeneous group and was characterized by a more equally represented abundance of 
strictly anaerobic bacteria, including Prevotella, Dialister, Atopobium, Gardnerella, Megasphaera, 
Peptoniphilus, Sneathia, Eggerthella, Aerococcus, Finegoldia, and Mobiluncus. Interestingly, all 
communities contained members that have been assigned to genera known to produce lactic acid, 
including Lactobacillus, Megasphaera, Streptococcus, and Atopobium. This suggests that the 
production of lactic acid may be conserved among communities despite differences in the species 
composition. Although this high-throughput technique has provided more detailed information, the 
findings are consistent with those of previous studies wherein the species composition of vaginal 
communities was investigated by cloning and sequencing of 16S rRNA genes (Ferris et al, 2004; 
Ferris et al, 2007; Fredricks et al, 2005; Srinivasan and Fredricks, 2008; Verhelst et al, 2004; 
Verstraelen et al, 2004; Zhou et al, 2007; Zhou et al, 2009). Somewhat unexpectedly, Prevotella 
spp. were detected in more than 50% of the samples, therefore their prevalence may have been 
previously underappreciated. Although their role in the community is unknown, it should be noted 
that Prevotella spp. positively affect the growth of the species linked to bacterial vaginosis G. 
vaginalis and Peptostreptococcus anaerobius, by producing key nutrients for these species, such as 
ammonia and aminoacids. Hence the wide distribution of Prevotella spp. in the vaginal microbiota 
might be a factor that facilitates bacterial vaginosis (Pybus and Onderdonk, 1999). 
One objective of studies on the human vaginal microbiota is to determine whether there is a 
core set of microbial species associated with the vaginal ecosystems of all healthy women. It is 
postulated that changes to this “core microbiome” may be correlated with risk to disease. The 
results from pyrosequencing and molecular-based studies (Fredricks et al, 2005; Ravel et al, 2011; 
Zhou et al, 2007; Zhou et al, 2009) suggest that for the human vagina there is no single “core 
microbiome”. Instead, it seems there are multiple “core microbiomes” that can be defined by the 
community groups I-V detected in the study by Ravel et al (Ravel et al, 2011). Despite differences 
in their species composition, it may be hypothesized that core functions are conserved among 
communities (Konopka, 2009).  
Conversely, the small number of different kinds of vaginal communities is somewhat 
surprising given that these communities are probably assembled independently after birth. The 
repeatability of community assembly suggests that a host exerts strong selection for a rather limited 
number of different kinds of bacteria. This is especially evident in the limited number of 
Lactobacillus phylotypes and other lactic acid-producing bacteria that are abundant in these 
communities. It can be supposed that vaginal microbial communities exist in a state of dynamic 
equilibrium and that homeostatic mechanisms exist to provide resilience. Given the fundamental 
differences in the species composition of these communities, one can speculate that they will differ 
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in terms of relative resistance and resilience of each community type to disturbances. Hay et al 
stated that lactobacilli are in a continuous effort to acidify the vaginal milieu after the disturbing 
events that may occur in this dynamically changing environment. Whether and how easily they 
succeed in maintaining predominance, providing colonization resistance to anaerobes, depends on 
the combination of the ease and speed with which the lactobacilli can acidify/colonize the vaginal 
econiche after a disturbing event and the number of disturbing events they are confronted with 
(Hay, 2005). This capability appears to be strongly different between individual women, depending 
on genotypic differences between their vaginal lactobacilli (different Lactobacillus species or 
strains, and differences in production of lactic acid, hydrogen peroxide and bacteriocins), between 
women (differences in hormone metabolism and innate immunity), and between the match of 
certain strains to certain hosts (Santiago et al, 2011). Then invasive species, including both 
opportunistic and pathogens, are more likely to become established in communities that exhibit low 
stability (Hobbs and Huenneke, 1992). 
1.2.1. Dynamics of the vaginal microbiota 
The composition of the vaginal ecosystem is not static but changes rapidly over time and in 
response to endogenous and exogenous influences (Eschenbach et al, 2000; Eschenbach et al, 2001; 
Priestley et al, 1997; Schwebke et al, 1999). Variables include age, host genetic background, diet 
and nutritional status, hormonal status/phase of menstrual cycle, pregnancy, use of contraceptive 
agents, sexual behaviors, hygiene practices, and utilization of antibiotics or other medications with 
immune or endocrine activities. 
One of the main variable factors is the age, which is closely related to the estrogen levels. The 
vaginal microbiota changes in a typical manner during the female life cycle. At birth, the vagina is 
sterile. After only a few days, estrogen from the mother induces colonization by lactobacilli 
(Granato, 2003). The growth of lactobacilli is the consequence of the estrogen-induced increase in 
glycogen content in vaginal epithelial cells, since glucose derived from the metabolism of glycogen 
constitutes the main nutritional factor for lactobacilli, which convert it to lactic acid, lowering the 
vaginal pH (Boskey et al, 1999; Eschenbach et al, 2000; Hillier et al, 1993-a). On the other hand, 
the availability of glucose potentially could also promote the growth of other microorganisms 
(Mårdh, 1991). During childhood, skin commensals and bowel bacteria colonize and dominate the 
microbial content of the vagina. At the time of menarche, the rise in estrogen increases glycogen 
deposition in the vaginal epithelial cells, which is a prerequisite for the development of the adult 
vaginal microbiota. This ecosystem is predominant until menopause, when it is replaced with a 
microflora similar to that found prior to the menarche, unless hormonal replacement therapy (HRT) 
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is started (Cauci et al, 2002). Postmenopausal status involves major vaginal environment changes 
that are not confined to the glycogen content of epithelial cells. In spite of the impressive decrease 
in Lactobacillus spp. colonization, increase in vaginal pH, increase in levels of Gram-positive cocci 
and increase in coliform colonization (Hillier and Lau, 1997), the prevalence of BV is significantly 
lower than in fertile women (Cauci et al, 2002). 
Due to fluctuations of estrogen levels, the vaginal econiche is also subject to cyclical changes 
during the menstrual cycle, whereby the normal domination of the lactobacilli is frequently 
challenged (Hay, 2005). The cyclic fluctuation of estrogen and progesterone levels affects the 
vaginal epithelial cell surface receptor expression, the amount and viscosity of cervical mucus, the 
amount of vaginal transudate, the glycogen level, vaginal oxygen and carbon dioxide tension, the 
reduction-oxidation potential, the pH, and the vaginal innate immune response (Hill et al, 2005; 
Wagner and Ottesen, 1982; Wira et al, 2010). Several studies indicated that Lactobacillus spp. 
growth increases throughout the menstrual cycle, but decreases during the menses, when the 
concentration of non-Lactobacillus species, such as G. vaginalis, Gram-positive cocci and Candida 
albicans is increased (Eschenbach et al, 2000; Keane et al, 1997; Santiago et al, 2011; Srinivasan et 
al, 2010). Recent molecular studies pointed out that G. vaginalis is a natural constituent of the 
vaginal microflora (De Backer et al, 2007; Hummelen et al, 2010; Santiago et al, 2011), but it may 
produce transient dominance in healthy women as a result of perturbations, such as an increase in 
pH, during menstruation (Srinivasan et al, 2010). During this period, the increase in G. vaginalis 
levels is accompanied by decreased quantities of L. jensenii and L. crispatus; the latter being the 
species that is most negatively affected by the menses (Santiago et al, 2011). The growth of G. 
vaginalis may be tied to the availability of iron during menstruation. Iron enhances the replication 
of many pathogens and is an essential growth factor for most bacteria (Litwin and Calderwood, 
1993; Miethke and Marahiel, 2007; Weinberg, 2009); one of these microorganisms is G. vaginalis, 
that cannot grow in iron-limiting conditions and is well adapted to harvest iron from the 
environment (Jarosik et al, 1998). During menses, concentrations of L. iners tended to increase 
along with levels of G. vaginalis, in fact both the species are easily cultivated on blood agar 
medium (Srinivasan et al, 2010). Besides G. vaginalis, also Gram-positive cocci, especially the 
Streptococcus anginosus group, P. anaerobius and Peptostreptococcus asaccharolyticus, were 
predominant during non-infectious conditions that alter the normal vaginal pH, such as menses, 
recent sexual intercourse and use of antibiotics (Santiago et al, 2011). In general, the increased 
presence of Gram-positive cocci seems to be a characteristic feature of the disturbances of the 
vaginal ecology, and could be explained as an absolute increase of the Gram-positive cocci loads or 
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as the already present Gram-positive cocci becoming more easily detectable, due to the 
disappearance of the lactobacilli. 
Racial variation and geographical area are also important (Pavlova et al, 2002), and different 
racial groups within the same geographical region have significant differences in what is the 
dominant vaginal organism (Anukam et al, 2006-b). In a recent pyrosequencing study, Ravel et al 
demonstrated that vaginal bacterial communities of Asian and White women are dominated by 
species of Lactobacillus, while communities not dominated by Lactobacillus spp. are more 
common in Hispanic and Black women; for this reason the latter are characterized by higher median 
pH values (Ravel et al, 2011). Thus, the previous acceptance that the occurrence of high numbers of 
lactobacilli and pH < 4.5 is synonymous with “healthy” suggests that a significant proportion of 
asymptomatic Hispanic and Black women are “unhealthy”, a notion that seems implausible. 
Bacterial communities not dominated by species of Lactobacillus are common and appear normal in 
Black and Hispanic women (Ravel et al, 2011; Zhou et al, 2007; Zhou et al, 2009). Hence, the 
enhanced diagnosis of bacterial vaginosis in Black women as opposed to White women might 
merely reflect an increased likelihood that bacteria other than lactobacilli typically predominate in 
the former population, and not that these women have an “abnormal” microflora. The reasons for 
these differences among ethnic groups are unknown, but it can be hypothesized that the species 
composition of vaginal communities could be governed by environmental as well as genetic 
differences between hosts, such as differences in innate and adaptive immune systems, the 
composition and quantity of vaginal secretions, and ligands on epithelial cell surfaces (Schwebke, 
2009-a). Alternatively, diet might influence the Lactobacillus species resident in the gastrointestinal 
tract, and hence the vagina, as the lactobacilli of the gut varies between women from different 
geographic locations, such as Japanese and Western women (Ahrné et al, 1998). 
As regards sexual and vaginal hygiene practices, they have been associated with differences 
in Lactobacillus spp. colonization and vaginal microbial composition (Schwebke et al, 1999; Vallor 
et al, 2001). Identified risk factors for a lack of H2O2-producing lactobacilli, and thus for BV, 
include douching (particularly frequent and recent) (Hawes et al, 1996; Ness et al, 2002), having 
had multiple sex partners during the preceding year (Beigi et al, 2005), and frequent sexual 
intercourse (Vallor et al, 2001). Sexual intercourse may cause a disruption of the local vaginal 
microbiological and/or inflammatory milieu; therefore, more frequent and/or new partners may 
accentuate these proposed changes. As regards the distribution of bacterial species among lesbian 
and bisexual women, different studies reported a decreased quantity of protective H2O2-producing 
lactobacilli and a higher likelihood of colonization with G. vaginalis, causing a major risk of BV 
(Marrazzo et al, 2009; Mitchell et al, 2011). Sexual practices involving receptive vaginal sex with a 
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toy and receptive digital-vaginal sex were associated with a higher likelihood of acquiring an 
“abnormal” vaginal flora (Bradshaw et al, 2005; Mitchell et al, 2011). This could potentially be due 
to more contact with the perianal skin and rectal bacteria and suggests that BV could be a sexually 
facilitated condition. 
A major impact on the composition of vaginal microbial communities was also observed by 
usage of antimicrobial agents. Assuming that the antibiotics also affect the rectal microbiota, this 
might suggest that antibiotic treatment on its own is insufficient to restore a woman’s vaginal 
microbiota and that additional therapeutics, such as probiotics with vaginal lactobacilli, might be 
useful for restoring a Lactobacillus-dominated microflora, as indicated by several studies (Martinez 
et al, 2009; Mastromarino et al, 2009; Reid, 1999; Rossi et al, 2010; Santiago et al, 2011). 
 
1.3 Lactic acid bacteria 
Lactic acid bacteria (LAB) are Gram-positive, low GC content, acid-tolerant and non-spore-
forming rods or coccobacilli (Hugenholtz, 1998). They generally lack catalase, although in rare 
cases pseudocatalase can be found. They are chemo-organotrophic and grow only in complex 
media. Fermentable carbohydrates are used as energy sources and are degraded to lactate (homo-
fermentatives) or to lactate and additional products such as acetate, ethanol, carbon dioxide, formate 
or succinate (hetero-fermentatives). 
LAB might be the most numerous group of bacteria linked to humans. Their natural habitat 
varies widely, from food, plants and sewage, to the oral, genital and gastrointestinal tracts of 
humans and animals (Hammes and Vogel, 1995). LAB play an essential role in food technology, 
because of preservative action due to acidification, and/or enhancement of flavor, texture and 
nutrition (Jay, 1996; Stiles, 1996). They are used for industrial fermentation of dairy products, 
meats, and vegetables, and they are also critical for the production of wine, coffee, silage, cocoa, 
and sourdough (Dunny and Cleary, 1991; Wood and Holzapfel, 1995; Wood and Warner, 2003). In 
addition, they are an important source of antimicrobial agents (Cotter et al, 2005). However, not all 
of the LAB are useful, some of them, such as several Streptococcus spp., are involved in food 
spoilage or may even be pathogen. 
The definition of LAB is biological rather than taxonomical and refers to the basal 
metabolism of these bacteria, which primarily leads to the production of lactic acid. However, they 
do not comprise a monophyletic group of bacteria. Among the genera comprising the LAB, 
Lactobacillus is the largest genus (Hugenholtz, 1998), with over 100 species described. It belongs 
to the phylum Firmicutes, class Bacilli, and order Lactobacillales (Hammes and Hertel, 2003). 
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Lactobacilli are strictly fermentative and can be divided into three groups based on fermentation 
characteristics: obligate homo-fermentative, facultative hetero-fermentative and obligate hetero-
fermentative (Hammes and Vogel, 1995; Pot et al, 1994). However, this phenotypic classification 
does not match the rRNA-based phylogeny (Vandamme et al, 1996). The high degree of diversity 
and complex phylogeny of Lactobacillus and related genera was acknowledged by Schleifer and 
Ludwig (Schleifer and Ludwig, 1995), who divided the species into three groups, based on 16S 
rRNA studies. The first group comprises Lactobacillus delbrueckii and many other obligate homo-
fermentative lactobacilli (L. acidophilus, L. gasseri, and Lactobacillus johnsonii). The second 
group, the so-called Lactobacillus casei-Pediococcus group, is the largest of the three groups and 
contains both homo-fermenters and hetero-fermenters species (Lactobacillus plantarum, L. casei, 
Pediococcus pentosaceus, and Lactobacillus brevis). The Leuconostoc group is composed of all 
members of the genus Leuconostoc and some obligate hetero-fermentative lactobacilli (Leuconostoc 
mesenteroides and Oenococcus oeni). Streptococci (Streptococcus thermophilus) and lactococci 
(Lactococcus lactis subsp. lactis and Lactococcus lactis subsp. cremoris) form a separate branch 
(Siezen et al, 2004). Reclassifications have been frequent following the identification of new 
species and classification techniques, and the taxonomy is generally considered unsatisfactory (Felis 
and Dellaglio, 2007; Schleifer and Ludwig, 1995). 
1.3.1. Vaginal lactobacilli 
The genus Lactobacillus comprises a phenotypically heterogeneous group of facultatively 
anaerobic, catalase-negative, rod-shaped LAB (Kandler and Weiss, 1986). Over 120 species of 
Lactobacillus have been identified, and more than 20 species have been detected in the vagina, 
where lactobacilli are recognized as markers of “normal” vaginal microflora (Donders, 2007). Some 
of the species initially identified using phenotypic assays include L. acidophilus, L. fermentum, L. 
plantarum, L. brevis, L. jensenii, L. casei, L. delbrueckii, L. vaginalis, and L. salivarius (Levison et 
al, 1977; Nagy et al, 1991; Rogosa and Sharpe, 1960). The most recent studies on the vaginal 
Lactobacillus microbiota report that the most frequently occurring species are L. crispatus, L. 
gasseri, L. iners, and L. jensenii, with the vaginal ecosystem of most healthy women dominated by 
a single Lactobacillus species (Ravel et al, 2011; Shi et al, 2009; Thies et al, 2007; Vásquez et al, 
2002; Vitali et al, 2007; Yamamoto et al, 2009; Zhou et al, 2004). 
Recently, a new classification of the undisturbed vaginal microflora was suggested, based on 
the Ison and Hay criteria (Ison and Hay, 2002), that classified the vaginal microflora through an 
estimation of the ratios of the observed cellular types: 0, no bacteria; I, normal microflora; II 
intermediate microflora; III, bacterial vaginosis; and IV, streptococci-associated microflora. 
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Verhelst et al splitted up grade I “normal” microflora into four categories, designated grade Ia, Ib, 
Iab and I-like (Verhelst et al, 2005). Grade Ia was shown to contain predominantly L. crispatus, 
grade Ib predominantly L. gasseri and L. iners, grade Iab a mixture of these three species and grade 
I-like Bifidobacterium spp. rather than Lactobacillus spp. Grade I-like microflora was considered as 
not representative for normal vaginal microflora, but as probably an unrecognized type of disturbed 
vaginal ecosystem (Verstraelen et al, 2007) that had previously not been distinguished from a 
healthy vaginal microflora. 
The existence of L. iners was unknown prior to 1999, but is now known to play a significant 
role in the vaginal microbial ecosystem. Phylogenetically, the new species clusters with the L. 
delbrueckii group of species and shows a specific association with L. gasseri and L. johnsonii 
(Falsen et al, 1999). The first report of the isolation of L. iners in a woman with a “normal” vaginal 
microflora was in 2002 (Burton and Reid, 2002). L. iners only grows on blood agar (Falsen et al, 
1999) and previous works using cultivation-based techniques failed to isolate L. iners because 
Rogosa or MRS agar were used (Antonio et al, 1999; Giorgi et al, 1987; Pavlova et al, 2002; Song 
et al, 1999; Wilks et al, 2004). Hereafter, cultivation-independent methods have detected L. iners at 
high levels in most subjects with and without BV, and in some studies it was the only Lactobacillus 
species detected in BV-positive women (Burton and Reid, 2002; Fredricks et al, 2005; Thies et al, 
2007; Verhelst et al, 2004; Wertz et al, 2008). It has been postulated that this might be because L. 
iners may be better adapted to the conditions associated with BV, such as the polymicrobial state of 
the vaginal microflora and elevated pH (Wertz et al, 2008). Alternatively, L. iners could be resistant 
to unknown factors that lead to the demise of other Lactobacillus spp. during the onset of BV. In a 
real-time PCR-based study, De Backer et al reported a significant negative correlation between L. 
iners and L. gasseri, and a positive correlation between L. iners and G. vaginalis (De Backer et al, 
2007). They categorized women using the Ison and Hay criteria, as refined by Verhelst et al 
(Verhelst et al, 2005), and observed that L. iners was abundantly present in most grades, but 
predominantly in grade III, as it was G. vaginalis; while it was virtually absent in grades I and II, 
where L. gasseri was more prevalent. It has also been suggested that L. iners may become a 
dominant part of the vaginal microbiota during the transitional stage between abnormal and normal, 
following the resolution of bacterial vaginosis (Ferris et al, 2007; Jakobsson and Forsum, 2007; 
Kalra et al, 2007). When analyzing the stability of the normal vaginal ecosystem in pregnancy 
(Verstraelen et al, 2009), it appeared that the presence of L. gasseri or L. iners is associated with a 
weakly stable microflora. They possibly offer poorer colonization resistance thereby allowing the 
overgrowth of other bacteria and predisposing to the occurrence of “abnormal” vaginal microbiota. 
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L. crispatus and L. jensenii are the predominant species of lactobacilli that colonize the vagina 
of women of reproductive age. As H2O2-producing lactobacilli, they may protect a woman from 
developing BV by inhibiting the growth of BV-related microorganisms, such as G. vaginalis, 
anaerobic Gram-negative rods, and Mycoplasma hominis (Antonio et al, 1999). They are found in 
samples of all grades, even if the concentration of L. crispatus is much higher in grade I, 
particularly grade Ia (De Backer et al, 2007). The presence of L. jensenii is associated with normal 
microflora, but this species elicits both poor colonization strength and poor colonization resistance, 
conferring only intermediate stability. On the contrary, L. crispatus is associated with a particularly 
stable vaginal ecosystem (Verstraelen et al, 2009). Vaginal bacterial communities dominated by L. 
crispatus also show the lowest median pH (~ 4.0), while communities dominated by other species 
of Lactobacillus have slightly higher pH, ranging from 4.4 to 5.0 (Figure 2), indicating that these 
communities as a whole might not produce as much lactic acid as those dominated by L. crispatus 
or might have different buffering capabilities (Ravel et al, 2011). 
The production of H2O2, the maintenance of vaginal pH ~ 4.0 and the capability to colonize 
the vaginal ecosystem with high colonization strength and high colonization resistance, make L. 
crispatus the main marker of a healthy and stable vaginal ecosystem, which is less likely to shift 
away to an abnormal microbiota. 
1.3.2. Defense factors of vaginal lactobacilli 
The ability of lactobacilli to maintain the normal vaginal ecosystem has been attributed to the 
secretion of lactic acid, hydrogen peroxide (H2O2), and bacteriocins (Hillier, 1998). The production 
of organic acids maintains the vaginal pH at < 4.5, thereby creating an inhospitable environment for 
the growth of most endogenous pathogenic bacteria. In addition, H2O2 inhibits the growth of 
vaginal microorganisms either directly or through the enhancement of the enzyme peroxidase-
halide (Eschenbach et al, 1989; Hillier et al, 1992). Hydrogen peroxide was found to be lethal to G. 
vaginalis, Prevotella bivia, and Escherichia coli (Cantoni et al, 1989; Hillier et al, 1993-a; 
Klebanoff et al, 1991), and vaginal colonization with H2O2-producing lactobacilli was associated 
with a decreased occurrence of BV (Hawes et al, 1996). The production of bacteriocin or lactocin 
with a broad range of antibacterial activity further suppresses the endogenous pathogenic bacteria, 
to maintain a healthy vaginal ecosystem (Klaenhammer et al, 1988; McGroarty and Reid, 1988; 
Skarin and Syl, 1986). Finally, the growth of Lactobacillus species maintains a higher oxidation-
reduction potential in the vaginal environment, inhibiting the growth of the obligate anaerobic 
bacteria. 
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It is highly probable that all these factors act synergistically to suppress the growth of 
pathogens and other opportunistic organisms (Aroutcheva et al, 2001-a). Several investigators have 
demonstrated that the activity of the Lactobacillus-produced bacteriocins is influenced by the 
hydrogen ion concentration in the environment, and is higher at a low pH (Dembélé et al, 1998; 
Skarin and Syl, 1986). The activity of H2O2 was also found to be pH-dependent. Hydrogen peroxide 
was stable in an acid environment and degraded as the hydrogen ion concentration decreased 
(Fontaine and Taylor-Robinson, 1990). Therefore, as the pH of the vagina increases, bacteriocin 
loses its effectiveness, hydrogen peroxide is degraded, and lactobacilli cannot compete against the 
other bacteria. Lactic acid appears to be the primary vaginal acidifier, but the concentration of lactic 
acid in the medium is not solely responsible for the pH change, it depends also on the production 
and secretion of other organic acids, including acetic acid (Radler and Bröhl, 1984). Lactic acid and 
acetic acid have the ability to inhibit bacterial growth and act synergistically, indeed the activity of 
acetic acid is potentiated by the lower pH produced by lactic acid. Furthermore, the biocell mass or 
numbers of bacteria in the vaginal environment is responsible for pH changes, thus the active 
growth of bacteria present is also important (Aroutcheva et al, 2001-a). It is possible that a 
reduction in growth of lactobacilli results in an elevation in the pH of the vagina and therefore in an 
overgrowth of other bacteria that leads to an imbalance within the endogenous vaginal microflora. 
1.3.3. Other lactic acid-producing bacteria 
As previously reported, three lactic acid-producing taxa, namely A. vaginae, Megasphaera 
spp. and Leptotrichia spp., were found to be constituents of the normal microflora of some women 
(Ravel et al, 2011; Rodriguez et al, 1999; Zhou et al, 2004; Zhou et al, 2007). Possibly, when 
lactobacilli are unable to predominate in a particular vagina for whatever reason, another lactic-acid 
producing species fills this niche, in order to maintain the acidification activity which is essential to 
promote a healthy vaginal environment. 
A. vaginae belongs to the genus Atopobium, which lies within the family Coriobacteriaceae, 
and forms a distinct branch within the phylum Actinomycetes (Stackebrandt and Ludwig, 1994). 
Three species formally designated Lactobacillus minutus, Lactobacillus rimae, and Streptococcus 
parvulus, within the lactic acid-producing group of bacteria (Collins and Wallbanks, 1992), have 
been reclassified as the genus Atopobium. In 1999, an organism similar to these three species was 
isolated from the vagina of a healthy woman in Sweden, and the organism was named Atopobium 
vaginae (Rodriguez et al, 1999). In addition to producing lactic acid (Dewhirst et al, 2001; Downes 
et al, 2001), some species of Atopobium exhibit peptidyl peptidase activity, and produce significant 
quantities of ammonia in environments where sugars are a scarce source of energy (Eschenlauer et 
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al, 2002; Kazor et al, 2003; Kumar et al, 2003). This may be why A. vaginae is found more often in 
the vagina of postmenopausal women who are not on hormone replacement therapy (Burton et al, 
2004). Moreover, ammonia is known to act as a substrate to promote the growth of G. vaginalis 
(Pybus and Onderdonk, 1997), and A. vaginae is found much more commonly in women with BV 
than in those with normal flora (Biagi et al, 2009; Bradshaw et al, 2006-b; Ferris et al, 2004; 
Fredricks et al, 2005; Menard et al, 2008; Oakley et al, 2008; Verhelst et al, 2004; Verstraelen et al, 
2004; Vitali et al, 2007; Zhou et al, 2007). The renamed Atopobium parvulum, Atopobium minitum, 
and Atopobium rimae have been associated with dental abscesses and oral infections (Downes et al, 
2001; Kumar et al, 2003; Olsen et al, 1991; Paster et al, 2001), tubo-ovarian abscesses (Geissdörfer 
et al, 2003), and abdominal wound infection, supporting the view that these organisms may be 
pathogenic to the host. 
Leptotrichia, an anaerobic Gram-negative rod, is reportedly part of the normal oral flora and 
has rarely been isolated from clinical material (Könönen et al, 1994; Kroes et al, 1999; Tee et al, 
2001). However, Leptotrichia sanguinegens/amnionii has been reported in association with 
postpartum endometritis, adnexal masses, and fetal death (Gundi et al, 2004; Hanff et al, 1995; 
Shukla et al, 2002), and has been detected in the amniotic fluid of women with preterm labor, 
premature prelabor rupture of membranes (PPROM), and pre-eclampsia (DiGiulio et al, 2008; 
DiGiulio et al, 2010). Little is known about the ecology of Leptotrichia spp., but they do produce 
lactic acid as the primary fermentation product from glucose (Tee et al, 2001) and may represent 
opportunistic pathogens. Megasphaera spp. isolated from the vagina had modest similarity (89–
95%) to Megasphaera cerevisiae, a Gram-negative, obligate anaerobe that is associated with beer 
spoilage by causing turbidity, off-flavors and off-odors (Doyle et al, 1995; Ziola et al, 2000). 
Megasphaera and Leptotrichia are also capable of producing malodorous metabolites (Kazor et al, 
2003; Ziola et al, 2000). This renders detection of a vaginal odor in women lacking a Lactobacillus-
dominated vaginal microflora as not indicative of BV or any other disease condition, especially in 
asymptomatic women. 
 
1.4 Abnormal and intermediate vaginal microflora 
Lactobacillary grade III, and to a lesser extent Lactobacillary grade IIb, are more likely to be 
linked with pathological conditions, and are said to be “abnormal vaginal microflora”. 
Up to the 1950s, symptomatic women with Lactobacillary grade III were diagnosed with “non-
specific vaginitis”, as the microbial etiology of lactobacillary deficiency was still uncertain at that 
time. This was resolved by Gardner and Dukes, who discovered a new genus of bacteria held 
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responsible for the condition we now know as bacterial vaginosis (BV) (Gardner and Dukes, 1955). 
The use of the wet mount was usually preferred to the Gram stain for the diagnosis of such 
abnormal lactobacillary grades (Donders et al, 2000-b), but BV is characterized by the overgrowth 
of different microorganisms, and most of them cannot be visualized on wet-mount microscopy. For 
this reason many attempts were made to cast the diagnosis in microbiological terms; quantitative 
bacteriology was used to try and explain symptoms in terms of numbers of different bacteria 
(Lindner et al, 1978). The diagnosis of BV based on Gram-stained specimens was first done by 
Spiegel et al (Spiegel et al, 1983-a) and later refined and quantified by Nugent et al (Nugent et al, 
1991), thereby progressively moving the diagnosis of a common clinical condition into the 
laboratory. By counting the different cell types (Lactobacillus spp., G. vaginalis/Bacteroides spp., 
Mobiluncus spp.) a score between 0 and 10 is obtained (Table 1). A score of 1–4 of lactobacillary 
morphotypes, a score of 1–4 of G. vaginalis/Bacteroides morphotypes, and a score of 1 or 2 for 
Mobiluncus morphotypes has to be added to obtain the global Nugent score (Nugent et al, 1991); 
whereby a score of ≥ 7 corresponds to BV, a score of ≤ 3 corresponds to normal microbiota, and a 
score of 4–6 is considered “intermediate microflora”. Even if Nugent score is nowadays accepted as 
the gold standard for the diagnosis of BV in most clinical trials, it is not an ideal scoring system, as 
on a continuous scale of 1–10 there is no consensus on what the intermediate group with a score of 
4–6 stands for. Ideally the “intermediate microflora” state represents a turning point from a normal 
state into BV, or from BV to normal. In reality, however, most of the women with so-called 
“intermediate microflora” according to Nugent will have neither BV nor a normal ecosystem. 
Different studies reported that the intermediate group was linked to a different and usually more  
 
Table 1. Nugent criteria for the diagnosis of bacterial vaginosis (BV). 
 
Lactobacillus 
morphotypes 
G. vaginalis/Bacteroides 
morphotypes 
Mobiluncus 
morphotypes 
0 4 + 0 0 
1 3 + 1 + 1-2 + 
2 2 + 2 + 3-4 + 
3 1 + 3 +  
4 0 4 +  
 
BV: score ≥ 7; normal microflora: score ≤ 3; “intermediate microflora”: score 4–6. 
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serious range of complications, including mid-trimester pregnancy loss, than the full-blown BV 
(Donders et al, 1998; Hay et al, 1994; McDonald et al, 1994). Therefore, in the intermediate group, 
“partial BV” as well as other “abnormal” conditions, such as aerobic vaginitis (AV), may be present 
(Donders, 2007). AV is a newly recognized disorder of the vaginal ecosystem, and should not be 
confused with BV. Hence, although BV is a condition of abnormal vaginal flora, abnormal vaginal 
flora is not always BV. 
The “abnormal” microflora can be disturbed by anaerobic overgrowth (BV) (Figure 1E) or by 
aerobic microorganisms, such as E. coli, group B streptococci, and enterococci, (AV) (Figure 1D), 
or can be a mixture of both (mixed abnormal microflora). Concomitant infectious conditions, such 
as candidiasis, trichomoniasis, BV, AV or cervicitis may occur (Donders et al, 1993). Appropriate 
diagnosis and distinction between these infectious conditions is crucial as their treatments are 
different; for example, AV does not respond well to metronidazole, the treatment of choice for 
trichomoniasis and BV. In order to get to such a diagnosis, the use of Lactobacillary grades to 
decide whether or not a bacterial ecosystem is “normal” (Lactobacillary grade I or IIa) is essential 
(Donders, 1999). In the case of an “abnormal” microbiota (Lactobacillary grade IIb or III), extra 
criteria based on microscopy are added to distinguish between BV and AV, and a further scrutiny is 
required to find other pathogens such as Trichomonas or Candida. As abnormal Lactobacillary 
grades are also associated with Chlamydia trachomatis, gonorrhoea and syphilis, a screen for 
sexually transmitted pathogens should also be considered (Donders et al, 1993). 
 
 
Figure 3. Vaginal infectious disease in different types of microflora (Donders, 2007). 
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Figure 3 represents the different pathogenic conditions of vaginal microbiota disturbance; the 
progressive loss of lactobacilli is seen as one dimension (x axis) and the gradual redox potential 
(aerobic–anaerobic) as the other (y axis). On the anaerobic side, normal microflora may gradually 
become partial BV, which contains some anaerobic microorganisms but not enough to cause the 
appearance of clue cells, and further down the line full-blown BV. On the aerobic side normal 
microflora may be progressively altered into moderate AV and further deteriorates to severe AV or 
“desquamative inflammatory vaginitis” (DIV). Trichomonas vaginalis will usually be found in 
cases with “abnormal” Lactobacillary microflora, but can also be accompanied by anaerobic-
dominant or with aerobic-dominant microflora, or both. Candida will be more frequently found in 
the aerobic rather than the normal Lactobacillary microflora (lower left in the diagram), but it can 
also be encountered in all other compartments of the diagram. On the aerobic side, Candida may 
often grow together with group B streptococci (Monif, 1999). 
1.4.1. Bacterial vaginosis (BV) 
Bacterial vaginosis is an ecological disorder of the vaginal microbiota in which the normal 
Lactobacillus-dominant microflora is replaced by a 100–1000-fold increase in the numbers of 
anaerobic bacteria (Eschenbach, 1993-a). Thus, BV is usually a polymicrobial infection, and 
organisms responsible for infection include: G. vaginalis, M. hominis, Bacteroides spp., 
Peptostreptococcus spp., Fusobacterium spp., Prevotella spp. (Forsum et al, 2005; Spiegel, 1991). 
Symptoms are few, and most women do not realize they have the condition. When present, the most 
common symptom is a thin, gray, non-pruritic discharge with a fishy odor, while the vagina is not 
red or inflamed and there are no prominent symptoms of burning, pain or dyspareunia. These 
together with a pH > 4.5 and typical clue cells on microscopy suggest the clinical diagnosis 
according to Amsel et al (Amsel et al, 1983). A typical feature of bacterial vaginosis is the absence 
of inflammation. In BV there is only a slight increase in IL-1β and an unexpectedly low production 
of IL-8, preventing the attraction of inflammatory cells such as macrophages and neutrophils 
(Cauci, 2004; Sodhani et al, 2005). In non-pregnant women, the presence of BV is associated with 
an increased risk of upper genital tract and sexually transmitted infections (Plitt et al, 2005; 
Schwebke, 2003; Soper et al, 1990) and with the acquisition of HIV (Cohen et al, 1995; Martin et 
al, 1999; Taha et al, 1998). In pregnancy, BV increases the risk of post-abortal sepsis (Larsson et al, 
2000), early miscarriage (Ralph et al, 1999), recurrent abortion (Llahi-Camp et al, 1996), late 
miscarriage (Hay et al, 1994; Llahi-Camp et al, 1996), preterm prelabor rupture of membranes 
(PPROM) (Azargoon and Darvishzadeh, 2006), spontaneous preterm labor (SPTL) and preterm 
birth (PTB) (Hay et al, 1994; Hillier et al, 1995; Kurki et al, 1992; Lamont, 2004), histological 
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chorioamnionitis (Gibbs, 1993; Martius and Eschenbach, 1990), and postpartum endometritis 
(Jacobsson et al, 2002; Watts et al, 1990). 
1.4.2. Aerobic vaginitis (AV) 
Aerobic vaginitis (AV) is defined as a disruption of the lactobacillary population, 
accompanied by signs of inflammation and the presence of a rather scarce, predominantly aerobic 
microflora, composed of enteric commensals or pathogens (Donders et al, 2011). 
 
Table 2. Criteria for the microscopic diagnosis of aerobic vaginitis (AV) (×400 magnification, phase 
contrast microscope). 
 
AV score 
 
Lactobacillary 
grades 
 
Number of 
leukocytes 
 
Proportion 
of toxic 
leukocytes 
 
Background 
microflora 
 
Proportion of 
parabasal 
epitheliocytes 
 
0 
 
I and IIa 
 
≤10/hpf1 
 
None or 
sporadic 
 
Unremarkable 
or cytolysis 
 
None or <1% 
 
1 
 
IIb 
 
>10/hpf and 
≤10/epithelial 
cell 
 
≤50% of 
leukocytes 
 
Small coliform 
bacilli 
 
≤10% 
 
2 
 
III 
 
>10/epithelial 
cell 
 
>50% of 
leukocytes 
 
Cocci or 
chains 
 
>10% 
 
“Severe AV” or “desquamative inflammatory vaginitis”: score > 6; “moderate AV”: score 5–6; “light AV”: 
score; “no signs of AV”: score < 3. 
1
hpf: high-power field (×400 magnification). 
 
The diagnosis of AV is based on five microscopic criteria, each of which can be absent (0 
points), moderate (1 point) or severe (2 points) (Table 2). The first criterion is Lactobacillary 
grading (LBG): LBG I and LBG IIa are considered normal (score 0), LBG IIb scores 1 point, LBG 
III scores 2 points, and is characterized by the complete replacement of lactobacilli by other 
bacterial morphotypes, such as cocci, anaerobic coccobacilli, or small bacilli. The second criterion 
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is the proportional number of leukocytes: if there are more than 10 leucocytes present per high-
power field (1 point), the mean number surrounding each epithelial cell is counted, and a score of 2 
is assigned when there is a mean of > 10 leukocytes per epithelial cell. The third criterion is the 
presence of toxic leukocytes, that is round and bloated leukocytes, containing swirling lysosomes: if 
the proportion of toxic leukocytes vs the total number of leukocytes is < 50% of the total 
leukocytes, 1 point is given; if there are > 50%, 2 points are given. The fourth criterion is the type 
of background flora: if it is unremarkable, or shows debris and bare nuclei from lysed epithelial 
cells (cytolysis) a score of 0 is assigned; a score of 1 is given if the lactobacillary morphotypes are 
very coarse or resemble small bacilli (other than lactobacilli); and a score of 2 is given if prominent 
single or chained cocci are visible. Finally, the presence of parabasal epithelial cells, that are small, 
rounded cells with large nucleus and dark cytoplasm, is evaluated: superficial and intermediate 
epitheliocytes are normal (score 0), but the presence of parabasal epithelial cells are abnormal. If 
between 1 and 10% of epitheliocytes are parabasal cells 1 point is given, but if more than 10% are 
parabasal cells, 2 points are assigned (Donders et al, 2002). The sum of the points establishes the 
composite AV score, with a maximum score of 10. A composite score of 1–2 represents normality, 
a score of 3–4 corresponds to slight AV, a score of 5–6 to moderate vaginitis, and a score > 6 to 
severe AV. In practice, a score of 8–10 matches the definition of “desquamative inflammatory 
vaginitis”, so that such a diagnosis can be seen as the most extreme form of AV (Gardner, 1968; 
Sobel, 1994). 
AV is recognized to be a separate vaginal microbiota disorder, and should not be confused 
with BV. Clinical features associated with the two entities and the host response are specific and 
clearly different for each condition. First of all, the diagnosis of AV is best accomplished on wet 
mounts, in order to better identify the presence of the signs of inflammation, such as the presence of 
toxic leukocytes and parabasal cells (Figure 4). The microscopic evaluation also permits to 
distinguish between the presence of aerobic enteric commensals, such as E. coli, Staphylococcus 
aureus, and group B streptococci, which is typical of AV, and the overgrowth of anaerobic bacteria 
(G. vaginalis, Mobiluncus spp., Bacteroides spp., Prevotella spp., Peptostreptococcus spp.), 
representative of BV. Not only are the microscopic details different between AV and BV, the local 
immune response elicited in the host is unique in each condition. The concentrations of pro-
inflammatory cytokines, IL-1β, IL-6 and IL-8, are clearly linked to an abnormal vaginal microflora, 
and are inversely proportional to the numbers of lactobacilli (Donders et al, 2000-a; Donders et al, 
2003). BV is associated with a moderate elevation of the pro-inflammatory cytokine IL-1β, but does 
not result in the subsequent induction of IL-6 and IL-8 (Cauci et al, 2003). Whereas in AV, IL-1β is 
produced in the vagina to a much greater extent, and even more dramatic is the elevated 
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concentration of IL-6 (Donders et al, 2002). IL-6 is a well-known marker for bacterial amnionitis 
and imminent term and preterm delivery, and, together with IL-8, is a chemo-attractant directly 
linked to increased prostaglandin production and delivery (Imseis et al, 1997; Romero et al, 1993). 
 
 
Figure 4. Images of phase-contrast microscopy (×400) of vaginal fluid from patients with aerobic vaginitis 
(AV): (A) The toxic leukocytes, full of lysozymic granules. (B) The typical AV flora, also illustrating the 
parabasal cells. (Donders, 2007). 
 
Many women have microscopic signs of AV with the apparent absence of any symptoms. 
Probably the severity of the abnormalities found by microscopy (AV score) is linked to the severity 
of symptoms. As a consequence of the increased immune response in AV, symptoms are related to 
the thinned vaginal mucosa and increased inflammatory reaction. There is almost invariably an 
increased vaginal discharge, which is abundant and yellowish, but devoid of fishy amine odor. Also, 
severe burning and stinging is often prominent, and is commonly linked to dyspareunia. Because of 
this thinning of the vagina and the possible ulcerations, AV may predispose women to the 
acquisition of HIV or other sexually transmitted infections (Donders et al, 1991; Donders et al, 
1993). 
The best approach for treating AV in both pregnant and non-pregnant women is unknown. 
The inflammatory component of most patients with AV suggests that antibiotics may not be 
sufficient. Clindamycin may be a better choice than metronidazole for pregnant women with an 
abnormal vaginal flora. Some local, non-absorbable antibiotics may hold special promise because 
they induce a favorable anti-inflammatory environment (Brown et al, 2010), as these treatments 
have led to high cure rates in inflammatory bowel diseases such as Crohn’s disease, diverticulitis 
and colitis ulcerosa (Guslandi, 2010; Latella and Scarpignato, 2009; Shafran and Burgunder, 2010). 
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1.4.3. Candida vaginitis (CA) 
Candida vaginitis is one of the most common causes of vaginal infections (Anderson et al, 
2004). Candida albicans is responsible for the 70% to 90% of cases, the remaining cases being 
caused by Candida glabrata, Candida tropicalis, Candida parapsilosis, and Saccharomyces 
cerevisiae (Nyirjesy, 2008; Richter et al, 2005; Sobel, 2007). In the absence of immunosuppression 
or damaged mucosa, Candida spp., mostly C. albicans, can be isolated in the vaginal tracts of 20% 
to 30% of healthy asymptomatic non-pregnant women (Beigi et al, 2004-b); it is usually not 
associated with any signs of disease and is thus referred to as colonization (Figure 5). Vaginal 
colonization typically begins following menarche and stems from increased vaginal glycogen stores 
induced by the rise in endogenous estrogen levels. If the balance between colonization and the host 
is temporarily disturbed, Candida can cause vaginitis, which is associated with clinical signs of 
inflammation. Risk factors that can precipitate infection include conditions with broad-spectrum 
antibiotic use, inadequately controlled diabetes mellitus, infection, and genetic predispositions 
(Goswami et al, 2000; Sobel, 2007). Episodes of CA occur mostly during childbearing years and an 
increased frequency has been reported during the premenstrual week (Eckert et al, 1998) and during 
pregnancy (Cotch et al, 1998). 
In most women, the hallmark symptoms of CA are vulvar pruritus and burning, frequently 
accompanied by soreness and irritation leading to dyspareunia and dysuria (Anderson et al, 2004). 
On physical exam, vulvar and vaginal erythema, edema, fissures, and a thick curdy vaginal 
discharge are commonly found (Eckert et al, 1998). The clinical symptoms are nonspecific and can 
be associated with a variety of other vaginal diseases and infections. However, the vaginal pH is 
normal (4.0 to 4.5), and previous studies have failed to find an altered or abnormal bacterial vaginal 
ecosystem in patients affected by CA, as a predominant presence of lactobacilli was observed 
(Sobel and Chaim, 1996; Vitali et al, 2007; Zhou et al, 2009). However, a PCR-DGGE study by  
 
 
 
 
 
Figure 5. Images of phase-contrast microscopy (×400) 
of vaginal fluid from women with Candida in a normal 
bacterial microflora (Lactobacillary grade I) (Donders, 
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2007). 
Vitali et al, showed a different frequency of particular Lactobacillus species in respect to the 
frequency detected under healthy conditions, with a decrease in H2O2-producing species (L. 
acidophilus, L. gasseri, and L. vaginalis) and an increase of non-H2O2-producing L. iners (Vitali et 
al, 2007). Thus, hydrogen peroxide rather than lactic acid, could be responsible for the control of 
Candida spp. overgrowth in the vaginal environment (Sobel and Chaim, 1996). 
The 2006 STD Treatment Guidelines from the Centers for Disease Control and Prevention 
(CDC) classifies Candida vaginitis as either uncomplicated or complicated (Centers for Disease 
Control and Prevention, 2006). Uncomplicated infections are easily treated and defined as sporadic 
or infrequent infections of mild-to-moderate severity caused by C. albicans in immunocompetent 
women. Complicated infections include cases of severe vaginitis, CA caused by non-C. albicans 
species, CA associated with pregnancy or other concurrent conditions, such as uncontrolled diabetes 
or immunosuppression, and recurrent Candida vaginitis. Recurrent CA is defined as at least four 
episodes of Candida vaginitis during 1 year (Sobel et al, 1998). 
Successful treatment of uncomplicated CA is achieved with single-dose or short-course 
therapy in over 90% of cases. Several topical and oral drugs are available, without evidence for 
superiority of any agent or route of administration (Pappas et al, 2009), although among the 
topically applied drugs, azoles are more effective than nystatin (Centers for Disease Control and 
Prevention, 2006). Non-C. albicans-related disease is less likely to respond to azole therapy 
(Nyirjesy et al, 1995). Vaginal boric acid, administered in a gelatin capsule, AmB suppositories, or 
topical 17% flucytosine cream alone or in combination with 3% AmB cream are all rather good 
treatment options for non-C. albicans CA (Pappas et al, 2009; Phillips, 2005; Sobel et al, 2003). In 
cases of recurrent CA, long-term suppressive therapy with oral fluconazole is the most convenient 
and well-tolerated regimen among other options and was shown to be effective in over 90% of 
patients. Against expectations, these patients have shown little evidence of developing fluconazole 
resistance in C. albicans isolates or superinfection with non-C. albicans species (Shahid and Sobel, 
2009; Sobel et al, 2004). Many women with recurrent CA turn to probiotics as adjunct or sole 
therapy to control their recurrences. Most probiotics, in oral or topical formulation, contain 
lactobacilli, which are felt to inhibit or reduce the growth of Candida spp. in the vaginal tract, but 
results from different clinical trials are in disagreement (Falagas et al, 2006). 
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1.4.4. Cytolytic vaginosis 
Cytolytic vaginosis is a non-inflammatory condition in which H2O2-producing lactobacilli 
cause an extreme vaginal acidity (pH < 4), leading to epitheliolysis (Cibley and Cibley, 1991). 
Usually the abundant presence of coarse, equal-sized lactobacilli is evident, together with bare 
nuclei, patches of cytoplasmic debris of lysed epithelial cells, and paucity of leukocytes (Figure 6). 
The condition can typically cause a burning sensation and increased vaginal discharge, and is often 
confused with Candida vaginitis (Demirezen, 2003). 
 
 
 
Figure 6. Images of phase-contrast microscopy (×400) of 
vaginal fluid from patients with cytolysis of epithelial cells, 
with numerous bare epithelial nuclei and cytolyic debris 
clearly visible (cytolytic vaginosis) (Donders, 2007). 
 
1.4.5. Trichomonial vaginitis (TV) 
Trichomonas vaginalis is one of the most frequent sexually transmitted pathogens worldwide 
(Kingston et al, 2003). It is a unicellular, flagellated protozoan and is responsible for 15% to 20% of 
patients with vaginitis (Anderson et al, 2004). Up to 50% of patients may be asymptomatic (Sobel, 
2005), while a frothy, malodorous, yellow-green discharge is a common complaint of the 
symptomatic women affected by TV. Like BV, studies have demonstrated a link between 
trichomonas infection and a higher risk for premature rupture of membranes, chorioamnionitis, and 
preterm birth during pregnancy. In non-pregnant women, infection is felt to be a risk factor for the 
transmission of HIV, cervical neoplasia, atypical pelvic inflammatory disease, tubal infertility, and 
post-hysterectomy infection (Soper, 2004). 
1.4.6. Cervicitis 
Cervicitis is an inflammation of the uterine cervix, frequently asymptomatic. It is generally 
considered to result from infection with a sexually acquired microorganism, such as Chlamydia 
trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium (Cohen et al, 2002; Gaydos et al, 
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2009; Marrazzo et al, 1997; Miller and Zenilman, 2005). In many women with cervicitis these 
microorganisms are not always detected, even when highly sensitive diagnostic tests are performed 
(Marrazzo et al, 2002-a; Nyirjesy, 2001). Cervicities should be suspected in women with a yellow 
endocervical discharge, easily induced cervical bleeding, edema of the cervical ectropion, or 
leucorrhea (> 10 white blood cells per high-power field on microscopic examination of vaginal 
fluid) (Marrazzo and Martin, 2007). Because cervicitis increases the risk of poor pregnancy 
outcome, predicts upper genital tract disease, and is associated with increased shedding of HIV-1 
from cervix, determining the etiology of this condition should be a priority. 
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2. Bacterial vaginosis 
 
2.1 Overview 
Bacterial vaginosis (BV) is the most common vaginal tract syndrome in women of child-
bearing age (Holst et al, 1987), and occurs at a rate between 5% and 50% (Sobel, 2000). It is 
characterized by dramatic shifts in the types and relative proportions of a diverse community of 
bacteria as the vaginal ecosystem changes from a healthy to a diseased state (Eschenbach, 1993-b; 
Fredricks et al, 2005). Because BV is fundamentally a result of changes to the vaginal microbial 
community, several studies focused on the knowledge of how the healthy community is altered in 
its taxonomic composition, community structure and function, in order to understand the etiology of 
BV and develop a successful treatment. 
Up to the 1950s, symptomatic women with Lactobacillary grade III were diagnosed with 
“non-specific vaginitis”, as the microbial etiology of lactobacillary deficiency was still uncertain at 
that time. In 1923, Curtis had described a vaginal discharge syndrome in women and called it the 
“white-discharge” syndrome (Curtis, 1914), then renamed “non-specific vaginitis”. Using culture 
techniques, he associated this syndrome with black-pigmented anaerobes, curved anaerobic motile 
rods, anaerobic cocci and Gram-variable diphtheroidal rods. He also noted a relative death of the 
“Döderlein’s bacillus” in women with this syndrome. Thus, over 80 years ago, it was known that 
significant shifts in the vaginal microbiota were associated with a symptomatic vaginal discharge 
syndrome in women, but many investigators believed that this syndrome was caused by a single 
microorganism. In 1955, Gardner and Dukes isolated a small, pleomorphic Gram-variable 
coccobacillus from women with “non-specific vaginitis”, the condition now known as BV, and 
postulated that this was the primary etiological agent (Gardner and Dukes, 1955). This organism, 
first called Haemophilus vaginalis and then repeatedly renamed, is now classified as Gardnerella 
vaginalis, the sole member of the genus Gardnerella (Greenwood and Pickett, 1979; Piot et al, 
1980). Phylogenetic analysis based on 16S rRNA places Gardnerella in the Gram-positive family 
Bifidobacteriales. In their paper on Haemophilus vaginalis vaginitis, Gardner and Dukes provided 
retrospective evidence that more than one organism is required to establish BV (Gardner and 
Dukes, 1955). They reported that when 15 clinically healthy volunteers were inoculated with 
vaginal material from BV patients, 11 developed BV. However, when 13 volunteers were 
inoculated with pure cultures of G. vaginalis, only one developed BV, suggesting that G. vaginalis 
alone was not sufficient to induce disease and that additional factors/organisms were necessary. 
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Since that time, numerous BV-associated bacteria have been identified using both standard culture 
and cultivation-independent techniques and BV is generally regarded as a polymicrobial disease. 
 
2.2 Etiology and risk factors 
BV represents an imbalance in the ecology of the normal vaginal microflora (McDonald et al, 
2003), characterized by a reduction in the prevalence and concentration of H2O2-producing 
lactobacilli (Eschenbach et al, 1989; Hawes et al, 1996) and an increase in the prevalence and 
concentration of other bacteria, including G. vaginalis, Mycoplasma hominis, Ureaplasma 
urealyticum, Mobiluncus spp., anaerobic Gram-negative rods belonging to the genera Prevotella, 
Porphyromonas and Bacteroides, and anaerobic Peptostreptococcus spp. (Hillier et al, 2008; 
Larsson and Forsum, 2005; Livengood, 2009; Marrazzo, 2003; Srinivasan and Fredricks, 2008; 
Verhelst et al, 2004; Verstraelen et al, 2004). All these organisms are of relatively low virulence. 
Therefore, BV is not caused by the mere presence of the potential pathogens but rather by their 
unrestrained increase in number, reaching cell counts that are 100- to 1000-fold above the normal 
bacterial levels of the vagina (Eschenbach, 1993-a; Forsum et al, 2005; St John et al, 2007). The 
majority of bacterial species (> 99%) have not been cultivated in the laboratory (Hugenholtz et al, 
1998), but molecular approaches now enable their detection. 
Recent studies using cloning and sequencing of the 16S rRNA gene for the identification of 
genital microbiota, have demonstrated a high diversity of organisms in women with BV compared 
with women with normal microflora. Collectively, these studies showed that bacteria that were 
previously unidentified represent a substantial fraction of the BV microbiota in many women 
(Ferris et al, 2004; Fredricks et al, 2005; Hyman et al, 2005; Oakley et al, 2008; Verhelst et al, 
2004; Zozaya-Hinchliffe et al, 2008). Atopobium vaginae, Leptotrichia amnionii, Megasphaera 
spp., Sneathia spp., Eggerthella-like uncultured bacteria, and three newly described members of the 
Clostridiales order (BVAB1, BVAB2 and BVAB3) have been found to have high specificity for 
BV (Ferris et al, 2004; Fredricks et al, 2005); although A. vaginae has also been detected in subjects 
without bacterial vaginosis (Zhou et al, 2004). Moreover, the number of phylotypes found in 
association with BV was statistically significantly greater than the number detected in the presence 
of a normal microbiota (Biagi et al, 2009; Burton and Reid, 2002; Diao et al, 2011; Fredricks et al, 
2005; Vitali et al, 2007). These studies have demonstrated that different subjects with BV have 
different microbial profiles, indicating heterogeneity in the composition of bacterial taxa in women 
with BV. Unlike healthy women, whose bacterial communities are dominated by Lactobacillus 
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spp., women with BV does not possess a single dominant phylotype, but instead had a diverse array 
of vaginal bacteria, often at relatively low abundances. 
The etiology of bacterial vaginosis remains enigmatic. BV does not follow Koch’s postulate 
that a single pathogen is responsible for a specific disease, and many cultivated bacteria linked to 
this condition, especially G. vaginalis, frequently colonize the vagina of healthy women (Sobel, 
1989). Thus, even if G. vaginalis remains one of the most frequently isolated organisms in women 
with BV (Menard et al, 2008), its presence ‘‘per se’’ is not sufficient for the development of BV 
and it probably acts synergistically with other microorganisms to cause the syndrome (Aroutcheva 
et al, 2001-b; Totten et al, 1982). It has never been resolved which microorganisms within the 
mixture associated with BV are essential for its development and maintenance (Hill, 1993), and the 
factors which lead to the decline of the lactobacilli and the overgrowth of other bacteria remain 
unknown (Eschenbach, 1989; Sobel, 1989). Microbial interactions can exert their effect either by 
modifying the environment, so it becomes suitable for another organism, or by releasing particular 
metabolites which influence the growth of other organisms (Atlas and Bartha, 1993). These may, in 
turn, contribute to the pathogenesis of BV. 
In 1999, Pybus and Onderdonk reviewed the positive interactions among three 
microorganisms that were recognized as being significantly associated to BV: G. vaginalis, 
anaerobes, and M. hominis (Pybus and Onderdonk, 1999). They highlighted that both M. hominis 
and G. vaginalis could be either dependent on nutrients produced by the BV-associated microflora 
which precede them in colonizing the vagina or are a consequence of alterations to the vaginal 
environment as a result of BV. Several studies reported that when M. hominis and G. vaginalis were 
isolated from the female genital tract they were invariably associated with anaerobic organisms, 
suggesting that their presence in the vagina is dependent on other BV-associated bacteria (Blanco et 
al, 1983; Hill et al, 1985; Holst et al, 1987; Rosenstein et al, 1996). Further analysis regarded the 
identification of specific nutritional pathways involving BV-related organisms, to support their 
interactions. Chen et al hypothesized a commensal relationship between G. vaginalis and 
anaerobes, such that amino and keto acids, especially pyruvate, produced by G. vaginalis are 
utilized by anaerobes (Chen et al, 1979). Furthermore, they demonstrated the production of the 
volatile amines putrescine and cadaverine by metronidazole-resistant organisms. Pybus and 
Onderdonk suggested the existence of a commensal relationship between Prevotella bivia and both 
G. vaginalis (Pybus and Onderdonk, 1997) and Peptostreptococcus anaerobius (Pybus and 
Onderdonk, 1998). They reported that the growth of the two microorganisms was stimulated in P. 
bivia-conditioned supernatants, as G. vaginalis utilizes ammonia, and P. anaerobius utilizes 
aminoacids, both produced by P. bivia. In addition, it was postulated that anaerobes, via the 
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production of the alkaline metabolites amines and ammonia, could raise the pH of the vaginal 
environment and thus encourage the growth of G. vaginalis (Chen et al, 1979; Spiegel et al, 1980). 
Therefore, the massive overgrowth of vaginal anaerobes is associated with increased production of 
proteolytic carboxylase enzymes, which act to break down vaginal peptides to a variety of amines 
(trimethylamine, putrescine, and cadaverine), which, in high pH, become volatile and malodorous 
(Figure 7). The amines are associated with increased vaginal transudation and squamous epithelial 
cell exfoliation, creating the typical discharge. In conditions of elevated pH, G. vaginalis more 
efficiently adheres to the exfoliating epithelial cells, creating clue cells. Amines further provide a 
suitable substrate for M. hominis growth. What remains unknown is whether the loss of lactobacilli 
precedes or follows this massive disturbance in the microflora (Sobel, 2000). 
 
 
Figure 7. Pathophysiology of bacterial vaginosis (Sobel, 2000). 
 
2.2.1. Risk factors 
Numerous epidemiologic investigations have been done to identify factors that increase a 
woman’s risk of BV. The risk of BV is increased in women of African ethnicity (Cherpes et al, 
2008; Klatt et al, 2010; Simhan et al, 2008), and in other women who have no or low amounts of 
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H2O2-producing lactobacilli in the vagina (Hawes et al, 1996). Other risk factors include low 
socioeconomic status, cigarette smoking, douching, menses, use of intrauterine devices, antibiotic 
treatment for another condition, lack of condom use, and acquisition of a new sex partner. In 
general, women with BV have more sex partners and an earlier age of sexual debut than women 
without BV (Cherpes et al, 2008; Fethers et al, 2009; Merchant et al, 1999; Schwebke and 
Desmond, 2005; Schwebke et al, 1999; Verstraelen, 2008; Verstraelen et al, 2010; Yen et al, 2003). 
The fact that many of the high-risk behaviors are also well-established risk factors for 
acquisition of common sexually transmitted infections (STIs) suggests that BV could be transmitted 
sexually (Gardner and Dukes, 1955; Verstraelen, 2008). Additionally, the concordance of BV status 
in monogamous lesbian couples, ranging up to 95% (Berger et al, 1995; Marrazzo et al, 2002-b), 
strongly suggests that BV may be sexually associated, although an infectious correlate has not been 
identified (Schwebke, 2009-b). Since the original transmissible nature of BV was demonstrated by 
Gardner and Dukes in 1955, several studies have confirmed that G. vaginalis and other BV-
associated organisms may be transferred sexually; however, transmission alone does not seem 
enough to cause disease because most of the microorganisms are normally found in low numbers in 
the healthy vagina. The fact that there is no evidence for a decrease in the rates of BV recurrence 
following antibiotic treatment of men sexually involved with affected women is another distinction 
between BV and the common STIs (Verstraelen et al, 2010). In fact, many researchers prefer to 
view BV not as an infection but as a complex microbial imbalance, with a significant role played by 
the indigenous vaginal lactobacilli (Guise et al, 2001; Hay, 2005; Schwiertz et al, 2006). 
 
Five decades of intense research established many risk factors for acquisition of BV; 
however, because of the complexity of BV and lack of a reliable animal model for this condition, its 
exact etiology remains enigmatic. Afterwards the major theories on the etiology of BV are 
described, but none of them on their own can reliably explain the epidemiological data. Instead, BV 
is caused by a complex interaction of multiple factors, which include the numerous components of 
the vaginal microbial ecosystem and their human host, and many of them are yet to be characterized 
(Turovskiy et al, 2011). 
2.2.2. The “Gardnerella vaginalis” theory 
BV was initially thought to be a STI propagated by a bacterium that is now known as G. 
vaginalis. As the polymicrobial nature of BV became evident, the role of this microorganism in the 
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etiology of this condition became less clear. As a result, general interest in G. vaginalis declined in 
the late 1980s, only to re-emerge in recent years as its relationship to BV was re-evaluated. 
The original discovery of G. vaginalis was made by Leopold in 1953 (Leopold, 1953), while 
Gardner and Dukes were the first to describe the microorganism in relation to BV (Gardner and 
Dukes, 1955). The bacterial cell’s morphology, apparent negative reaction to Gram staining, and 
inability to grow on agar media lacking blood convinced these researchers that they were dealing 
with a new Haemophilus species, which they named Haemophilus vaginalis. Afterwards, because 
of its unique cell wall structure and nutritional requirements, the microorganism has been renamed 
several times (Catlin, 1992; Deane et al, 1972; Dunkelberg et al, 1970). Finally, two large 
taxonomic studies evaluating multiple criteria (Greenwood and Pickett, 1980; Piot et al, 1980) 
proposed a new genus named Gardnerella, with G. vaginalis being the only species in it. Due to the 
uncertainties in the taxonomic status of G. vaginalis, its cell wall has been investigated for decades. 
Gardnerella vaginalis is commonly described as a Gram-variable or Gram-uncertain 
microorganism, because its reaction to Gram staining can vary from negative to positive (Catlin, 
1992). It is likely that the age of the culture and the growth conditions may influence the reaction to 
Gram staining, determining fluctuations in thickness of the peptidoglycan layer, which becomes 
thinner as the culture ages (Catlin, 1992; Sadhu et al, 1989). Overall, the cells of G. vaginalis are 
small, pleomorphic rods having average dimensions of 0.4 by 1.0–1.5 µm (Catlin, 1992). The 
bacterium is immotile, with the cells frequently occurring in clumps in vaginal smears and when 
grown in liquid media (Greenwood and Pickett 1980; Taylor-Robinson, 1984). Strands of 
exopolysaccharide produced by cells are presumed to be responsible for the cell clumping effect 
(Catlin, 1992). Recently, the genomes of several G. vaginalis strains were sequenced, providing 
new information about the microorganism. These studies estimated the genome of G. vaginalis to 
be 1.62–1.67 Mb with a low GC content (41–42%) (Yeoman et al, 2010); thus, the bacterium’s 
genome size is relatively small. This, together with its deficiencies in important biochemical 
pathways, are consistent with the parasitic lifestyle of G. vaginalis. Among the other biochemical 
properties, G. vaginalis has a hemolytic activity, which is thought to be mainly due to secretion of 
vaginolysin (VLY). VLY is a cytolysin with specific activity against human erythrocytes, which, in 
vivo, is thought to increase nutrient availability for its producer strain (Yeoman et al, 2010). 
Gardner and Dukes were the first to report that G. vaginalis was isolated from the lower 
genital tract of BV-affected women in 92% of cases, compared to a 0% isolation rate from healthy 
women (Gardner and Dukes, 1955). Consequently, they hypothesized that the microorganism was 
the only etiological cause of BV (Eschenbach et al, 1989). Subsequent studies found G. vaginalis in 
the vaginas of 14–69% of BV-free women, an incidence that is considerably higher than the 0% 
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originally reported (Cristiano et al, 1989; Gardner and Dukes 1955; Masfari et al, 1986; Mikamo et 
al, 2000; Totten et al, 1982). To explain epidemiological data showing the common occurrence of 
G. vaginalis in healthy women, numerous studies were directed to identify specific virulent 
subtypes of this organism responsible for BV (Aroutcheva et al, 2001-b; Benito et al, 1986; 
Briselden and Hillier, 1990; Piot et al, 1984), but it is still unclear whether any of the biochemical 
characteristics selected for biotyping G. vaginalis are linked to the virulence of the microorganism. 
Genetic subtyping proved to be challenging because of the great variability in the DNA sequence of 
different G. vaginalis isolates. Different strains isolated from women with or without BV showed 
genomic differences regarding adherence, aggregation, and cytolysin productions (Harwich et al, 
2010; Yeoman et al, 2010)  
The most interesting factor that might be of importance in the pathogenesis of BV is the 
ability to adhere to the vaginal epithelia and to form biofilms (Harwich et al, 2010). Swidsinski et al 
showed by FISH with specific probes that a characteristic dense biofilm in confluent or patchy 
layers was attached to the epithelial surface in 90% of the vaginal biopsies of patients with BV 
(Swidsinski et al, 2005; Swidsinski et al, 2008). Bacteria within the biofilm were calculated to 
reach concentrations of nearly 10
11
 per mL; Gardnerella were the predominant bacteria, while 
Atopobium were present in 80% and contributed up to 40% of the biofilm mass. It was shown that 
the classical clue cells were desquamated cells from the biofilms (Swidsinski et al, 2005). The 
adherent G. vaginalis biofilm typically resist antibiotic treatment (Swidsinski et al, 2008; 
Swidsinski et al, 2010), which might explain the high recurrence rates of BV. The metabolic 
activities of Gardnerella and other microbes stop during treatment but slowly start again after 
treatment cessation, eventually leading to vaginal discharge and odor that are products of enzymatic 
activities (Hillier et al, 2008). 
In a recent review, Turovskiy et al proposed that, under favorable conditions, BV infection 
can be seeded by G. vaginalis, as well as a group of other microorganisms (including A. vaginae) 
that are relatively tolerant to the healthy vaginal environment, thus allowing the more fastidious 
opportunists to take advantage of the created niche (Turovskiy et al, 2011). 
2.2.3. The “incompetent vaginal lactobacilli” theory 
The role of vaginal lactobacilli as a primary line of defense against various vaginal pathogens 
has been recognized for decades. Accordingly, researchers hypothesized that women affected by 
recurring BV are colonized by Lactobacillus strains that are not particularly competent as 
“defenders”. In 1989, Eschenbach et al were the first to postulate that H2O2 production by vaginal 
lactobacilli is critical for sustainment of healthy vaginal microbiota (Eschenbach et al, 1989). 
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Afterwards, several studies recognized an inverse association between BV and the occurrence of 
vaginal H2O2-producing Lactobacillus spp. (Dimitonova et al, 2007; Hawes et al, 1996; Hillier et 
al, 1992; Hillier et al, 1993-a; Martinez et al, 2008; Nagy et al, 1991). Additionally, the presence of 
many BV-related pathogens including G. vaginalis, P. bivia, Bacteroides spp. and Mobiluncus spp. 
was inversely related to the presence of H2O2-producing Lactobacillus spp. (Hillier et al, 1993-a). 
Therefore, a protective role for the production of H2O2 by vaginal lactobacilli against BV has been 
suggested. 
Multiple studies attempted to model the antagonism between vaginal H2O2-producing 
Lactobacillus spp. and BV-related pathogens in vitro. The great majority of these studies 
demonstrated the inhibitory and⁄or bactericidal properties of vaginal H2O2-producing lactobacilli 
against pathogens (Atassi et al, 2006; Atassi and Servin, 2010); however, the relative contribution 
of the H2O2 produced by the Lactobacillus spp. to the overall antimicrobial effect is still a matter of 
debate. Some in vitro studies tried to quantify the levels of H2O2 produced by the vaginal 
Lactobacillus spp., but the concentration of H2O2 largely depended on oxygen availability, thus 
multiple studies reported undetectable levels of H2O2 in vaginal Lactobacillus cultures grown under 
anaerobic conditions (McLean and McGroarty, 1996; O’Hanlon et al, 2010; Strus et al, 2006). In 
hypoxic conditions, the metabolism of H2O2-producing Lactobacillus strains shifts away from 
production of H2O2 and towards the production of lactic acid, because the enzymes involved in 
these two metabolic pathways compete for NADH (McLean and McGroarty, 1996). 
Some clinical trials also evaluated the efficacy of topical application of H2O2 in restoring the 
microbial balance in BV-affected individuals (Cardone et al, 2003; Chaithongwongwatthana et al, 
2003; Winceslaus and Calver, 1996). It has been reported that intravaginal administration of 
hydrogen peroxide may represent a promising treatment for BV; however, additional clinical trials 
are needed to evaluate the efficacy of this approach. 
It has been demonstrated that H2O2 is an integral part of the natural defenses produced by 
vaginal lactobacilli (Atassi and Servin, 2010). Conversely, the expected levels of H2O2 production 
in the vaginal environment, which is hypoxic, are very low. Therefore, the role of this antimicrobial 
in vivo is still unclear, and the causal relationship between vaginal H2O2-producing Lactobacillus 
spp. and BV is yet to be established. 
2.2.4. The “phage” theory 
Some theories state that the overgrowth of pathogens characteristic to BV has to be preceded 
by a major disturbance within the Lactobacillus population (Blackwell, 1999; Pavlova et al, 1997). 
The resultant decline of lactobacilli allows for a shift in the vaginal microbiota composition. 
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Pavlova et al proposed that bacteriophages could cause a decline in vaginal lactobacilli 
(Pavlova et al, 1997). The involvement of bacteriophages in the etiology of BV would explain why 
this condition is epidemiologically similar to STIs, and yet the rate of its recurrence in women is 
unaffected by an antibiotic treatment of their male partners (Blackwell, 1999). In vivo and in vitro 
studies identified Lactobacillus strains that were phage carriers (lysogens), especially from BV-
affected women (Kilic et al, 2001; Pavlova et al, 1997). Some of these phages were able to infect a 
broad range of Lactobacillus species originating from different women. All the phages identified 
were temperate, but, once released from a bacterial cell, some of these phages would undergo a lytic 
cycle in a different bacterial strain (Kilic et al, 2001; Pavlova et al, 1997). It has been proposed that, 
in vivo, some external factors can induce these normally temperate phages into a lytic cycle 
(Blackwell, 1999; Kilic et al, 2001). For example, a study revealed that the lysogenic Lactobacillus 
strains of vaginal origin can be induced to release phages by cigarette smoke chemicals (Pavlova 
and Tao, 2000). The phage theory of the lactobacilli decline, along with this finding, may explain 
why cigarette smoking is a significant risk factor for BV. 
If bacteriophages truly play a significant role in the etiology of BV, then intravaginal 
installation of phage-resistant probiotic strains could be effective for treatment and prophylaxis of 
this condition (Blackwell, 1999). 
2.2.5. The “altered immunity” theory 
BV-associated pathogens can frequently be detected in the lower genital tract of 
asymptomatic women, and it remains unclear why certain women are unaffected by these pathogens 
while others develop BV. Furthermore, the specific factors determining the severe BV-related 
complications in some women but not in others are also poorly understood (Witkin, et al, 2007-b). 
Currently, many researchers are leaning towards the idea that host immunity is a decisive factor in 
the equation determining the initial development and later course of BV (Forsum et al, 2005; St 
John et al, 2007; Witkin, et al, 2007-b). The main purpose of these studies is to relate the etiology 
of both BV and the associated complications to the differences in the immune response of diverse 
hosts. So far, research primarily targeted components of the innate immune system, because of their 
prominent role in other infectious conditions (Genc and Schantz-Dunn, 2007; Misch and Hawn, 
2008). The innate immune system recognizes pathogen-associated molecular patterns that are non-
variant components of many microbial invaders. Recognition of microorganisms by the innate 
immune system is the initial trigger for a successful antimicrobial immune defense. 
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Witkin et al proposed that BV develops as a result of inhibition of Toll-like receptors (TLR) 
activation and that the negative consequences of BV are facilitated by a decrease in 70-kDa heat 
shock protein (hsp70) production and release and/or inadequate mannose-binding lectin (MBL) 
function (Witkin, et al, 2007-b). TLRs are transmembrane proteins and represent the major 
determinants for the recognition of microbial pathogens and the initiation of immune system 
activation (Janssens and Beyaert, 2003; O’Connell et al, 2005). The binding of an invariant 
microbial component to a specific TLR triggers a sequence of events leading to the selective 
activation of genes coding for pro-inflammatory cytokines (O’Connell et al, 2005). These 
cytokines, in turn, initiate a microbial pathogen-specific immune response. TLRs have been 
identified on a variety of cell types, including epithelial cells in the female genital tract (Abrahams, 
2005; Fazeli et al, 2005). The inducible hsp70 is a newly recognized component of innate 
immunity. Its synthesis is greatly up-regulated under non-physiological conditions, such as 
infection, inflammation, ischemia, and exposure to toxic chemicals. Intracellularly, hsp70 binds to 
other proteins, preventing their denaturation and degradation, but it can also be released from cells 
into the extracellular milieu in response to stress. This extracellular hsp70 functions as an early 
warning signal. By binding to TLRs, hsp70 initiates a nonspecific pro-inflammatory immune 
response to fight any microbial pathogens that might be present (Campisi et al, 2003). MBL 
possesses antimicrobial activity against fungi, bacteria, and viruses. It recognizes and binds to 
specific carbohydrate patterns that are present on the surface of many microorganisms (Babovic-
Vuksanovic et al, 1999). Subsequent to MBL binding to a microbial surface, serine proteases 
associated with MBL are activated and initiate complement system activation (Fujita et al, 2001). In 
addition to being present in serum, MBL has also been identified in vaginal secretions (Babula et al, 
2003), suggesting a role in antimicrobial defense at this site. 
It has been proposed that the bacteria present in the vaginas of healthy women maintain 
vaginal epithelial cell TLR activation at a steady level, resulting in sufficient cytokine production to 
inhibit the proliferation of abnormal BV-associated bacteria. Examination of vaginal secretions of 
women with Lactobacillus-dominant microflora has identified the pro-inflammatory cytokines IL-
1β, TNF-α, and IL-6 in low concentrations (Donders et al, 2003). However, various effector 
molecules, such as bacterial proteases and toxins produced by BV-related bacteria, might inactivate 
TLRs on cervicovaginal epithelia. These compounds can inactivate local immune response through 
a direct degradation of TLRs, by interference with TLR-ligand recognition, or by inducing anti-
inflammatory cytokines, such as IL-10 (Witkin et al, 2007-b). The inactivation of the innate 
immune response would allow unrestrained multiplication of pathogens, manifested as BV. Most 
importantly, it has been suggested that certain polymorphisms in genes coding for innate immune 
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system components, such as TLRs, would make women susceptible to these bacterial molecules and 
therefore vulnerable to BV (Witkin et al, 2007-b). 
The role of intrinsic host factors in the etiology of BV is still unclear, requiring more research 
to be conducted. Moreover, predisposition to BV is probably determined not by a single allele but 
by a specific allelic combination known as a haplotype (Cauci et al, 2007). Nevertheless, it is also 
important to take into account that although heredity may predispose a woman towards BV, the 
condition itself is caused by interaction of intrinsic host factors with the environment. 
2.2.6. The “coitus-induced” theory 
In a recent review, Leppäluoto wrote about the thesis of the “coitus-induced dynamics of 
vaginal bacteriology”, in which the etiology BV is considered in relation to sexual behaviors and 
BV is seen as a physiological phenomenon instead of a sexually transmitted infectious disease 
(Leppäluoto, 2011). He hypothesized that the dual concept of BV as a monobacterial and 
polymicrobial entity may derive from a common physiological etiology. 
The impetus for the physiological concept derived from an observation that spermatozoa were 
frequently seen in the cocci dominant (Leppäluoto, 1971-a) conventional cytologic smear (Wied 
and Bahr, 1959), which also provided a clue to the presence of G. vaginalis (Bergman et al, 1965; 
Gardner and Kaufman, 1969). Studies revealed that in most of the women, after free intravaginal 
deposition of an ejaculate, the dominant Lactobacillus morphotype microflora seen in pre-coital 
smears was replaced by G. vaginalis morphotype dominant microflora in post-coital smears. An 
hypothesis was suggested, that coitus-connected factors would effect a physiological change of the 
vaginal Lactobacillus microflora to a Gardnerella microflora (Leppäluoto, 1971-a). In vivo 
observations on vaginal acidity in relation to intravaginal deposition of an ejaculate indicated that 
the alkalinity of the ejaculate might neutralize the pre-coital high vaginal acidity (Masters and 
Johnson, 1966), which is associated to the Lactobacillus microflora of healthy women. This could 
lead to replacement of the Lactobacillus microflora with Gardnerella microflora, which instead is 
associated with a relatively low acidity (Gardner and Dukes 1955). The pre-coital highly acidic 
environment would then be restored along with a decreasing neutralizing effect of an ejaculate that 
lasted from six to seven up to 16 hours (Masters and Johnson, 1966), with a resultant replacement 
of Gardnerella by Lactobacillus microflora, seen in the pre-coital smears (Leppäluoto, 1971-a; 
Leppäluoto, 1971-b). The biological purpose of the elevated pH of post-coital vaginal acidity 
associated with G. vaginalis microflora, together with immobilization of G. vaginalis bacteria in a 
thin film on the vaginal wall (Gardner and Dukes 1955) and the paucity of leukocytes, could be 
necessary to help protect ejaculated spermatozoa (Leppäluoto, 1989). Accordingly, as a proposed 
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physiological phenomenon, the coitus-induced change of vaginal acidity and microbial ecosystem 
would thus reflect a conditional and reversible event (Leppäluoto, 1971-b). 
The occurrences of BV in virginal adolescent girls (Bump and Buesching, 1988; Vaca et al, 
2010) and in women who have sex with women (Marrazzo et al, 2002-b) could be a result of a 
psychic and/or physical sexual stimulation (Masters and Johnson, 1966). This practice could induce 
and maintain vaginal “lubrication”, a transudation of neutrally acidic vaginal fluid with initial pH 
7.3 (Moghissi, 1979) that would neutralize vaginal acidity to a degree that would favor G. vaginalis 
microflora and BV. 
Leppäluoto also suggested that the dual occurrence of BV as a monobacterial physiological 
entity and as a polymicrobial disease would basically be due to alterations in the vaginal milieu 
attributable to changing sexual habits in the era of the contraceptive pills, rather than to improved 
diagnosis of vaginal microbiology (Leppäluoto, 2011). Oral contraception and the increasingly 
liberal sexual attitudes will have made free deposition of an ejaculate in the vagina much more 
common. Coital acts repeated at short intervals might first have resulted in an incidental post-coital 
Gardnerella microflora and then in a prolonged duration of or repeated change to lower vaginal 
acidity, which could have predisposed to transfer and colonization of predominantly anaerobic 
bacteria, presumably from the perianal region (Holst, 1990). 
The connotation that BV, a common genital condition, is in origin a normal physiological 
state, and not a suspected transmitted sexual disease, would be immensely important to women, in 
terms not just of physical health but also self-esteem and the image of women as individuals in a 
social setting. 
 
2.3 Clinical features and diagnosis 
Clinical presentation of BV is typical. Women have an unpleasant, “fishy-smelling” discharge 
that is more noticeable after intercourse. The discharge is off-white, thin, and homogeneous. 
Erythema and inflammation are usually absent, and most patients are asymptomatic (Sobel, 1997). 
The diagnosis of BV (Centers for Disease Control and Prevention, 2006) is based on clinical 
criteria or Gram stain, which are both fairly subjective and thus complicate research and clinical 
practice. Simple diagnostic criteria established by Amsel et al have proved useful in clinical 
practice (Amsel et al, 1983). At least 3 of the following 4 elements must be present for diagnosis of 
BV: 1) the presence of “clue cells” on microscopic examination, that are vaginal epithelial cells 
heavily coated with bacteria; 2) a thin, homogeneous, milky discharge that smoothly coats the 
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vaginal walls; 3) pH of vaginal fluid > 4.5; 4). a positive whiff test, that is the production of a fishy 
odor when 10% KOH is added to a slide containing vaginal fluid (Amsel et al, 1983). Amsel’s 
criteria, although widely accepted as the best available means to diagnose BV in the clinical setting, 
may fail to identify women with asymptomatic BV.  
Alternatively, BV maybe diagnosed using the Nugent scoring system (Nugent et al, 1991) for 
interpretation of Gram-stained vaginal smears (see paragraph 1.4). This method assesses the number 
of lactobacilli relative to BV-associated bacterial morphotypes in order to characterize vaginal 
microbiota as normal, intermediate or abnormal (BV) (Table 1), and is generally preferred in the 
scientific community (Schwiertz et al, 2006). 
The diagnostic criteria used are a critical issue in studies on the etiology of BV. While 
numerous studies have shown that women with high numbers of Lactobacillus spp. generally do not 
have BV, it is misleading to conclude that women whose vaginal communities contain few or no 
Lactobacillus spp. have BV. Unfortunately, this erroneous belief is the premise of the Nugent 
criteria wherein the degree of “healthiness” is largely influenced by scoring the relative abundance 
of Lactobacillus spp. with typical cell morphology. It can be stated that while high numbers of 
lactobacilli corresponds to a “normal and healthy” microbiota, the converse is not necessarily true, 
that is low numbers of or no lactobacilli does not always correspond to an “unhealthy” ecosystem 
(Forney et al, 2006). Thus, BV is often over-diagnosed by Gram’s staining. This could partly 
account for the reported high incidence of so-called asymptomatic BV in reproductive-age women 
(Eschenbach et al, 1988; Sobel 2000) and could also explain a proportion of BV treatment failures 
and apparent recurrences of BV in women (Hillier and Holmes, 1990; Schwebke and Desmond, 
2007). 
 
2.4 Complications and sequelae 
BV may lead to potentially severe complications and sequelae. A large body of literature 
confirms that BV is associated with considerable gynecologic and obstetric disease (Table 3). 
Several studies have demonstrated an increased risk of abortion in the first trimester and late 
miscarriage, premature ruptures of the membranes, chorioamnionitis, and preterm birth in women 
with BV (Azargoon and Darvishzadeh, 2006; Gibbs, 1993; Hay et al, 1994; Hillier et al, 1995; 
Jacobsson et al, 2002; Llahi-Camp et al, 1996; Ralph et al, 1999). A causal relationship has been 
established also between BV and pelvic inflammatory disease (PID), plasma cell endometritis, 
postpartum fever, post-hysterectomy vaginal-cuff cellulitis, and post-abortion infection 
(MacDermott, 1995; Ness et al, 2005; Oleen-Burket and Hillier, 1995). Moreover, epidemiologic 
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studies have demonstrated that BV is associated with a markedly increased risk for acquisition 
(Cherpes et al, 2003; Martin et al, 1999; Peters et al, 2000; Wiesenfeld et al, 2003) and 
transmission (Cherpes et al, 2005; Cohn et al, 2005; Coleman et al, 2007; Cu-Uvin et al, 2001; Sha 
et al, 2005) of sexually transmitted infections, including HIV (Atashili et al, 2008; Cu-Uvin et al, 
2001; Martin et al, 1999). 
2.4.1. Preterm birth and chorioamnionitis 
The association between BV and preterm birth has been confirmed repeatedly and 
consistently, even if the role of BV itself in the pathogenesis of preterm labor and delivery is not 
well understood (McGregor and French, 2000). A recent meta-analysis study concluded that BV 
more than doubled the risk of preterm delivery in asymptomatic patients and of preterm labor in 
patients with symptoms, and also significantly increased the risk of late miscarriages and maternal 
infection (Leitich and Kiss, 2007). 
A possible explanation to this association involves alterations in the host defense mechanism 
that leads to chorioamnionitis. Chorioamnionitis refers to inflammation of the fetal membranes and 
placental chorion most typically due to an ascending bacterial infection. It is believed that vaginal 
organisms first invade the choriodecidual space (between the maternal tissues and the fetal 
membranes) and then infect the amniotic fluid by crossing intact chorioamniotic membranes 
(Goldenberg et al, 2000). The presence of microbes in the chorioamnion generates a maternal and, 
in some cases, a fetal inflammatory response characterized by the release of pro-inflammatory 
cytokines and chemokines (Hillier et al, 1993-b) that may lead to cervical ripening, membrane 
injury, labor at term or premature birth at earlier gestational ages (Tita and Andrews, 2010). 
Intrauterine infection may result from a chronic infection early in pregnancy that eventually 
becomes symptomatic with contractions and leads to spontaneous abortion or preterm birth 
(Goldenberg et al, 2000). This hypothesis is supported by the results of two studies, which 
confirmed that BV in early pregnancy may be a stronger risk factor for preterm delivery (Hay et al, 
1994; Kurki et al, 1992). 
In most cases of preterm labor and delivery, intrauterine infection is not clinically apparent. 
This might be because many hospital laboratories still use the traditional culturing methods for 
detecting bacterial infections (Han et al, 2009). When molecular methods has been used, then 
bacteria has been found in the membranes of up to 70% of women undergoing elective caesarean 
section at term (Steel et al, 2005). Since these were not cases of preterm birth, these findings 
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suggest that the presence of bacteria in the chorioamnion alone is not always sufficient to cause an 
inflammatory response. It seems that after entering the amniotic cavity, the bacterial numbers must  
 
Table 3. Bacterial vaginosis and adverse pregnancy outcome: patients, methods and results of individual 
studies (Donati et al, 2010). Modified from Leitich and Kiss, 2007. 
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breach some threshold to trigger an intra-amniotic inflammatory response, which in turn induces 
preterm labor (Romero et al, 2002). U. urealyticum, Fusobacterium spp., and M. hominis are the 
bacterial species most commonly isolated from the amniotic cavity of women with preterm labor 
(Gerber et al, 2003; Perni et al, 2004). Other microorganisms found in the amniotic fluid include 
Streptococcus agalactiae, Peptostreptococcus spp., Staphylococcus aureus, G. vaginalis, 
Streptococcus viridians, and Bacteroides spp. (Gardella et al, 2004; Hitti et al, 1997; Oyarzun et al, 
1998). While some of these bacteria have been associated with skin, fecal, and gut microbiota, most 
are related to those found in the human “abnormal” vagina, which can be a potential source of 
infecting organisms (Goldenberg et al, 2008). 
2.4.2. Other gynecologic complications 
Another important complication of BV is spontaneous abortion. Three studies analyzed the 
risk of spontaneous abortion in women with BV and reported that the risk was significant and was 
nearly 10-fold in women with BV. However, more evidence is needed to study this association. 
Vaginal anaerobic microflora has also been incriminated in pelvic inflammatory disease 
(PID), especially in the absence of Chlamydia trachomatis and Neisseria gonorrhoeae (Hillier and 
Holmes, 1999). The relationship of pelvic inflammatory disease to BV has to be established, but it 
has been postulated an association with endometritis, which, in turn, is associated with PID (Hillier 
et al, 1996; Korn et al, 1998; Wiesenfeld et al, 2002). Moreover, vaginal BV-associated anaerobes, 
such as Prevotella spp. and Peptostreptococcus spp. were found in fallopian tube tissue or on 
endometrial biopsy of patients with acute PID (Soper et al, 1994).  
Numerous studies have shown an association of BV with mucopurulent endocervicitis (Moi, 
1990; Paavonen et al, 1986), and with inflammatory changes noted on cervical cytology (Eltabbakh 
et al, 1995). Postoperative infections, including post-abortion PID, post-hysterectomy cuff cellulitis, 
and post-Caesarian endomyometritis, have been shown to be associated with asymptomatic BV 
(Soper et al, 1990). Moreover, preoperative antibiotic prophylaxis that covers BV-associated 
microflora can reduce these complications (Penney et al, 1998). 
2.4.3. Acquisition of sexually transmitted infections 
Numerous longitudinal studies have demonstrated that BV-associated vaginal microbiota is 
related with increased incidence of STIs (Brotman et al, 2010; Cherpes et al, 2003; Martin et al, 
1999; Peipert et al, 2008). BV diagnosed by Nugent score increases the risk of infections by 
Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, HIV, HSV, and Human 
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papillomavirus (Brotman et al, 2010; Cherpes et al, 2003; Watts et al, 2005). Both ulcerative 
(Syphilis, Cancroid, and herpes) and non-ulcerative (Gonorrhea and Chlamydia) STIs have been 
associated with higher rates of transmission and acquisition of HIV (Laga et al, 1993; Wasserheit, 
1992). In the largest longitudinal cohort study to evaluate vaginal microbiota as a risk factor for 
incidence of STIs, the NIH Longitudinal Study of Vaginal Flora (LSVF) study team found that 
intermediate and high Nugent scores were associated with a 1.5- to 2-fold increased risk for incident 
trichomonal, gonococcal, and/or chlamydial infection (Brotman et al, 2010). The LSVF study is 
consistent with other longitudinal studies of vaginal microbiota and STI risk (Cherpes et al, 2003; 
Martin et al, 1999). 
A large randomized trial of home screening of BV to prevent acquisition of STIs is ongoing 
and seeks to determine whether restoring the vaginal microbiota to a stable, low pH, high lactic acid 
and/or Lactobacillus-dominated state may help prevent acquisition of STIs upon exposure (NIAID, 
2011). Only a few molecular studies and, to date, no longitudinal molecular studies have 
investigated the interaction between vaginal microbiota and STIs (Spear et al, 2008). The strong 
interaction between vaginal microbiota and acquisition of STIs has already been highlighted, while 
the details of how the vaginal ecosystem provides protection against STI is still an active area of 
research. The lack of lactic acid–producing bacteria in vaginal microbiota of women with BV in 
addition to the high pH and local cytokine production that accompany BV appear to be the major 
factors affecting STI risk (Hillier, 1998; Redondo-Lopez et al, 1990; Yudin et al, 2003). 
Information obtained from future longitudinal molecular studies may form the basis for new 
intervention strategies to prevent STIs based on the protective features of the vaginal microbiome. 
2.4.4. BV and HIV 
Various evidences suggest that BV may increase the risk of human immunodeficiency virus 
(HIV) acquisition and transmission. It is feasible that absence of H2O2-producing lactobacilli 
increases susceptibility to HIV as well as BV. Alternatively, BV per se may facilitate HIV 
transmission. 
The magnitude of the association between BV and HIV has varied in epidemiological studies. 
Analyses of HIV incidence studies indicate that BV increases the risk of HIV acquisition by 
approximately 60%. In several populations of women studied, BV prevalence was higher, reaching 
rates as high as 70% (Atashili et al, 2008). Studies of HIV prevalence tended to find higher HIV 
prevalence in women with BV, but recent studies have also associated an increased risk of HIV 
acquisition in women with intermediate grades of vaginal microflora (van de Wijgert et al, 2009). 
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A disturbed vaginal ecology caused by BV creates a more permissive environment for 
acquiring HIV (Schmid et al, 2000; Schwebke, 2003; Sha et al, 2005; Watts et al, 2005). The 
depletion of H2O2-producing lactobacilli may reduce vaginal defense against microorganisms, 
including HIV (Hillier, 1998; Schmid et al, 2000), and increases vaginal pH, which makes the 
vaginal environment more favorable for HIV proliferation (Taha et al, 1998). High vaginal pH may 
increase the availability of vaginal HIV target cells (Hill and Anderson, 1992), the adherence and 
survival of HIV (Taha et al, 1998), and intravaginal levels of IL-10, making macrophages more 
susceptible to HIV (Cohen et al, 1999); on the contrary, the levels of secretory leukocyte protease 
inhibitor (SLPI) (Hillier et al, 2004), which has been shown to block HIV infection in vitro (Draper 
et al, 1998), are reduced in BV vaginal fluid. Furthermore, major BV-associated organisms, such as 
G. vaginalis, P. bivia and Peptostreptococcus asaccharolyticus directly upregulate HIV replication 
(Al-Harthi et al, 1999; Hashemi et al, 2000; Simoes et al, 2001; Zariffard et al, 2005). These 
changes, combined with the difficulties of successfully eradicating BV (Wilson, 2004), may explain 
the increased risk observed in most epidemiology studies. 
Moreover, it has been hypothesized that some intravaginal practices, such as the use of cloth 
or paper to wipe out the vagina, the application of products intended to dry or tighten the vagina, or 
the use of soap to clean the vagina, could increase the risk of HIV infection by causing physical 
abrasions or by disrupting the vaginal epithelium and increasing the occurrence of BV (Hilber et al, 
2007; Myer et al, 2005; Shattock and Moore, 2003). 
If these associations are true, then treatment of BV has the potential to decrease the incidence 
of STIs significantly and could have a major impact in the HIV epidemic, especially in Africa and 
other locations where prevalent rates of BV are very high. 
 
2.5 Antibiotic treatment 
The currently recommended treatment regimes for BV are oral or vaginal metronidazole or 
vaginal clindamycin (ACOG Practice Bulletin, 2006). Treatment efficacy is supposed to be high 
(Joesoef and Schmid G, 2004; Kane and Pierce R, 2001), but many women remained colonized by 
BV-associated anaerobes after antibiotic therapy (Boris et al, 1997; Ferris et al, 1995). In clinical 
practice the efficacy is not more than 60% after 4 weeks (Larsson and Forsum, 2005), with a 
recurrence rate of 30–40% (Bannatyne and Smith, 1998; Colli et al, 1997; Eriksson et al, 2005; 
Paavonen et al, 2000). Reasons for recurrence are unclear and include the possibility of reinfection, 
but it more likely reflects vaginal relapse with failure to eradicate the offending organisms and/or 
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failure of the normal protective Lactobacillus-dominant vaginal microflora to reestablish itself 
(Sobel, 2000). 
Lots of studies focused on the evaluation of the success of different antibiotic treatment, but 
often the results were not comparable because the approaches have varied widely from study to 
study (Joesoef and Schmid G, 1995; Sobel, 1997). The major differences among diverse studies 
regarded the diagnostic criteria for BV before or after treatment, the inclusion and exclusion 
criteria, the time of follow-up evaluation after treatment, the design of the study, the dose and 
duration of antibiotic therapy, and the study populations. 
2.5.1. Metronidazole and clindamycin 
The most established method of treating BV is with oral metronidazole. It is employed in a 
number of different therapy regimens most commonly with 400 or 500 mg twice daily for 7 days. 
Alternatively, topical therapy with 2% clindamycin once daily for 7 days or 0.75% metronidazole 
gel once daily for 5 days has been shown to be as effective as oral metronidazole (Ferris et al, 
1995). Two studies compared metronidazole vaginal gel and clindamycin efficacy (Beigi et al, 
2004-a; Ferris et al, 1995). One of them considered a follow-up time of 35–45 days after start of 
treatment and reported a resolution of BV of only 49% vs 48% for treatment with metronidazole 
vaginal gel and clindamycin ovules, respectively (Beigi et al, 2004-a). Management of acute BV 
symptoms during relapse includes oral or vaginal metronidazole or clindamycin, usually prescribed 
for a longer treatment period (10–14 days). However, maintenance antibiotic regimens have had 
largely disappointing results, and new approaches include exogenous Lactobacillus re-colonization 
using suppositories that contain selected bacteria (Sobel, 2000). 
Although both antibiotics have been recommended for the treatment of symptomatic BV, their 
antimicrobial spectrum is not identical. Clindamycin and other macrolides have a broader 
antimicrobial activity against organisms involved in BV, including Mobiluncus spp. and 
Mycoplasma spp. (Barry et al, 1987; Spiegel, 1987; Spiegel et al, 1983-b). Importantly, these 
antibiotics have anti-inflammatory properties (Esterly et al, 1978; Konno et al, 1994; Mikasa et al, 
1992). A study, reported that patients with the highest Nugent score (7-10), in which Mobiluncus 
spp. is frequently found, respond better to clindamycin than those who had intermediate flora 
(Nugent score 4-6) (Lamont et al, 2003; Rosenstein et al, 1996). In vitro studies have demonstrated 
that metronidazole and other nitroimidazoles are largely inactive against G. vaginalis, M. hominis, 
U. urealyticum, and A. vaginae (Ferris et al, 2004; Goldstein et al, 2002; Xiao et al, 2006). Yet, 
metronidazole administration to women with symptomatic BV is associated with a treatment 
success rate similar to clindamycin (Centers for Disease Control and Prevention, 2007). This has 
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been attributed to the activity of the hydroxy metabolite of the drug in vivo, which is effective 
against the organisms involved in BV. Alternatively, metronidazole may change the microbial 
ecosystem by eradicating bacteria susceptible to it; this elicits the lack of nutritional and metabolic 
interactions typical of the BV-associated bacteria, and favors cure of BV (Bradshaw et al, 2006-a; 
Pybus and Onderdonk, 1999). A recent study found that treatment of BV with clindamycin ovules is 
associated with significant development of antimicrobial resistance of anaerobic isolates. The 
anaerobic isolates had 17% baseline resistance to clindamycin, which increased to 53% after 
treatment, while less than 1% of the anaerobic isolates had resistance to metronidazole (Beigi et al, 
2004-a). Thus, clindamycin treatment is questionable from a bacterial ecology point of view and 
metronidazole remains the preferred treatment. 
2.5.2. BV treatment during pregnancy 
BV is associated with late miscarriage and preterm delivery, but the mechanisms involved are 
not yet fully understood. Clinical trials of antibiotic therapy to reduce these complications have 
yielded conflicting results. However, these trials were conducted in mixed populations of pregnant 
women with variable risk profiles for preterm delivery, and investigators used different criteria for 
diagnosis, treated with different antibiotics at different doses and via different routes, and initiated 
treatment at different gestational ages. Due to the heterogeneity of the studies, the results of various 
systematic reviews were limited. 
In general, the results of trials to treat BV in pregnancy have not proved to be effective in 
reducing the incidence of preterm birth; for example, treatment with intravaginal therapy with 2% 
clindamycin increased the incidence of preterm delivery, possibly because of an anti-Lactobacillus 
effect (Koumans et al, 2002). In an review of antibiotics for treating BV in pregnancy it is reported 
that 13 high-quality trials involving 5300 women found that antibiotic treatment was effective in 
eradicating BV in pregnancy but it was not significant in reducing the risk of preterm birth, 
reducing the risk of pPROM, or decreasing the risk of subsequent preterm birth in women with a 
previous preterm birth. Only in women with a previous preterm birth the use of antibiotics was 
associated with decreased risk of pPROM and low birth weight (McDonald et al, 2005). 
BV is present in as many as 15 to 20% of pregnant women; however, most of them do not 
experience preterm birth or postpartum infectious complications. A higher relative risk for preterm 
delivery is found among women with BV early in pregnancy and it is associated with early 
miscarriage in the first trimester; thus it has been proposed that priority should be given to studies 
that examine screening and treatment strategies before pregnancy or in early pregnancy (Koumans 
and Kendrick, 2001). The importance of the timing of antibiotic administration has recently become 
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more apparent because there is evidence that exposure to either bacterial products or bacteria itself, 
may predispose to a subsequent viral infection, and this, in turn, leads to both preterm labor and 
fetal damage (Cardenas et al, 2010). Antimicrobials must be used early enough so that eradication 
of the microorganisms would be followed by resolution of any inflammatory response (Cauci et al, 
2003; Donders et al, 2002; Donders et al, 2003) and its unintended consequences (Gomez et al, 
1998; Gotsch et al, 2007; Kim et al, 2009). 
 
2.6 Probiotics in the treatment of BV 
2.6.1. Definition and general features 
Probiotics are dietary supplements containing potentially beneficial microorganisms. 
According to the currently adopted definition by FAO/WHO, probiotics are: “Live microorganisms 
which when administered in adequate amounts confer a health benefit on the host” (FAO/WHO, 
2001). The most common type of microorganisms used are usually lactic acid producers, in 
particular strains of the genera Lactobacillus and Bifidobacterium (Tannock, 2005). 
The rationale for the use of probiotics is based on the gastrointestinal and genitourinary 
regulatory role played by the commensal microflora and the need for restoration of this microbial 
ecosystem after insult. In particular, probiotics were initially developed as dietary supplements to 
assist the gut microbiota to re-establish themselves after such detrimental events. 
An effective probiotic should have the following features: 
 exert a beneficial effect on the host; 
 be non-pathogenic and non-toxic; 
 contain a large number of viable cells; 
 be capable of surviving and metabolizing in the gut; 
 remain viable during storage and use; 
 have good sensory properties; 
 be isolated from the same species as its intended host. 
Health advantages associated with probiotic intake are the following: 
 alleviation of symptoms of lactose intolerance; 
 increase in natural resistance to infectious and inflammatory diseases of the gastrointestinal 
tract, such as Helicobacter pylori infections, acute gastroenteritis, antibiotic-associated 
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diarrhea, travelers’ diarrhea, irritable bowel syndrome, inflammatory bowel disease, pouchitis, 
diverticular disease; 
 suppression of cancer; 
 reduction in serum cholesterol concentrations; 
 improved digestion; 
 stimulation of gastrointestinal immunity (Fuller, 1992; Gibson and Roberfroid, 1995; Gonzalez 
et al, 1995; Saavedra, 1995). 
The mechanisms involved may include the following: 
 a reduced gut pH through stimulation of the lactic acid–producing microflora (Langhendries et 
al, 1995); 
 direct antagonistic effects on pathogens (De Vuyst and Vandamme, 1994; Gibson and Wang, 
1994); 
 competition for binding and receptor sites that pathogens may occupy (Fujiwara et al, 1997); 
 improved immune function and stimulation of appropriate immunemodulatory cells (Isolauri et 
al, 1995); 
 competition for available nutrients and other growth factors. 
There is no published evidence that probiotic supplements are able to replace the body’s 
natural microflora when these have been killed off; indeed bacterial levels in feces disappear within 
days when supplementation ceases. It is hoped, however, that probiotics do form beneficial 
temporary colonies which may assist the body in the same functions as the natural microbiota, while 
allowing the natural microflora time to recover from depletion. The probiotic strains are then 
thought to be progressively replaced by a naturally developed gut microbiota. 
2.6.2. Probiotic lactobacilli in the vaginal ecosystem 
The well-known physiological role played by a normal and stable Lactobacillus-dominated 
microbiota in preventing vaginal infections have raised interest for the potential of bacteriotherapy 
with probiotic lactic bacteria in the setting of urogenital infections. The rationale for urogenital 
probiotics comes from the belief that replenishing the normal microbes will counteract pathogens 
and lead to a return to the Lactobacillus-dominated state found in healthy women.  
In the development of a probiotic product, several properties of the candidate Lactobacillus 
strains should be considered, in order to assure the maintenance of a pathogen-free vaginal 
environment. The characteristics needed for a Lactobacillus strain to serve effectively as a probiotic 
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include avid adherence to epithelial cells, interference with the adhesion of pathogens, and 
production of antimicrobial molecules capable of inhibiting the growth of pathogens (Mastromarino 
et al, 2002). The adherence in an essential factor for the antimicrobial activity of lactobacilli (Reid 
and Sobel, 1987), as it establishes the ability of lactobacilli to colonize the vaginal mucosa (McLean 
and Rosenstein, 2000). It has been suggested to be the result of specific and non-specific binding 
mechanisms, with the latter involving electrostatic or hydrophobic interactions. Thus, cell surface 
charge and hydrophobicity influence the strength of adhesion. In particular, the reduction in surface 
negative electric charge promotes the attachment of several lactobacilli to the cell membrane. In 
vitro evidence indicates that different Lactobacillus strains have varying degrees of adhesion to 
vaginal epithelial cells, with the greatest adhesion among specific strains of L. gasseri, L. brevis and 
L. acidophilus (Mastromarino et al, 2002; McLean and Rosenstein, 2000). Another important 
feature can be the coaggregation activity, that is the capability of a probiotic strain to bind a 
pathogen to block adhesion and/or displace previously adherent pathogens on vaginal epithelial 
cells. The coaggregation could be an important factor in establishing and maintaining a healthy 
ecosystem because of the production of a microenvironment around the pathogen where the 
concentration of inhibiting substances produced by lactobacilli is exacerbated. Finally, for use as 
probiotics in genitourinary tract, lactobacilli must exhibit adequate antibacterial activity. The most 
relevant property in this context is the ability to maintain a vaginal pH ≤ 4.5. This ability depends 
particularly on the number of lactobacilli present to produce lactic acid, re-emphasizing the 
importance of colonization. An acidic vaginal environment is conducive to replication of 
lactobacilli and subsequent production of additional antibacterial substances, including bacteriocin 
and hydrogen peroxide. However, different strains of lactobacilli produce varying amounts of these 
substances (Aroutcheva et al, 2001-a). In addition, lactobacilli may offer protection against 
infections through production of biosurfactants. These substances discourage the growth of 
uropathogens by inhibiting adhesion of microorganisms along uroepithelial cells (Velraeds et al, 
1996). The contribution of these individual antibacterial properties to clinical efficacy is unclear, as 
the properties vary by Lactobacillus strain and by the susceptibility of specific pathogens. Only 
randomized controlled trials can establish the role of lactobacilli in the treatment and prevention of 
bacterial urogenital infections. 
2.6.3. Probiotic lactobacilli against BV 
Probiotic preparations containing lactobacilli represent the most common alternative therapy 
used by women with BV (Nyirjesy et al, 1997).  
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The first example of vaginal probiotics use was that of Stanley Thomas in 1928 following his 
observation that lactobacilli were absent in the presence of gonococci. He reported on two 
experiments, one in vitro and the other in vivo, in which the addition of a thin layer of whey broth 
from a culture of L. acidophilus demonstrated the eradication of Neisseria gonorrhoeae (Thomas, 
1928). Exogenous strains of lactobacilli have then been suggested as a means of establishing or re-
establishing normal vaginal microflora. Of the strains that showed the most promise, a combination 
of two, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 were developed in oral and 
intravaginal formulations. Numerous studies have reported the different attributes of these two 
organisms, with several recent studies further illustrating clinical effectiveness and potential 
application to prevent preterm labor (Reid et al, 2009). Use of oral formulations of these strains has 
been associated with normalization of vaginal lactobacilli within 28 to 60 days after the initiation of 
treatment (Reid and Burton, 2002; Reid et al, 2003). Evidence of fecal and vaginal colonization by 
these strains was observed after 14 days of oral administration (McLean and Rosenstein, 2000). 
With vaginal formulations, local colonization by these strains was noted after 3 days and continued 
to be evident at 12 days (Gardiner et al, 2002; Reid et al, 2001). Other clinical trials presented 
significant variations in the study design and reported different outcomes. Three randomized 
controlled trials reported enhanced cure rates or a reduced recurrence of BV among premenopausal 
women treated with oral (capsules or yogurt) lactobacilli (Anukam et al, 2006-a; Neri et al, 1993; 
Shalev et al, 1996). On the contrary, other four randomized controlled trials found no beneficial 
effect of probiotics in the treatment of BV (Anukam et al, 2006-c; Eriksson et al, 2005; Fredricsson 
et al, 1989; Hallén et al, 1992). The results do not provide sufficient evidence for or against 
recommending probiotics for the treatment of BV. Further clinical trials, including larger samples 
of women with BV, in which lactobacilli are compared either with a placebo or metronidazole, need 
to be conducted before it will be possible to reach definitive conclusions as to whether probiotics 
represent an effective and safe method for treating women with BV. 
Alternatively research might be focused on the predominant lactobacilli strains inhabiting the 
vagina, L. crispatus and L. jensenii. These species intrinsically meet two requirements for use in 
successful probiotic therapy: they are endogenous vaginal lactobacilli, and they adhere to vaginal 
epithelial cells. In addition, they are known to be good producer of H2O2. Strains of probiotic L. 
crispatus CTV-05 have been demonstrated to have high mean adherence to vaginal epithelial cells 
in vitro, and have established vaginal colonization in seven out of nine women when administered 
vaginally. Combined vaginal and rectal colonization by H2O2-producing lactobacilli is associated 
with a four-fold decrease in the incidence of BV (Antonio et al, 2005; Antonio and Hillier, 2003). 
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Vaginal colonization of women with endogenous species may be advantageous in the maintenance 
of a normal microflora and the prevention of sexually transmitted diseases. 
2.6.4. VSL#3 
VSL#3 is a probiotic preparation characterized by a very high bacterial concentration (300 
billion/g), consisting of eight strains of viable lyophilized probiotic bacteria: four strains of 
Lactobacillus (L. casei, L. plantarum, L. acidophilus, L. delbrueckii subsp. bulgaricus), three strains 
of Bifidobacterium (B. longum, B. breve, B. infantis) and one strain of Streptococcus salivarius 
subsp. thermophilus. Rationale for the use of a cocktail containing large numbers of different strains 
has been the concept of high efficacy through a synergistic action of the different strains in the 
mixture. 
Numerous experimental studies have been exerted in the attempt to unravel the precise 
mechanisms by which probiotic bacteria in VSL#3 and their metabolic products (short-chain fatty 
acids, vitamins) exert their beneficial effects. Data obtained from these studies indicate that the 
VSL#3 bacterial strains have immunomodulatory effects. Attenuation of severity of disease activity 
by means of improvement of histologic grading has been described in various animal models 
(Madsen et al, 2001). A decrease of neutrophil tissue influx and activity has also been shown 
(Shibolet et al, 2002). Further, a diminished pro-inflammatory IL-1β, TNF-α, IFN-γ, IL-12, and IL-
8 cytokine production and an enhanced production of the anti-inflammatory cytokine IL-10 have 
been reported (Hart et al, 2004; Jijon et al, 2004; Lammers et al, 2002; Lammers et al, 2003; 
Madsen et al, 2001; Otte and Podolsky, 2004; Ulisse et al, 2001). Coincubation of probiotic 
bacteria with pro-inflammatory stimuli or pathogenic bacteria revealed that probiotic bacteria 
inhibited the pro-inflammatory cytokine production induced by these inflammatory stimuli, and 
further, that probiotics prevented Salmonella-induced damage of the intestinal barrier integrity 
(Lammers et al, 2002; Otte and Podolsky, 2004). Maintenance of the epithelial barrier function is 
necessary for preserving mucosal integrity. Impaired barrier function and increased permeability are 
observed in gastrointestinal diseases (Schmitz et al, 1999). Therefore, reinforcement of the barrier 
function, together with immunomodulatory and metabolic properties, may be central in the 
mechanism of action of probiotic bacteria. The exact mechanisms by which probiotics can influence 
barrier function remain to be elucidated. It is known that certain lactobacilli adhere to mucosal 
surfaces, inhibit the attachment of pathogenic bacteria, and enhance the secretion of mucins, 
improving the mucosal barrier function and decreasing the permeability to macromolecules and 
toxins (Bernet et al, 1994; Mack et al, 1999; Willemsen et al, 2003). Recently it was shown that 
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VSL#3 probiotic bacteria reinforce the barrier function by secreting soluble factors that enhance the 
barrier integrity and by regulating tight junctions (Madsen et al, 2001; Otte and Podolsky, 2004). 
VSL#3 has been widely investigated for inflammatory and functional bowel disorders. In 
particular, clinical trials have been developed to assess the efficacy of VSL#3 in the maintenance 
treatment of patients with ulcerative colitis in remission (Venturi et al, 1999), in the maintenance 
treatment of patients with chronic pouchitis (Gionchetti et al, 2000), in the maintenance of 
antibiotic-induced remission in patients with refractory or recurrent pouchitis (Mimura et al, 2004), 
in the prevention of pouchitis onset in patients operated (Lammers et al, 2005), and in the 
prevention of post-operative recurrence of Crohn’s disease (Gionchetti et al, 2003). In general, 
encouraging results have been obtained from these studies. More than one study reported that fecal 
concentrations of lactobacilli, bifidobacteria and S. thermophilus increased significantly in all 
patients and persisted through the treatment period. Within a few days after the end of the treatment, 
bacterial concentrations of lactobacilli, bifidobacteria and S. thermophilus turned to basal levels, 
whereas no modification of fecal concentrations of Bacteroides, enterococci, coliforms, clostridia 
and total anaerobes and aerobes was observed (Gionchetti et al, 2000; Venturi et al, 1999). These 
data suggest that the effect was not mediated by suppression of endogenous luminal bacteria. 
The ability of several bacterial species to colonize both the gastrointestinal tract and the 
reproductive tract has been demonstrated in several studies (Antonio et al, 2005; El Aila et al, 2009; 
Morelli et al, 2004). Thus, it has been suggested that a healthy gut microbiota contributes to 
protecting against female genitourinary tract infections and that imbalance in the intestinal 
microbiota favors the suppression of lactobacilli, which in turn leads to overgrowth of anaerobes in 
the vagina (Petricevic et al, 2012). In the light of such assumption, oral probiotic products primarily 
designed for the treatment of gastrointestinal disorders, such as VSL#3, could be used for the 
prevention of vaginal tract imbalances and their sequelae. 
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3. Microbial ecology: molecular culture-independent approaches 
 
3.1 From cultivation to molecular techniques 
The characterization of the community composition is the first step in the study of a complex 
bacterial ecosystem. The microbial inhabitants of the female genital tract and the contribution of 
these organisms to health and disease have been investigated for well over a century, yet they 
remain incompletely understood. 
The earliest studies focused on the microbiology of the lower genital tract and relied upon 
growth of bacteria in rich medium and identification based on observable characteristics, such as 
morphology, Gram stain, and arrangement of cells. These investigations led to important insights 
including the identification of lactobacilli as the predominant members of the vaginal ecosystem in 
most women, and to the hypothesis that these organisms might serve protective functions at the 
vaginal mucosal surface. However, only a fraction of microbes can be cultured in the laboratory 
even with the most modern bacteriological techniques, which resulted inadequate to describe the 
true complexity of the vaginal microbiota accurately. In fact, it is now recognized that < 20% of the 
organisms comprising the human microbiome may be cultivatable (Dethlefsen et al, 2007). 
Additionally, culture-based methods are laborious, time-consuming, and prone to statistical and 
methodological errors. Thus, in the last decade many molecular tools have been developed, 
allowing faster and more accurate investigations of complex microbial ecosystems. 
Cultivation-independent techniques bypass the need to grow microbes in culture and rely 
instead upon isolation of DNA from a given 
sample followed by techniques to identify 
individual microbial community members. The 
most efficient culture-independent strategies for 
exploring microbial biodiversity are based on the 
16S ribosomal RNA (rRNA) gene sequence. The 
16S rRNA gene (Figure 8) consists of about 1,500 
nucleotides and contains regions highly conserved 
 
Figure 8. E. coli 16S rRNA secondary structure. 
Position of the 9 hypervariable regions (V1-V9) is 
indicated (Tannock, 1999). 
Microbial ecology: molecular culture-independent approaches 
 
55 
 
among all the bacteria, interspersed with 9 hypervariable regions (V1-V9), that can allow 
identification of different bacterial phylotypes to the genus or species level (Tannock, 1999). 
Sequencing of the 16S rRNA genes has resulted in more than one million small subunit rRNA 
entries, which are available through databases, such as GeneBank, EMBL, Ribosomal Database 
Project (RDP). 
Molecular studies of microbial ecosystems are based on nucleic acid extraction, amplification 
and sequencing of variable regions of the 16S rRNA gene using oligonucleotide primer sequences 
that complement the conserved regions of this gene. The polymerase chain reaction (PCR) 
amplicons represent a sample of all the bacteria present in a specimen, and they can be analyzed in 
several ways to assess community structure. Cloning and sequencing of 16S rRNA genes yields the 
most detailed data and gives significant information about the identity of uncultured bacteria, but is 
laborious, expensive and hardly quantitative. The so-called “fingerprinting techniques” are more 
appropriate and economical to study a complex bacterial community, although they are only semi-
quantitative. Denaturing/temperature gradient gel electrophoresis (D/TGGE) and terminal-
restriction fragment length polymorphism (T-RFLP) are the most important; they are used for 
monitoring community shifts, for example in response to a treatment, or comparing individuals.  
D/TGGE separates the PCR product on the base of sequence differences by subjecting them to the 
activity of a gradient of denaturing chemicals (DGGE) or to an increasing temperature (TGGE). T-
RFLP digests the ampolicons with restriction enzymes, yielding patterns of fragments used for 
identification. Even if limited to genus-level identification of microbes, these studies provides a 
glimpse of the vast, unappreciated diversity of uncultivated bacteria present at the vaginal mucosal 
surface. Other culture-independent approaches frequently applied to characterize environmental 
samples are the real time-PCR and the Fluorescent In-Situ Hybridization (FISH). These are 
quantitative techniques that use specific 16S rRNA-targeted primers and probes, respectively. The 
disadvantage of these quantitative techniques resides in the fact that primers and probes can be 
designed and validated only for bacterial groups which are known, and whose 16S rRNA has been 
sequenced. Moreover, the study consists in one experiment for each probe or primer set. 
16S-based studies have largely confirmed the broad conclusion of Döderlein, that lactobacilli 
are the dominant organisms in the vaginal tract of most healthy premenopausal women, but they 
have also refined that view significantly. The microbiota of the vagina has been revealed as 
considerably more dynamic and complex than previously suspected, with important implications for 
the health of women. 
More recently, the microarrays technology has been applied to the study of the diversity of 
complex ecosystems. Diversity microarrays allow identification of bacterial species in unknown 
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samples. In the majority of the cases they are based on the 16S rRNA gene, but microarrays based 
on other functional genes (rpoB, recA, gyrB, groEL, and atpD) can be used to distinguish between 
closely related bacteria, having a resolution below the species level. Lots of efforts have been made 
to develop a diversity microarray specific for the intestinal tract (Paliy et al, 2009; Palmer et al, 
2007; Rajilic-Stojanovic et al, 2009; Wang et al, 2002). As regards the analysis of vaginal 
microbiota, Dols et al recently developed a PCR-based microarray containing probes that represent 
BV-associated genera, to provide a more insightful diagnosis of this condition (Dols et al, 2011). 
The microarray technology, with its ability to detect and measure thousands of distinct sequences 
simultaneously, has been recognized as a valuable tool to explore and systematically characterize 
complex microbial communities. However, further efforts should be made to develop a microarray 
able to cover the complete diversity of the human vaginal microbiota in health and diseased states, 
in order to fully characterize this complex ecosystem. 
3.1.1. PCR-DGGE 
Genetic fingerprinting techniques provide a pattern or profile of the genetic diversity in a 
microbial community; one of the most used is DGGE (Denaturing Gradient Gel Electrophoresis) 
(Muyzer and Smalla, 1998). 
In DGGE DNA fragments of the same length but with different sequences can be separated 
(Fischer and Lerman, 1983). Separation is based on the decreased electrophoretic mobility of a 
partially melted double-stranded DNA molecule in polyacrylamide gels containing a linear gradient 
of DNA denaturants (a mixture of urea and formamide). The melting of DNA fragments proceeds in 
discrete so-called “melting domains”, that is stretches of base-pairs with an identical melting 
temperature. Once a domain with the lowest melting temperature reaches its melting temperature 
(Tm) at a particular position in the denaturing gradient gel, a transition of a helical to a partially 
melted molecule occurs, and migration of the molecule will practically halt. Sequence variation 
within such domains causes the melting temperatures to differ, and molecules with different 
sequences will stop migrating at different positions in the gel. 
By using DGGE, 50% of the sequence variants can be detected in DNA fragments up to 500 
bp (Myers et al, 1985). This percentage can be increased to nearly 100% by the attachment of a GC-
rich sequence, a so-called GC-clamp, to one side of the DNA fragment (Myers et al, 1985; 
Sheffield et al, 1989). A sequence of G and C is added to the 5’end of one of the PCR primers, co-
amplified and thus introduced into the amplified DNA fragments (Sheffield et al, 1989). The GC-
rich sequence acts as a high melting domain preventing the two DNA strands from complete 
dissociation into single strands. DNA bands in DGGE profiles can be visualized using ethidium 
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bromide. Alternatively, a more sensitive detection method is silver staining (Bassam et al, 1991), 
which permits to identify community members by sequencing of DNA eluted from excised DGGE 
bands. 
Prior to DGGE analysis of DNA fragments it is necessary to determine the melting behavior 
of the DNA fragments. Furthermore, to obtain the best separation of different DNA fragments, it is 
necessary to optimize the gradient and the duration of electrophoresis. The melting behavior of 
DNA fragments, as well as the optimal gradient, can be determined experimentally with 
perpendicular gradient gels. These gels have an increasing gradient of denaturants from left to right, 
perpendicular to the direction of electrophoresis. The electrophoretic pattern will appear as a 
sigmoid-shaped curve: DNA molecules at the left side of the gel, where the concentration of 
denaturants is low, will migrate as double-stranded DNA; at the other side of the gel, where the 
concentration of denaturants is high, the molecules melt into branched molecules as soon as they 
enter the gel and therefore halt; at intermediate concentrations of denaturants, the molecules have 
different degrees of melting, and concomitantly different mobility. The optimal time of 
electrophoresis is determined by parallel gradient electrophoresis. Parallel gradient gels have an 
increasing gradient of denaturants from top to bottom, parallel to the direction of electrophoresis 
and they are used for analyzing multiple samples on the same gel. By using parallel DGGE many 
samples taken at different time intervals during the study can be simultaneously analyzed. 
Limitations of the technique are represented by the possibility to separate only relatively small 
fragments, up to 500 bp (Myers et al, 1985) and the limited number of different DNA fragments 
which can be separated by DGGE. In general, this electrophoretic technique will only display the 
rDNA fragments obtained from the predominant species present in the community. Furthermore, 
co-migration of DNA fragments can be a problem for retrieving clean sequences from individual 
bands. Another problem is the presence in some bacteria of multiple rrn operons with sequence 
micro-heterogeneity, which might lead to an overestimation of the number of bacteria within natural 
communities. Nevertheless, substantial information about the species composition can be obtained 
from very complex microbial communities by DGGE analysis. It can give a direct display of the 
predominant constituents in microbial communities and are remarkably suited to investigate the 
temporal and spatial distribution of bacterial populations. This aspect is certainly the most important 
reason for the popularity of this technique in microbial ecological studies. Other aspects are its 
easiness, reproducibility, reliability, and speed (Muyzer and Smalla, 1998). 
The use of DGGE might be especially interesting to answer questions on the behavior of 
microbial communities or certain “indicator microorganisms” after environmental perturbations in 
the vaginal ecosystem, such as the onset of a vaginal infection or a probiotic/antibiotic treatment. 
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3.1.2. Real-time PCR 
Real-time PCR is a quantitative technique in which the amount of product formed during the 
amplification is monitored during the course of the reaction. By monitoring the fluorescence of dyes 
or probes introduced into the reaction, that is proportional to the amount of product formed, it is 
possible to calculate the number of DNA molecules of the amplified sequence that were initially 
present in the sample. Typical uses of real-time PCR include pathogen detection, gene expression 
analysis, single nucleotide polymorphism (SNP) analysis, and phylogenetic analysis. 
Differently from a traditional PCR reaction, where end-point measurements only distinguish a 
positive from a negative sample but tell nothing about the initial amounts of target molecules, real-
time PCR allows the monitoring of the growth phase of the reaction, thanks to a fluorescent reporter 
that generates a fluorescence signal proportional to the amount of product formed. During the 
growth phase of the reaction response curves are separated on the basis of the difference in their 
initial amounts of template molecules. The difference is quantified by comparing the number of 
amplification cycles required for the samples’ response curves to reach a particular threshold 
fluorescence signal level (CT). The amplification response curves are expected to be parallel in the 
growth phase of the reaction, and the setting of the threshold level is usually made manually. This 
does not affect significantly the differences between CT values, though it affects the values of the 
individual CTs. Thus, comparing individual CT values between experiments should be avoided, and 
one reference per run to which all the other response curves can be related should be included. 
Typically, a standard curve based on serial dilution of a standard, which can be a purified PCR 
product or a purified plasmid that contains the target sequence, is included. The CT values of the 
diluted standards are read out, and plotted versus the logarithm of the samples’ concentrations, 
number of template copies or dilution factor. 
Today fluorescence is exclusively used as the detection method in real-time PCR. Both 
sequence specific probes and non-specific labels are available as reporters. One of the most popular 
dyes is the intercalator SYBR Green I (Zipper et al, 2004). This dye has virtually no fluorescence 
when it is free in solution, but it becomes brightly fluorescent when it binds to double-stranded 
DNA, presumably to the minor groove. In real-time PCR the fluorescence of SYBR Green I 
increases with the amount of double-stranded product formed, hence, the dye is excellent for 
quantitative PCR when samples are compared at the same level of fluorescence in absence of 
interfering DNA. Although minor groove binding dyes show preference for runs of AT base-pairs, 
SYBR Green I is considered sequence non-specific reporters in real-time PCR. It gives rise to 
fluorescence signal in the presence of any double stranded DNA including undesired primer–dimer 
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and non-specific products. It is therefore good practice to control for primer–dimer formation or 
non-specific amplification. This can be done by melting curve analysis after completing the PCR. 
The temperature is gradually increased and the fluorescence is measured as function of temperature. 
The fluorescence decreases gradually with increasing temperature and, when the temperature is 
reached at which the double-stranded DNA strands separate, the dye comes off and the fluorescence 
drops abruptly (Ririe et al, 1997). 
Other kinds of reporter are labeled primers and probes based on nucleic acids or some of their 
synthetic analogues (Costa et al, 2004; Egholm et al, 1992). The dye labels are of two kinds: 
fluorophores with intrinsically strong fluorescence, such as fluorescein and rhodamine derivatives, 
which through structural design are brought into contact with a quencher molecule, and 
fluorophores that change their fluorescence properties upon binding nucleic acids. Examples of 
probes with two dyes are the hydrolysis probes, popularly called Taqman probes (Holland et al, 
1991). The dyes form a donor–acceptor pair, where the donor dye is excited and transfers its energy 
to the acceptor molecule if it is in proximity. Energy transfer and quenching are distance-dependent 
and structural rearrangement of the probe, or, in the case of hydrolysis probes, degradation, change 
the distance between the donor and acceptor and, hence, the fluorescence of the system. 
Real-time PCR is a very useful technique, as it is rapid and reliable, and allows the specific 
quantification of targeted groups of bacteria. However, primers and probes can be designed only for 
bacterial groups which are covered by the reference sequences. Differently from DGGE and the 
other fingerprinting techniques, that can characterize complex bacterial communities, real-time PCR 
yields more complete information on a limited number of selected bacteria. 
 
3.2 Pyrosequencing: a deep sequencing approach 
The molecular techniques used to characterize complex ecosystems were limited in that the 
number of sequences that could be reasonably analyzed by traditional Sanger sequencing is far too 
low to enable a complete understanding of a microbial community structure. Even if diversity 
microarrays are very straightforward techniques to use for comparative community profiling, faster 
and cheaper than high-coverage sequencing, they can only detect taxa that are covered by the 
reference sequences. What microbiologists needed was a “high-throughput” sequencing technique 
that could provide thousands of sequences per specimen at a manageable cost. 
In recent years, next generation sequencing technologies have been developed, allowing the 
massive sequencing of a vast numbers of (partial) 16S rRNA genes from many complex bacterial 
ecosystems, at much lower cost than Sanger's capillary electrophoresis method (Claesson et al, 
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2009). Pyrosequencing is a sequencing-by-synthesis method, based on the detection of the 
pyrophosphate release occurring at the nucleotide incorporation during the sample amplification. 
This technique produces a shorter sequence length than the amplification and cloning approaches 
described earlier, but these shorter sequences are sufficient for identifying bacteria at least at the 
genus level in most cases. The number of reads available enables characterization of individual 
patient’s microbiota to the extent that there is reasonable confidence that the true structure of each 
individual community can be analyzed and compared with the microbiota of other individuals. 
The method first adapted to this purpose was pyrosequencing using the 454 FLX Sequencing 
System, in which hundreds of thousands of beads, each carrying millions of copies of a unique 
single strand DNA molecules, are sequenced in parallel (Spear et al, 2008). The availability of 
computational analysis programs to analyze large numbers of sequences and the drop in the cost of 
high-throughput sequencing, allowed the application of pyrosequencing to many life science fields. 
A key innovation, currently used in comparative studies of microbial communities, is multiplexing. 
In the so-called “barcoded pyrosequencing” each sample is tagged with a unique molecular barcode 
(a short key sequence added during PCR) and can be sequenced together with other barcoded 
samples in the same run (Hamady and Knight, 2009). Using this approach, Ravel et al recently 
reported the results of a pyrosequencing analysis of vaginal specimens from a sample of 400 
healthy women (Ravel et al, 2011). 
 
3.3 The “metagenomic” era 
Despite the advances in understanding the composition of microbial ecosystems brought 
about by pyrosequencing analyses of 16S rRNA sequences, the focus of research in this field may 
be shifting, as experts are suggesting the need for moving away from simply describing the 
microbiota to determining what the organisms are actually doing. One way to gain insight into 
potential functions and activities of microbes without the need of cultivation is the metagenomic 
approach. 
The term metagenomics was first used in the late 1990s, and was defined as the genomic 
analysis of microorganisms by direct extraction and cloning of DNA from an assemblage of 
microorganisms without the necessity for culturing. The availability of “next-generation” 
sequencing technologies have made it such that a cloning step is no longer essential for 
metagenomic projects and now the total microbial community or microbiome (the number and 
relative abundance of microbial species present) and their metagenomes (the microbial functional 
content) can be rapidly defined. Metagenomic studies using shotgun sequencing approaches are 
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being used to identify most of the bacterial genes present in the microbiota at a particular site at a 
specific time. Such data permit the determination of metabolic pathways most common in a chosen 
environment. Moreover, direct measurement of metabolites in samples is possible. An additional 
approach to discovering what the microbiota is doing is transcriptomics, which measures the 
specific mRNAs being produced by the microbiota. Ultimately, proteomic approaches can be used 
to identify and measure the gene products actually being produced by the microbiota (Figure 9). 
The application of all these meta-“omics” approaches will provide an understanding of the overall 
composition and physiology of the vaginal microbiome, as well as the other human microbiomes 
(Zoetendal et al, 2008). 
 
 
 
Figure 9. Schematic representation of the metagenomic and other community-based “omics” approaches 
(Zoetendal et al, 2008). 
 
Metagenomics holds significant promise for increasing our understanding of many microbial 
diseases associated with the human body, especially those considered to be polymicrobial in origin, 
such as BV. Indeed, the landscape of microbial ecology as it relates to human disease has led to the 
National Institutes of Health (NIH) Human Microbiome Project (HMP). The HMP has the overall 
goal of demonstrating the role the human microbiome plays in human health and disease by 
promoting a combined assessment of microbial population structure and of community function. 
This will establish at each body site if there is a “core microbiome” indicative of a healthy status 
and will provide the baseline community structure, which will enable application of Koch’s 
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postulates to previously intractable human diseases. That is, the correlation of microbial community 
structure or microbiome, rather than of a single microorganism, to healthy and diseased states 
(White et al, 2011). 
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4. Rifaximin 
 
Rifaximin (C43H51N3O11, molecular weight 785.9 daltons) is derived from rifamycin, and is a 
structural analogue of rifampin (Figure 10). The unique properties of this medication, including its 
broad spectrum of antimicrobial activity, high fecal concentrations, and low systemic absorption, 
make it an ideal agent for the treatment of gastrointestinal diseases. 
 
 
Figure 10. Chemical structure of Rifaximin. 
 
4.1 Mechanism of action 
Rifaximin is a highly potent inhibitor of bacterial RNA polymerase. It forms a complex with 
the β-subunit of the enzyme (RpoB), resulting in the blockage of the traslocation step that would 
ordinarily follow formation of the first phosphodiester bond during the transcription process 
(McClure and Cech, 1978). 
 
4.2 Metabolism and pharmacokinetics 
Rifaximin is a non-absorbable oral antibiotic that acts locally in the gastrointestinal tract. This 
enhances fecal concentrations of the antibiotic and limit its systemic toxicity, which is comparable 
to placebo (Descombe et al, 1994; Scarpignato and Pelosini, 2006). According to an FDA drug 
advisory briefing, absorption of rifaximin following oral dose is minimal, due to low intestinal 
permeability and poor water solubility; in addition, absorption is decreased by P-glycoprotein efflux 
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pump (FDA, 2010). Consistent with this finding, studies with radio-labeled rifaximin had 
demonstrated < 0.4% of detectable rifaximin dose in blood and urine, undetectable levels in bile and 
breast milk, and 97% recovered unchanged in the stool after oral ingestion (Descombe et al, 1994). 
As a virtually non-absorbed antibiotic, drug interactions with rifaximin are uncommon. 
Despite the fact that rifaximin is related to rifamycin and rifampin, it is not known to have major 
drug interactions through cytochrome P450 (CYP450) enzyme systems. According to the drug 
manufacturer, in vitro data show that rifaximin can induce CYP3A4; however, clinical studies have 
shown no significant effect on drug metabolism by cytochrome P450 isoenzymes (Pentikis et al, 
2007; Trapnell et al, 2007). 
With its lack of systemic absorption, rifaximin is relatively well tolerated drug and is 
associated with a low incidence of adverse events. Clinical trials evaluating rifaximin for several 
gastrointestinal diseases support the safety and tolerance of this medication (Leevy and Phillips, 
2007; Pimentel et al, 2006; Prantera et al, 2006). 
 
4.3 Antimicrobial activity and resistance 
Rifaximin is active against a variety of aerobic and anaerobic Gram-positive and Gram-
negative organisms, as well as protozoa infections (Table I) (Amenta et al, 1999; Gillis et al, 1995; 
Megraud et al, 1994; Ripa et al, 1987). In in vitro and in vivo studies, rifaximin levels in the stool 
were 160 to 250 times higher than MIC90 (4 to 64 µg/ml) for most intestinal pathogens (Jiang and 
DuPont, 2005; Jiang et al, 2000). 
The primary mechanism for developing resistance to rifaximin is chromosomal alteration of 
the drug target, the DNA-dependent RNA polymerase (Scarpignato and Pelosini, 2006; Spratt, 
1994). In vitro data showed that most common organisms to develop resistance to rifaximin are 
aerobic Gram-positive cocci. However, intestinal lumen is predominantly an anaerobic 
environment, theoretically limiting selection of isolates resistant to rifaximin (Scarpignato and 
Pelosini, 2006). In addition, because rifaximin lacks systemic absorption, drug concentrations stay 
well above the MIC of pathogens to disallow for subtherapeutic drug concentrations in the intestine. 
Despite these advantages, and potentially due to rifaximin’s structural relationship to other 
rifamycins, resistance rates for Enterococcus, Bacteroides, Clostridium, and Enterobacteriaceae 
range between 30% to 90% after 5 days of treatment. After rifaximin is stopped, these resistant 
strains tend to disappear within 1 to 12 weeks (De Leo et al, 1986). 
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Culture-dependent analysis of fecal samples showed that the antibiotic did not alter the 
concentration of some major bacterial groups, while it induced an increase in bifidobacteria (Jiang 
and DuPont, 2009). A recent study on the use of rifaximin in the treatment of travelers’ diarrhea 
further confirmed that clinical effectiveness of the antibiotic is not associated with evident 
alterations of the colonic microbiota (Jiang and DuPont, 2009). 
 
4.4 Therapeutic applications 
Since its approval in Italy in 1987, rifaximin has been licensed in over 30 countries for the 
treatment of a variety of gastrointestinal diseases. Rifaximin was approved by the US Food and 
Drug Administration (FDA) in 2004 for the management of travelers’ diarrhea caused by non-
invasive strains of Escherichia coli (Xifaxan, 2010). In 2010, rifaximin received an additional 
labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients 
with advanced liver disease (NDA, 2010). 
4.4.1. Treatment and prevention of travelers’ diarrhea 
The effectiveness of rifaximin as a therapeutic agent for travelers’ diarrhea has been 
demonstrated in several pivotal randomized, double-blind clinical trials. The primary endpoint of 
these trials was the time to last unformed stool (TLUS), defined as the time from the first dose of 
medication to the passage of the last unformed stool, after which patients are declared well. 
Rifaximin has been shown to be more effective than placebo (Steffen et al, 2003) and similar in 
efficacy to traditionally used antibiotics, trimethoprim–sulfamethoxazole (TMP-SMX) (DuPont et 
al, 1998) and ciprofloxacin (DuPont et al, 2001; Taylor et al, 2006), in shortening the duration of 
travelers’ diarrhea. The recommended dosage of rifaximin for the treatment of travelers’ diarrhea 
caused by non-invasive strains of E. coli, including ETEC and EAEC, in patients more than 12 
years of age is 200 mg three times per day for 3 days (DuPont et al, 2009-b). 
Some experts consider antibiotic chemoprophylaxis for travelers’ diarrhea to be unnecessary 
and excessive because of their fears of antimicrobial resistance promotion and potential risk of 
adverse events for a selflimited disease in the majority of travelers’ diarrhea cases. As a gut-
selective antibiotic with minimal systemic toxicity and a lack of drug interactions, rifaximin appears 
to be an ideal prophylactic drug for travelers’ diarrhea (DuPont et al, 2009-a). 
Rifaximin’s bactericidal activity appears to be limited to the lumen of the gastrointestinal 
tract. As a result, rifaximin is less effective in treating invasive bacterial pathogens, such as Shigella 
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spp., Campylobacter jejuni, and Salmonella spp. (Taylor et al, 2006). In contrast, rifaximin’s 
protective effect may extend to even travelers’ diarrhea cases associated with invasive enteric 
pathogens. It has been hypothesized that rifaximin may eradicate invasive diarrheagenic pathogens 
in the gastrointestinal tract prior to mucosal infiltration (DuPont, 2008). 
4.4.2. Clostridium difficile infection (CDI) 
According to the 2010 update on the Clinical Practice Guidelines for CDI in Adults by the 
Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of 
America (IDSA), rifaximin may be a treatment option for the management of patients with multiple 
recurrent episodes of Clostridium difficile infections (Cohen et al, 2010). 
Rifamycins have been considered as a treatment option for CDI on the basis of in vitro 
susceptibility data (Hecht et al, 2007). The high levels of rifaximin that can be achieved in the gut 
are ideal for treatment of CDI. The efficacy of rifaximin has been reported for the treatment of 
refractory or recurrent CDI in several studies (Basu et al, 2010; Garey et al, 2009; Johnson et al, 
2009; Neff et al, 2010), but optimal dosing, duration, and use of rifaximin for CDI is unclear. 
Caution is recommended with use of rifaximin because of the potential for isolates to develop 
resistance. In vitro studies suggest that rifampin resistance predicts rifaximin resistance in C. 
difficile (O’Connor et al, 2008). Prevalence of rifampin resistance in C. difficile may suggest 
limited utility with rifaximin; therefore, the SHEA-IDSA guidelines do not provide an official 
recommendation on its use. 
4.4.3. Irritable bowel syndrome (IBS) 
Irritable bowel syndrome is a chronic gastrointestinal illness estimated to affect between 1% 
and 20% of the general population. IBS can be characterized by constipation and/or diarrhea, 
change in bowel habits, abdominal pain, and bloating. IBS diagnosis is usually a diagnosis of 
exclusion; organic causes of the abdominal symptoms have to be ruled out before the diagnosis of 
IBS is made. Various clinical criteria could be used to diagnose IBS (Brandt et al, 2009). The 
etiology of IBS remains unknown. However, many causes have been proposed, such as changes in 
central and peripheral sensorium, altered intestinal motility, and exaggerated response to stress. 
Additionally, some data suggest that alterations in small intestinal flora and bacterial overgrowth 
may contribute to the pathophysiology of IBS, although available evidence is conflicting (Brandt et 
al, 2009). 
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Symptomatic improvement in IBS symptoms has been demonstrated with tetracyclines and 
fluoroquinolones, with high relapse rates following antibiotic discontinuation (Attar et al, 1999). 
There are concerns about the development of antibiotic resistance with the widespread use of 
antimicrobial agents. Two randomized, double-blind, placebo-controlled trials evaluated the 
efficacy of rifaximin treatment for IBS. Rifaximin patients experienced significantly greater 
symptomatic relief than the placebo group (Sharara et al, 2006). Though, long-term efficacy and 
tolerability data are currently lacking to support use beyond what was studied in short-term trials 
(Brandt et al, 2009). 
4.4.4. Inflammatory bowel disease (IBD) and pouchitis 
An abnormal host immune response associated with a loss of tolerance to the commensal 
intestinal microbiome is believed to play an important role in the pathogenesis of inflammatory 
bowel diseases (IBDs), including Crohn’s disease, ulcerative colitis, and pouchitis (Sartor, 2008). 
As a result, antibiotics such as metronidazole and ciprofloxacin have been used for the medical 
management of IBD. However, despite the potential beneficial effect of prolonged antimicrobial 
therapy in IBD, side effects of these antibiotics limit their extended use. 
As a non-absorbable antibiotic, rifaximin is an attractive alternative, but a lack of well 
designed clinical trials with sufficient power contribute to the difficulty in assessing the efficacy of 
rifaximin for IBD (Guslandi, 2010; Isaacs et al, 2007; Prantera et al, 2006; Shafran and Burgunder, 
2010; Shen et al, 2008). 
4.4.5. Colonic diverticular disease 
Although the majority of individuals with diverticular disease are asymptomatic, 
approximately 20% of patients experience clinical illness and are at risk for complications, such as 
diverticulitis and hemorrhage (Almy and Howel, 1980). Dietary fiber supplementation is considered 
the standard therapy for symptomatic diverticular disease and may prevent complications (Painter 
and Burkitt, 1975). Multiple randomized clinical studies have demonstrated that the addition of 
monthly rifaximin to fiber supplementation may further improve symptoms and prevent 
complications in patients with symptomatic, uncomplicated diverticular disease (Colecchia et al, 
2007; D’Inca et al, 2007; Latella et al, 2003; Papi et al, 1995). 
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4.4.6. Hepatic encephalopathy (HE) 
Hepatic encephalopathy is one of the complications associated with portal hypertension in 
patients with chronic liver disease and cirrhosis. Usually, HE presents as impaired thinking, 
confusion, and behavioral and motor changes. The etiology of HE is poorly understood. One of the 
proposed mechanisms is poor liver ability to remove nitrogenous waste produced by the 
gastrointestinal bacteria. Ammonia is a byproduct of protein catabolism, which is metabolized to 
urea and excreted renally in patients with normal liver function. Patients with HE are not able to 
convert NH3 to urea and have elevated ammonia concentrations in the blood and NH3 accumulation 
in the central nervous system, resulting in impaired neurotransmission (Ryan, 2010). 
In today’s clinical practice, the most frequently administered agents for both treatment of 
overt HE and prevention of recurrent HE episodes are lactulose and rifaximin (Bajaj, 2010). 
Lactulose exerts its effect by catharsis and by increasing conversion of NH3 to the ionized form, 
thereby decreasing its absorption into systemic circulation, leading to increased removal of 
nitrogenous waste via fecal route (Ryan, 2010). An alternative is the use of oral antibiotics to 
decrease the load of ammonia-producing bacteria in the gastrointestinal tract. However, use of 
antibiotics long term is limited due to adverse effects (Blei and Córdoba, 2001). Rifaximin showed 
a limited risk to select resistant bacteria. Multiple small trials investigated efficacy of rifaximin for 
this indication compared with other active control medications or placebo. They reported safety and 
effectivess of rifaximin for the prevention of recurrent HE in patients who also receiving lactulose. 
 
Rifaximin is a broad-spectrum non-absorbed rifamycin antibiotic with an excellent safety 
profile, a lack of drug interactions, and minimal effect on the intestinal microbiome. Thanks to these 
features and to its ability to they induce a favorable anti-inflammatory environment (Brown et al, 
2010), rifaximin appears promising as a therapeutic agent for infections and/or imbalances 
involving other human ecosystems, such as the vaginal microbiota. 
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Project outline 
Bacterial vaginosis (BV) represents a very common imbalance in the ecology of the normal 
vaginal microflora, affecting women of childbearing age (McDonald et al, 2003). It is a 
polymicrobial disorder associated with an increase of the taxonomic richness and diversity of the 
vaginal microbiota (Ling et al, 2010; Oakley et al, 2008), characterized by a reduction in the 
prevalence and concentration of H2O2-producing lactobacilli (Eschenbach et al, 1989; Hawes et al, 
1996) and an increase in the prevalence and concentration of other bacteria, including Gardnerella 
vaginalis, anaerobic Gram-negative rods, anaerobic Gram-positive cocci, Mycoplasma hominis, and 
Mobiluncus spp. (Ling et al, 2011; Turovskiy et al, 2011). The massive overgrowth of vaginal 
anaerobes is associated with increased production of proteolytic carboxylase enzymes, which act to 
break down vaginal peptides to a variety of amines (putrescine, cadaverine and trimethylamine) 
which, at high pH conditions, become volatile and malodorous. The amines are associated with 
increased vaginal transudation and squamous epithelial cell exfoliation, creating the typical 
discharge (Chen et al, 1979, Sobel, 2000). The clinical consequences of BV could be important. 
Indeed, 40% of the cases of spontaneous preterm labor and preterm birth are thought to be 
associated with BV or other types of “abnormal” vaginal microflora (Donders et al, 2011). A large 
body of literature confirms that BV is associated with these and other considerable gynecologic and 
obstetric diseases. Moreover, epidemiologic studies have demonstrated that BV is associated with a 
markedly increased risk for acquisition and transmission of HIV and other sexually transmitted 
infections, including Chlamydia trachomatis, Neisseria gonorrhoeae and Herpes simplex virus 
type-2 infection (Cherpes et al, 2003; Martin et al, 1999; Wiesenfeld et al, 2003). 
The association of lower genital tract infection, such as BV, with an increased risk of preterm 
delivery and preterm rupture of the fetal membranes has recently attracted great interest in the 
pathogenesis of such infection-related mechanisms (Goldenberg et al, 2008; Mattison et al, 2001). 
The mechanisms linking BV with preterm delivery have not been fully identified, but local immune 
response is hypothesized to be crucial (Beigi et al, 2007). Parturition is characterized by cervical 
ripening and myometrial maturation with subsequent uterine contractions leading to cervical 
dilatation and birth (Norwitz et al, 1999). The process of labor displays many of the hallmarks of 
inflammation. Acute inflammatory features, such as increased influx of leucocytes and elevated 
expression of pro-inflammatory cytokines, have been observed in cervical tissues and fetal 
membranes during both term and preterm labor (Challis et al, 2009; Dubicke et al, 2010; Houben et 
al, 2009). 
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BV is considered as a complex microbial imbalance, and is caused by the interaction of multiple 
factors, which include the numerous components of the vaginal microbial ecosystem and their 
human host, and many of them are yet to be characterized (Turovskiy et al, 2011). Due to the 
unknown etiology of BV, it is difficult to find an efficient cure for this condition. The currently 
recommended treatment regimes are oral or vaginal metronidazole or vaginal clindamycin (ACOG 
Practice Bulletin, 2006), but long-term follow-up suggests recurrence rates as high as 58% one year 
after treatment (Bradshaw et al, 2006-a). The reasons for recurrence may include the failure to 
eradicate the offending organisms, due to the formation of a prolific bacterial biofilm adherent to 
the vaginal epithelium (Swidsinski et al, 2005). The main components of this polymicrobial biofilm 
are G. vaginalis and Atopobium vaginae. Other hypothesis for the etiology and recurrence of BV 
may include the incapability of H2O2-producing Lactobacillus strains, which are considered 
competent as “defenders” (Atassi and Servin, 2010), to efficiently recolonize the vaginal 
environment after the antibiotic therapy; the depletion of these lactobacilli strains due to the 
activation of bacteriophages (Pavlova et al, 1997); or an incompetent immune response to BV-
associated pathogens by the host (Witkin, et al, 2007-b). 
The role of a healthy vaginal microbiota is fundamental to protect women from genital tract 
infections and to maintain the natural balance of the vaginal microbial ecosystem, especially during 
pregnancy (Donati et al, 2010). Thus, the high recurrence rates resulting in repeated exposure to 
antibiotics and the emergence of drug-resistant strains suggest a need for alternative therapeutic 
tools. 
A potentially novel way to prevent and to protect against infection-mediated preterm birth is to 
use probiotic bacteria. Probiotics, defined as “live microorganisms which, when administered in 
adequate amounts, confer a health benefit on the host” (FAO/WHO, 2002), are being studied for 
their ability to replenish vaginal lactobacilli and modulate immunity (Reid et al, 2003; Reid et al, 
2005). The ability of several bacterial species to colonize both the gastrointestinal tract and the 
reproductive tract has suggested that a healthy gut microbiota contributes to protecting against 
female genitourinary tract infections and depletion of lactobacilli (Antonio et al, 2005; El Aila et al, 
2009). 
Rifaximin is a semisynthetic rifamycin derivative, with a broad antimicrobial spectrum (Rivkin 
and Gim, 2011; Scarpignato and Pelosini, 2005) and a good safety profile because of its negligible 
grade of systemic absorption. Thanks to its antibacterial activity covering G. vaginalis and other 
pathogens responsible for urogenital infections (Hoover et al, 1993), rifaximin could be a suitable 
alternative for the local treatment of BV. 
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In the present study the impact of a dietary supplementation with the probiotic product VSL#3, 
a mixture of Lactobacillus, Bifidobacterium and Streptococcus strains, on the vaginal microbial 
ecology and immunological profiles of asymptomatic healthy women during late pregnancy, was 
evaluated. The dynamics of the vaginal bacterial communities prior and after the probiotic ingestion 
were assessed by PCR-DGGE and real-time PCR, while the modulation of the cytokine secretion in 
vaginal fluids was measured by Luminex
®
 Immunoassay. Although previous studies demonstrated 
the therapeutic efficacy of VSL#3 in the management of gastrointestinal disorders, this is the first 
study that investigates the indirect effects of this probiotic formula on the vaginal ecosystem. 
Afterward, the impact of two doses of rifaximin vaginal tablets (100 mg and 25 mg) 
administered for different periods (2 days and 5 days), on the vaginal microbiota of 102 European 
patients with BV enrolled in a multicentre, double-blind, randomized, placebo-controlled study was 
assessed. Bacterial DNA extracted from standardized vaginal rinsings was analyzed using the 
culture-independent techniques PCR-DGGE and real-time PCR. 
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Background 
The vaginal microbiota of healthy women consists of a wide variety of anaerobic and aerobic 
bacterial genera and species dominated by the facultative, microaerophilic anaerobic genus 
Lactobacillus (Lidbeck and Nord, 1993). The activity of lactobacilli is essential to protect women 
from genital tract infections and to maintain the natural healthy balance of the vaginal microbial 
ecosystem. This role is particularly important during pregnancy because vaginal infection has been 
claimed as one of the most important mechanisms responsible for preterm birth and perinatal 
complications (Donati et al, 2010). 
The association of lower genital tract infection with an increased risk of preterm delivery and 
preterm rupture of the fetal membranes has recently attracted great interest in the pathogenesis of 
such infection-related mechanisms (Goldenberg et al, 2008; Mattison et al, 2001). Earlier studies 
showed an increased rate of prematurity in women with bacterial vaginosis (BV). The mechanisms 
linking BV with preterm delivery have not been fully identified, but local immune response is 
hypothesized to be crucial (Beigi et al, 2007). Parturition is characterized by cervical ripening and 
myometrial maturation with subsequent uterine contractions leading to cervical dilatation and birth 
(Norwitz et al, 1999). The process of labor displays many of the hallmarks of inflammation. Acute 
inflammatory features, such as increased influx of leucocytes and elevated expression of pro-
inflammatory cytokines, have been observed in cervical tissues and fetal membranes during both 
term and preterm labor (Challis et al, 2009; Dubicke et al, 2010; Houben et al, 2009). 
A potentially novel way to protect against infection-mediated preterm birth is to use probiotic 
bacteria, especially lactobacilli. In addition, administration of probiotics to the mother during 
pregnancy and breast-feeding appears to be a safe and effective mode of enhancing the 
immunoprotective potential of the breast milk and preventing atopic eczema in the infant (Huurre et 
al, 2008; Rautava et al, 2002). 
In the present study the impact of a dietary supplementation with the probiotic product 
VSL#3, a mixture of Lactobacillus, Bifidobacterium and Streptococcus strains, on the vaginal 
microbial ecology and immunological profiles of asymptomatic healthy women during late 
pregnancy was evaluated. The dynamics of the vaginal bacterial communities prior and after the 
probiotic ingestion were assessed by PCR-DGGE and real-time PCR, while the modulation of the 
cytokine secretion in vaginal fluids was measured by Luminex® Immunoassay. This is the first 
study that investigates the indirect effects of this probiotic formula on the vaginal ecosystem. 
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Materials and methods 
Patients, study medication and sample collection 
A pilot, not randomized, controlled and perspective study was conducted. The study protocol 
was approved by the ethical committee of the University of Bari, Italy. Written informed consent 
was obtained from all the participants in the study. A total of 27 healthy pregnant women (21 to 42 
years of age; mean = 32) who had no symptoms of vaginal or urinary tract infection were included 
in the present study (Table 1.1). None of the subjects had received oral or local antimicrobial 
therapy within the previous 2 weeks. The recruited patients were divided into 2 groups: probiotic 
group [P (n=15)], and control group [C (n=12)] on the basis of their availability to consume the 
probiotic product. Patients of the P group consumed 1 sachet once/day of VSL#3 (VSL 
Pharmaceuticals, Fort Lauderdale, FL) for 4 weeks from the 33
rd
 (W33) to the 37
th
 (W37) week of 
gestation. Patients of the C group did not receive any dietary supplementation. VSL#3 sachet 
contains 900 billion viable lyophilized bacteria consisting of 4 strains of Lactobacillus (L. 
paracasei, L. plantarum, L. acidophilus, L. delbrueckii subsp. bulgaricus), 3 strains of 
Bifidobacterium (B. longum, B. breve, B. infantis) and 1 strain of Streptococcus thermophilus. Mid-
vaginal swabs were collected from the women of both P and C groups at the time points W33 and 
W37. Samples were placed in 1 ml of sterile saline and stored immediately at -80°C until use. 
The individual characteristics (age, type of delivery and gestational age at birth) of the women 
enrolled in the present study are reported in Table 1.1. Gestational age was determined by utilizing 
the last menstrual period and earliest ultrasound. 
DNA extraction from vaginal samples 
Frozen vaginal swabs were thawed, mixed by vortex shaker for 1 min and then removed from 
the liquid. The liquid was centrifuged at 10,000 × g for 15 min, and the pellet was washed 3 times 
in saline at 40°C. The pellet was resuspended in 180 μl of enzymatic lysis buffer (20 mM Tris-HCl, 
pH 8, 2 mM EDTA, 1.2% Triton X-100, 20 mg/ml lysozyme) and incubated at 37°C for 30 min. 
Glass beads (200 mg) were added and the sample was mixed by vortexing for 1 min. Total DNA 
was extracted by using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) following the 
protocol “Pretreatment for Gram-positive bacteria”. A slight modification was introduced: a 
centrifugation step (8000 × g for 5 min) was carried out after the incubation with proteinase K to 
remove glass beads. DNA amounts were quantified by using NanoDrop 1000 (Thermo Scientific, 
Wilmington, DE). 
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Table 1.1. Characterization of the subjects included in the study groups. 
Woman N. Age 
Type of 
delivery1 
Gestational age at birth 
    
Probiotic (n = 15)    
1 31 SD 39 week + 6 days 
2 32 CD 40 week + 3 days 
3 39 SD 40 week + 1 day 
4 31 SD 40 week + 2 days 
5 33 SD 40 week + 3 days 
6 30 SD 39 week 
7 33 SD 41 week + 3 days 
8 34 CD 39 week 
9 36 CD 38 week + 4 days 
10 38 SD 38 week + 5 days 
11 42 SD 39 week + 4 days 
12 30 SD 39 week 
13 29 SD 40 week + 2 days 
14 33 CD 39 week + 2 days 
15 25 SD 40 week + 1 day 
    
Control (n = 12)    
16 28 SD 40 week + 6 days 
17 33 SD 39 week + 3 days 
18 33 CD 37 week + 4 days 
19 32 CD 41 week + 3 days 
20 34 SD 40 week 
21 21 SD 39 week + 5 days 
22 30 SD 38 week + 6 days 
23 30 SD 40 week + 2 days 
24 34 CD 39 week + 6 days 
25 38 CD 41 week + 1 days 
26 38 CD 38 week + 5 days 
27 30 SD 40 week + 2 days 
 
1
 SD: spontaneous delivery; CD: caesarean delivery. 
PCR-DGGE and cluster analysis 
The amplification reactions were performed in a Biometra Thermal Cycler T Gradient 
(Biometra, Göttingen, Germany). GoTaq Flexi DNA Polymerase (Promega, Madison, WI) was used 
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as thermostable DNA polymerase. The reaction mixture contained 0.5 μM of each primer, 200 µM 
of each dNTP, 2 mM MgCl2 solution, 1.25 U of GoTaq Flexi DNA Polymerase, 5 μl of Green 
GoTaq Flexi buffer 5×, and 2 μl of the bacterial DNA template (30-40 ng) in a final volume of 25 
μl. The universal primers HDA1-GCclamp and HDA2 for bacteria (Walter et al, 2000) were used to 
amplify a conserved region within the 16S rRNA gene. The thermocycle program consisted of the 
following time and temperature profile: 95°C for 5 min; 30 cycles of 95°C for 30 s, 56°C for 30 s, 
72°C for 60 s; and 72°C for 8 min. The Lactobacillus genus-specific primers Lac1 and Lac2-
GCclamp (Walter et al, 2001) were used to amplify a specific region of the 16S rRNA gene of 
lactobacilli. The amplification program was 95°C for 5 min; 35 cycles of 95°C for 30 s, 61°C for 30 
s, 72°C for 60 s; and 72°C for 8 min. A volume of 8 µl of PCR samples was loaded on DGGE gels, 
containing 30-50% and 25-55% gradients of urea and formamide for universal bacteria and 
lactobacilli amplifications, respectively. DGGE analysis was performed by using the D-Code 
Universal Mutation System Apparatus (Bio-Rad, Los Angeles, CA), as previously described (Vitali 
et al, 2007). Following electrophoresis, the gel was silver stained (Bassam et al, 1991) and scanned 
using a Molecular Imager Gel Doc XR System (Bio-Rad). DGGE gel images were analyzed using 
the FPQuest software version 4.5 (Bio-Rad). In order to compensate for gel-to-gel differences and 
external distortion to electrophoresis, the DGGE patterns were aligned and normalized using an 
external reference marker. The marker for the DGGE analysis with the universal primers for 
bacteria contained PCR amplicons from Bacteroides, Coriobacterium, Enterococcus faecalis, 
Bifidobacterium bifidum, Lactobacillus casei, Acidaminococcus fermentas and Atopobium. The 
marker for the DGGE analysis with Lactobacillus-specific primers contained PCR amplicons from 
L. plantarum, L. paracasei, L. brevis, L. gasseri, L. acidophilus and L. delbrueckii subsp. 
bulgaricus. After normalization, bands were defined for each sample using the appropriate 
densitometric curve. The similarity in the profiles was calculated on the basis of the Pearson 
correlation coefficient with the Ward clustering algorithm. Cluster analysis of the DGGE patterns 
was performed using the FPQuest software. 
Sequencing of DGGE fragment 
The DNA fragment of interest was excised from the denaturing gel with a sterile scalpel, 
washed once in 1× PCR buffer, and incubated in 20 μl of the same buffer overnight at 4°C. Two μl 
of the buffer solution were used as template for PCR reaction. Reamplification of the 16S rRNA 
region was conducted as described above by employing the primers Lac1 and Lac2 (without the 
GC-clamp). The re-amplified fragment was purified using the Wizard SV Gel and PCR Clean-up 
system (Promega), and then subjected to automated sequence analysis of both DNA strands with 
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Lac1 and Lac2. BigDye terminators (ABI-PerkinElmer, Foster City, CA) were used with a 377 
sequencer (ABI). The sequence identity was determined by comparison with the rRNA gene 
sequences deposited in GenBank database using BLAST algorithm 
(www.ncbi.nlm.nih.gov/BLAST). 
Quantitative real-time PCR 
Quantitative PCR was performed in a LightCycler instrument (Roche, Mannheim, Germany) 
and SYBR Green I fluorophore was used to correlate the amount of PCR product with the 
fluorescence signal. Each DNA sample was amplified with different genus- or species-specific 
primer sets targeted to 16S rRNA gene or 16S-23S rRNA spacer region: Bact-0011f/Lab-0677r 
(Heilig et al, 2002) for Lactobacillus, Bif164/Bif662 (Kok et al, 1996) for Bifidobacterium, 
Th1/Th2 (Tilsala-Timisjärvi and Alatossava, 1997) for Streptococcus thermophilus, F-GV1/R-GV3 
(Zariffard et al, 2002) for Gardnerella vaginalis, c-Atopo-f/c-Atopo-r (Matsuki et al, 2004) for 
Atopobium, g-Prevo-f/g-Prevo-r (Matsuki et al, 2002) for Prevotella, VeilloF/VeilloR (Rinttilä et 
al, 2004) for Veillonella. Amplifications were carried out in a final volume of 20 μl containing 0.5 
μM of each primer, 4 μl of LightCycler-FastStart DNA Master SYBR Green I (Roche) and either 2 
μl of template or water (no-template control). 
The thermal cycling conditions were as follows: an initial denaturation step at 95°C for 10 
min followed by 30 (Lactobacillus, Atopobium, G. vaginalis, Veillonella), 35 (Prevotella) or 40 
(Bifidobacterium, S. thermophilus) cycles of denaturation at 95°C for 15 s; primer annealing at 
63°C (Lactobacillus, S. thermophilus), 62°C (Veillonella), or 60°C (Bifidobacterium, Atopobium, 
Prevotella, G. vaginalis) for 20 s; extension at 72°C for 45 s (Lactobacillus, Atopobium, Prevotella, 
G. vaginalis, Veillonella), 30 s (Bifidobacterium), or 15 s (S. thermophilus) and a fluorescence 
acquisition step at 85°C (Lactobacillus, Atopobium, G. vaginalis, Veillonella, S. thermophilus), 
87°C (Prevotella) or 90°C (Bifidobacterium) for 5 s. DNAs extracted from L. acidophilus NCFM, 
B. longum NCC2705, G. vaginalis ATCC 14018, Prevotella bivia ATCC 29303, Veillonella 
parvula ATCC 10790, Atopobium vaginae ATCC BAA-55 and S. thermophilus ATCC 19258 were 
used as standards for PCR quantification. DNAs extracted from vaginal samples were amplified in 
triplicate for each primer set and the mean value was used for statistical analysis. Data were 
expressed as ng of DNA of the targeted genus or species per μg of total DNA extracted from the 
vaginal sample. 
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Bioplex immunoassay 
Cytokine levels were determined using a multiplexed bead immunoassay. Prior to assay, 
vaginal samples were concentrated 10 times with Microcon spin devices (YM3, Millipore 
Corporation, Billerica, MA) and subsequently resuspended in Bio-Plex Assay Buffer. The levels of 
27 immune-mediators, 15 cytokines (IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-
12(p70), IL-13, IL-15, IL-17, IFN-β, TNF-α), 7 chemokines (MCP-1, MIP-1α, MIP-1β, RANTES, 
Eotaxin, IL-8, IP-10) and 5 growth factors (PDGF-BB, FGF basic, G-CSF, GM-CSF, VEGF), were 
measured using the human ultrasensitive cytokine 27-plex antibody bead kit (Bio-Rad). The assays 
were performed in 96-well filter plates, as previously described (Vignali, 2000). Briefly, the filter 
plate was prewetted with washing buffer (Bio-Rad) and the solution was aspirated from the wells 
using a vacuum manifold (Millipore Corporation). Microsphere beads coated with monoclonal 
antibodies against the different target analytes were added to the wells. Samples and standards were 
pipetted into the wells and incubated for 30 min with the beads. The wells were washed using a 
vacuum manifold (Millipore Corporation) and biotinylated secondary antibodies were added. After 
incubation for 30 min, beads were washed then incubated for 10 min with streptavidin-PE 
conjugated to the fluorescent protein, R-phycoerythrin (streptavidin/R-phycoerythrin). After 
washing to remove the unbound streptavidin/R-phycoerythrin, the beads (a minimum of 100 per 
analyte) were analyzed in the Luminex 200 instrument (MiraiBio, Alameda, CA). The Luminex 200 
monitors the spectral properties of the beads to distinguish the different analytes, while 
simultaneously measuring the amount of fluorescence associated with R-phycoerythrin, reported as 
median fluorescence intensity. The concentration of the samples was estimated from the standard 
curve using a fifth-order polynomial equation and expressed as pg/ml after adjusting for the dilution 
factor (Bio-Plex Manager software version 5.0). Samples below the detection limit of the assay 
were recorded as zero, while samples above the upper limit of quantification of the standard curves 
were assigned the highest value of the curve. The intra-assay CV including ultrafiltration and 
immunoassay averaged 19%. Concentrations of cytokines, chemokines and growth factors were 
then converted in pg of the target molecule per μg of total proteins present in the vaginal sample. 
Statistical analysis 
Statistical analysis was performed using SigmaStat (Systat Software, Point Richmond, CA). 
For each subject, variations of the DGGE profiles related to the time points W33 and W37 were 
analyzed by Pearson correlation. Significant differences in the intensity of each DGGE band among 
all vaginal samples and in the amounts of the bacterial genera and species determined by qPCR 
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were searched by using Wilcoxon Signed Rank Test. This test was also used to analyze differences 
in cytokines, chemokines and growth factors. A P value below 0.05 was considered statistically 
significant. 
 
Results 
Bacterial population profiling with PCR-DGGE 
PCR-DGGE analysis with universal primers for bacteria (HDA1-GC/HDA2) was used to 
investigate the stability of the predominant vaginal bacterial communities over a period of 4 weeks 
in the last trimester of pregnancy, from the 33
rd
 (W33) to the 37
th
 (W37) week of gestation, and the 
influence of the oral consumption of the probiotic VSL#3 from W33 to W37 on the predominant 
vaginal microbiota (Figure 1.1). DGGE band profiles displayed a relatively low complexity for both 
probiotic (P) and control (C) groups, as assessed by the richness index. Mean values of the richness 
index were 6.6 at both W33 and W37 for C group and shifted from 8.4 (W33) to 7.4 (W37) for P 
group without significant variations between W33 and W37. Pearson correlation was used to 
calculate the similarity index (SI) between DGGE patterns related to the time points W33 and W37 
for each pregnant woman (Table 1.2). The SI median values of P group and C group were 73% and 
79%, respectively. In particular, 3 women belonging to P group (N. 2, 9 and 10) and only one 
woman belonging to C group (N. 24) showed SI values lower that 50%. For each woman, 
significant differences between DGGE profiles related to W33 and W37 were searched by 
Wilcoxon Signed Rank Test. No significant variations were detected between W33 and W37 in 
control women. Significant differences (P < 0.05) were found for 5/15 (33%) women belonging to 
P group (N. 4, 5, 9, 10, 11). Interestingly, women N. 9 and 10 were the same presenting SIs < 50%. 
These data suggested a potential role of the probiotic formula in modulating the vaginal bacterial 
communities. The peak heights of the DGGE densitometric curves were analyzed using the 
Wilcoxon Signed Rank Test in order to search for significant differences in single species 
abundances between W33 and W37. No significant changes in species abundance were found for 
both P and C groups, even in women N. 4, 5, 9, 10, 11, suggesting that the modulation of the 
vaginal microbiota exerted by the probiotic VSL#3 was not related to a particular bacterial species. 
Cluster analysis confirmed the stability of the vaginal microbiota in the last trimester of pregnancy 
since the DGGE profiles related to the time points W33 and W37 clustered together for all the 
control women, except for the woman N. 24 (Figure 1.1). Four treated women (N. 2, 9, 10 and 15)  
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Table 1.2. Similarity index (SI) of DGGE profiles related to W33 and W37 obtained with universal 
(HDA1/HDA2) and Lactobacillus-specific (Lac1/Lac2) primers. 
Woman N. 
HDA1-GC/HDA2 
SI (%) 
Lac1/Lac2-GC 
SI (%) 
Probiotic (P)   
1 55.2 21.6 
2 28.4 62.0 
3 84.0 84.0 
4 87.7 84.1 
5 78.0 87.8 
6 64.5 68.1 
7 77.2 85.6 
8 88.5 95.5 
9 37.5 86.2 
10 41.3 91.9 
11 95.3 96.6 
12 94.5 93.3 
13 84.7 96.9 
14 94.3 94.3 
15 81.1 44.5 
Control (C)   
16 91.2 90.9 
17 87.8 93.7 
18 81.6 76.9 
19 83.7 91.5 
20 67.7 81.3 
21 87.1 94.3 
22 94.6 74.4 
23 85.3 74.1 
24 25.4 46.0 
25 84.7 84.2 
26 78.3 68.1 
27 84.5 86.3 
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Figure 1.1. PCR-DGGE analysis with universal primers for bacteria. Analysis was conducted on the 
vaginal samples collected at 33
rd
 (W33) and 37
th
 (W37) week of gestation from 15 women administered with 
the probiotic VSL#3 [(P) N. 1-15] and 12 control women [(C) N. 16-27]. N: woman number; W: week of 
gestation; T: type of treatment. (A) PCR-DGGE fingerprints. M, external reference marker. (B) Dendrogram 
of the DGGE profiles shown in panel A. Pearson correlation was used to calculate the similarity in DGGE 
profiles. 
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Figure 1.2. PCR-DGGE analysis with Lactobacillus-specific primers. Analysis was conducted on the 
vaginal samples collected at 33
rd
 (W33) and 37
th
 (W37) week of gestation from 15 women administered with 
the probiotic VSL#3 [(P) N. 1-15] and 12 control women [(C) N. 16-27]. N: woman number; W: week of 
gestation; T: type of treatment. (A) PCR-DGGE fingerprints. M, external reference marker. Band L16 
corresponds to L. helveticus (GenBank accession number: AB571603) (B) Dendrogram of the DGGE 
profiles shown in panel A. Pearson correlation was used to calculate the similarity in DGGE profiles.  
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showed W33 and W37 DGGE profiles not closely related. However, the DGGE patterns of the 
majority of the women administered with VSL#3 grouped according to the subject and not to the 
time point, revealing that the inter-individual variability was higher than the variability induced by 
the probiotic supplementation. 
Because of the importance of lactobacilli in the establishment of a healthy vaginal 
environment (Donati et al, 2010), DGGE analysis with Lactobacillus-specific primer set 
(Lac1/Lac2-GC) was also carried out. This analysis allowed to investigate the variations in 
lactobacilli population occurring physiologically from W33 and W37 and potentially associated 
with the VSL#3 intake (Figure 1.2). Richness indexes ranged from 5.7 (W33) to 5.4 (W37) for P 
group and from 6.3 (W33) to 6.8 (W37) for C group. Mean values of SI were 79% and 80% for P 
and C groups, respectively (Table 1.2). Only 2 women included in P group showed SIs < 50% (N. 1 
and 15). Wilcoxon Signed Rank Test highlighted significant differences between DGGE profiles 
related to W33 and W37 for women N. 7 and 10, accounting for 13% of the women included in P 
group. Comparing this percentage with the 33% obtained by DGGE analysis with HDA1-
GC/HDA2 primer set, the probiotic intake seemed to have a more extended impact on total bacteria 
than lactobacilli. Notably, only for woman N. 10, significant differences were found between W33- 
and W37-related DGGE patterns for both HDA1-GC/HDA2 and Lac1/Lac2-GC primer sets. The 
peak height analysis by Wilcoxon Signed Rank Test allowed to identify a band, denominated L16 
(Figure 1.2), which significantly changed after the probiotic treatment. The sequencing of the DNA 
extracted from this band revealed 100% homology with L. helveticus strains. The nucleotide 
sequence of this DGGE fragment has been deposited in DDBJ Nucleotide Sequence Database under 
the accession number AB571603. L. helveticus was found to be a representative species within 
lactobacilli population since it was detected in 9 women treated with VSL#3 and 2 control women, 
corresponding to a frequency of occurrence of 40.7%. Notably, a general decrease in the intensity of 
L. helveticus band was observed in P group while no variations were appreciable in C group. 
Cluster analysis showed that Lactobacillus-specific DGGE profiles related to the time points W33 
and W37 were closely related for all control women and for the majority of the women 
administered with VSL#3, except for the subjects N. 1 and 15 (Figure 1.2). 
Quantitative variations of vaginal bacterial populations 
Quantitative real-time PCR (qPCR) was performed to analyze changes in concentration of 
Lactobacillus, Bifidobacterium and Streptococcus thermophilus, that were included in the probiotic 
VSL#3, and Gardnerella vaginalis, Atopobium, Prevotella and Veillonella, that are important BV-
associated genera and species (Biagi et al, 2009; Vitali et al, 2007). qPCR efficiency for all assays 
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was between 90% and 110% and correlation coefficients for genomic DNA standards were > 0.99. 
The sensitivity of qPCR assays was 9.1 × 10
-3
, 1.5 × 10
-4
, 3.7 × 10
-4
, 1.7 × 10
-1
, 1.4 × 10
-2
, 4.9 × 10
-
4
, 3.3 × 10
-1
 ng of target DNA for Lactobacillus, Bifidobacterium, S. thermophilus, G. vaginalis, 
Atopobium, Prevotella and Veillonella, respectively. All patients naturally harbored strains 
belonging to Lactobacillus, Bifidobacterium, Atopobium and Prevotella, as demonstrated by the 
presence of these genera in the vaginal samples collected at W33. Woman N. 9 (P group) was the 
only exception lacking lactobacilli at both the 
baseline and after one-month intake of VSL#3 
(Table 1.3). G. vaginalis was found in two 
women belonging to C group (N. 18 and 20) at 
both time points at the concentration of 5.5 × 
10
1
 ± 3.8 (N. 18: W33), 7.5 × 10
1
 ± 4.6 (N. 18: 
W37), 2.2 × 10
2
 ± 1.8 × 10
1
 (N. 20: W33) and 
1.9 × 10
2
 ± 3.2 × 10
1
  (N. 20: W37). S. 
thermophilus and Veillonella were not detected 
in any pregnant woman enrolled in this study. 
Statistical elaboration of qPCR data related to 
Lactobacillus, Bifidobacterium, Atopobium and 
Prevotella was performed to search for 
significant variations of these genera associated 
with the going on of pregnancy or the probiotic 
treatment (Figure 1.3). No significant changes 
in the amounts of these bacteria were found  
Figure 1.3. qPCR evaluation of Lactobacillus (A), 
Bifidobacterium (B), Atopobium (C) and Prevotella 
(D). Analysis was performed on vaginal samples 
collected at 33
rd
 (W33) and 37
th
 (W37) week of 
gestation from pregnant women treated (P) and not 
treated (C) with VSL#3. Data are expressed as ng of 
DNA of the target genus per µg of total bacterial 
DNA extracted from the vaginal sample. The 
diagrams show the mean values with the error bars 
representing the standard deviations.
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Table 1.3. qPCR data of Lactobacillus, Bifidobacterium, Atopobium and Prevotella. 
  
ng of target DNA/µg vaginal genomic DNA (mean ± SD) 
Woman N. Time point Lactobacillus Bifidobacterium Atopobium Prevotella 
Probiotic (P)      
1 W33 2.4 × 10
1
 ± 1.1 1.9 × 10
-2
 ± 7.4 × 10
-3
 3.6 ± 1.5 2.1 × 10
-2
 ± 1.0 × 10
-2
 
 W37 3.0 × 10
1
 ± 3.1 3.1 × 10
-2
 ± 2.7 × 10
-4
 1.3 × 10
1
 ± 6.8 9.1 × 10
-2
 ± 1.6 × 10
-2
 
2 W33 9.6 ± 8.7 × 10
-1
 3.1 × 10
-2
 ± 8.8 × 10
-3
 5.4 × 10
1
 ± 7.4 1.4 × 10
-1
 ± 4.8 × 10
-2
 
 W37 5.9 × 10
-1
 ± 4.9 × 10
-2
 2.4 × 10
-2
 ± 1.2 × 10
-2
 2.4 × 10
1
 ± 1.9 × 10
1
 1.1 × 10
-1
 ± 1.1 × 10
-2
 
3 W33 2.4 × 10
1
 ± 2.9 2.4 × 10
-2
 ± 4.2 × 10
-3
 1.1 × 10
1
 ± 6.0 1.1 × 10
-1
 ± 7.7 × 10
-3
 
 W37 2.2 × 10
1
 ± 2.4 3.0 × 10
-2
 ± 2.4 × 10
-3
 4.0 ± 2.3 5.2 × 10
-2
 ± 8.2 × 10
-3
 
4 W33 2.2 × 10
1
 ± 2.0 6.8 × 10
-2
 ± 8.3 × 10
-3
 4.7 ± 1.9 7.3 × 10
-2
 ± 2.9 × 10
-2
 
 W37 1.5 × 10
1
 ± 1.4 2.1 × 10
-2
 ± 7.2 × 10
-3
 5.2 ± 2.0 4.6 × 10
-2
 ± 9.5 × 10
-3
 
5 W33 2.5 × 10
1
 ± 4.5 2.1 × 10
-2
 ± 3.4 × 10
-3
 1.2 × 10
1
 ± 3.0 9.3 × 10
-2
 ± 8.3 × 10
-3
 
 W37 2.2 × 10
1
 ± 4.5 1.4 × 10
-2
 ± 3.2 × 10
-3
 1.5 × 10
1
 ± 1.9 3.0 × 10
-2
 ± 1.1 × 10
-2
 
6 W33 1.1 × 10
-1
 ± 3.4 × 10
-3
 7.1 × 10
-2
 ± 7.1 × 10
-3
 1.0 × 10
1
 ± 4.1 1.2 × 10
-1
 ± 1.3 × 10
-2
 
 W37 2.2 ± 6.0 × 10
-1
 2.1 ± 1.7 × 10
-1
 2.4 × 10
1
 ± 1.0 × 10
1
 1.5 × 10
-1
 ± 1.2 × 10
-2
 
7 W33 4.1 × 10
1
 ± 8.5 3.7 × 10
-2
 ± 5.4 × 10
-3
 2.9 × 10
1
 ± 9.2 1.2 × 10
-1
 ± 2.1 × 10
-2
 
 W37 2.0 × 10
1
 ± 2.6 1.7 × 10
-2
 ± 4.4 × 10
-3
 2.6 × 10
1
 ± 7.7 1.1 × 10
-1
 ± 1.1 × 10
-3
 
8 W33 1.0 × 10
1
 ± 1.7 × 10
-1
 1.3 × 10
-2
 ± 1.9 × 10
-3
 5.5 ± 1.2 4.2 × 10
-2
 ± 1.9 × 10
-2
 
 W37 2.1 × 10
1
 ± 2.0 1.5 × 10
-2
 ± 2.6 × 10
-3
 1.6 × 10
1
 ± 6.6 5.1 × 10
-2
 ± 3.3 × 10
-3
 
9 W33 0.0 ± 0.0 7.1 × 10
-3
 ± 2.8 × 10
-5
 1.8 × 10
1
 ± 7.1 6.7 × 10
-2
 ± 1.5 × 10
-2
 
 W37 0.0 ± 0.0 1.1 × 10
1
 ± 1.0 1.5 × 10
1
 ± 6.8 2.3 × 10
-1
 ± 8.0 × 10
-2
 
10 W33 6.7 ± 6.1 × 10
-1
 2.0 × 10
-2
 ± 4.8 × 10
-3
 1.4 × 10
1
 ± 4.3 8.6 × 10
-2
 ± 2.0 × 10
-2
 
 W37 1.1 × 10
1
 ± 1.4 2.3 × 10
-2
 ± 1.5 × 10
-2
 1.7 × 10
1
 ± 9.7 8.0 × 10
-2
 ± 2.9 × 10
-2
 
11 W33 2.7 × 10
1
 ± 1.7 2.9 × 10
-3
 ± 1.7 × 10
-3
 2.3 ± 1.8 3.2 × 10
-2
 ± 3.3 × 10
-3
 
 W37 3.0 × 10
1
 ± 5.6 1.3 × 10
-2
 ± 8.5 × 10
-3
 1.3 ± 7.5 × 10
-1
 3.6 × 10
-2
 ± 1.3 × 10
-2
 
12 W33 2.2 ± 5.6 × 10
-1
 1.5 × 10
1
 ± 2.3 1.4 × 10
1
 ± 2.9 2.2 × 10
-1
 ± 2.1 × 10
-2
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 W37 2.0 ± 3.1 × 10
-1
 8.7 ± 5.6 × 10
-1
 1.2 × 10
1
 ± 2.3 1.0 × 10
-1
 ± 1.8 × 10
-2
 
13 W33 3.7 × 10
1
 ± 5.4 3.0 × 10
-2
 ± 4.5 × 10
-3
 7.0 ± 2.6 × 10
-1
 2.7 × 10
-2
 ± 5.0 × 10
-4
 
 W37 6.6 × 10
1
 ± 5.9 1.1 × 10
-2
 ± 2.2 × 10
-3
 6.8 ± 6.6 × 10
-1
 5.7 × 10
-2
 ± 2.0 × 10
-3
 
14 W33 2.2 × 10
1
 ± 8.5 1.7 × 10
-2
 ± 4.9 × 10
-3
 9.0 ± 4.4 × 10
-1
 6.7 × 10
-2
 ± 6.6 × 10
-3
 
 W37 1.6 × 10
1
 ± 4.9 2.8 × 10
-2
 ± 4.7 × 10
-3
 1.1 × 10
1
 ± 1.1 1.1 × 10
-1
 ± 1.8 × 10
-3
 
15 W33 2.2 × 10
1
 ± 7.1 1.4 × 10
-2
 ± 7.1 × 10
-3
 1.8 × 10
1
 ± 5.6 1.1 × 10
-1
 ± 1.4 × 10
-2
 
 W37 2.8 × 10
1 
± 3.4 4.7 × 10
-3
 ± 2.3 × 10
-3
 1.1 × 10
1
 ± 2.4 × 10
-1
 7.4 × 10
-2
 ± 2.4 × 10
-3
 
Control (C)      
16 W33 5.4 ×10
1
 ± 4.0 2.1 × 10
-2
 ± 5.6 × 10
-3
 1.1 × 10
1
 ± 4.6 6.8 × 10
-2
 ± 1.1 × 10
-2
 
 W37 2.0 × 10
1
 ± 1.7 2.0 × 10
-2
 ± 7.4 × 10
-3
 1.4 × 10
1
 ± 5.0 5.6 × 10
-2
 ± 5.4 × 10
-3
 
17 W33 5.5 ± 5.3 × 10
-1
 6.0 ± 1.6 × 10
-1
 1.2 × 10
1
 ± 4.3 5.9 × 10
-2
 ± 2.3 × 10
-2
 
 W37 1.5 × 10
1
 ± 2.9 9.3 ± 5.3 × 10
-1
 1.9 × 10
1
 ± 8.7 5.4 × 10
-2
 ± 1.0 × 10
-2
 
18 W33 2.6 ± 1.6 × 10
-1
 1.8 ± 3.5 × 10
-2
 1.3 × 10
1
 ± 5.5 8.8 × 10
-2
 ± 1.7 × 10
-2
 
 W37 1.2 × 10
1
 ± 2.0 2.9 ± 7.5 × 10
-2
 3.3 × 10
1
 ± 4.4 4.5 × 10
-2
 ± 2.8 × 10
-3
 
19 W33 7.6 × 10
1
 ± 3.3 × 10
-1
 1.2 ± 7.9 × 10
-3
 1.3 × 10
1
 ± 3.6 1.9 × 10
-1
 ± 3.2 × 10
-3
 
 W37 2.7 × 10
1
 ± 3.8 2.7 × 10
-2
 ± 4.7 × 10
-3
 8.2 ± 4.6 1.1 × 10
-1
 ± 2.6 × 10
-2
 
20 W33 1.6 × 10
1
 ± 1.4 1.1 × 10
1
 ± 1.2 1.2 × 10
1
 ± 5.5 8.6 × 10
-2
 ± 1.5 × 10
-2
 
 W37 1.0 × 10
1
 ± 6.4 × 10
-2
 1.1 × 10
1 
± 1.4 1.2 × 10
1
 ± 4.7 1.1 × 10
-1
 ± 3.1 × 10
-2
 
21 W33 5.6 × 10
1
 ± 8.3 1.7 × 10
-2
 ± 1.7 × 10
-3
 2.1 × 10
1
 ± 1.0 × 10
1
 1.3 × 10
-1
 ± 2.0 × 10
-2
 
 W37 6.4 × 10
1
 ± 1.5 3.3 × 10
-2
 ± 8.7 × 10
-3
 2.2 × 10
1
 ± 1.0 × 10
1
 1.2 × 10
-1
 ± 2.4 × 10
-2
 
22 W33 4.3 × 10
1
 ± 2.0 1.2 × 10
-1
 ± 2.8 × 10
-2
 2.3 × 10
-1
 ± 1.5 × 10
-2
 0.0 ± 0.0 
 W37 6.8 × 10
1
 ± 5.1 2.7 × 10
-2
 ± 6.6 × 10
-3
 1.9 × 10
-1
 ± 2.0 × 10
-2
 0.0 ± 0.0 
23 W33 2.6 × 10
1
 ± 5.6 2.3 × 10
-1
 ± 3.6 × 10
-2
 0.0 ± 0.0 0.0 ± 0.0 
 W37 6.3 × 10
1
 ± 2.0 8.2 × 10
-3
 ± 1.9 × 10
-3
 1.6 × 10
-1
 ± 2.9 × 10
-2
 5.3 × 10
-1
 ± 1.8 × 10
-1
 
24 W33 1.2 × 10
1
 ± 1.0 2.7 × 10
1
 ± 2.1 × 10
-1
 1.8 ± 1.5 × 10
-1
 6.8 × 10
-1
 ± 3.4 × 10
-2
 
 W37 7.5 × 10
1
 ± 3.8 9.7 × 10
-3
 ± 3.7 × 10
-3
 3.7 × 10
-1
 ± 3.4 × 10
-2
 0.0 ± 0.0 
25 W33 6.5 × 10
1
 ± 1.0 × 10
1
 3.0 × 10
-2
 ± 1.0 × 10
-2
 7.5 × 10
-2
 ± 7.5 × 10
-3
 0.0 ± 0.0 
 W37 6.6 × 10
1
 ± 7.1 9.1 × 10
-3
 ± 5.1 × 10
-4
 2.5 × 10
-1
 ± 2.7 × 10
-2
 0.0 ± 0.0 
26 W33 8.5 × 10
1
 ± 6.3 4.4 ± 9.3 × 10
-1
 3.2 × 10
-1
 ± 3.9 × 10
-2
 0.0 ± 0.0 
 W37 5.4 × 10
1
 ± 4.5 2.0 × 10
-2
 ± 6.1 × 10
-4
 3.6 × 10
-1
 ± 4.2 × 10
-2
 0.0 ± 0.0 
27 W33 7.0 × 10
1
 ± 1.5 × 10
1
 3.3 × 10
-2
 ± 4.7 × 10
-3
 2.8 × 10
-1
 ± 2.6 × 10
-2
 0.0 ± 0.0 
 W37 6.6 × 10
1
 ± 3.6 × 10
-1
 2.1 × 10
-2
 ± 1.6 × 10
-2
 4.0 × 10
-1
 ± 3.8 × 10
-2
 0.0 ± 0.0 
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between W33 and W37 in both P and C groups. However, in spite of the lack of statistical 
relevance, a weak modulation was observed for Bifidobacterium and Atopobium. Regarding 
bifidobacteria (Figure 1.3B), a physiological tendency to decrease was observed in vaginal samples 
of control women at the end of the study period (mean value, W33: 4.3 ± 2.2 × 10
-1
; W37: 2.0 ± 1.7 
× 10
-1
). This trend seemed to be counterbalanced in the women consuming VSL#3 since 
bifidobacteria amount slightly increased during the treatment period (mean value, W33: 9.9 × 10
-1
 ± 
1.6 × 10
-1
; W37: 1.4 ± 1.2 × 10
-1
). An opposite trend was observed for Atopobium (Figure 1.3C). 
This genus increased at W37 (mean value, 9.2 ± 3.2) compared to W33 (mean value, 7.0 ± 2.8) in C 
group, while it remained constant after the VSL#3 treatment (mean value, W33: 1.4 × 10
1
 ± 3.8; 
W37: 1.3 × 10
1
 ± 5.2). 
Immunological profiles 
The effect of the probiotic intake on the vaginal immune response was evaluated by 
measuring the levels of 27 cytokines, chemokines and growth factors in the vaginal samples of the 
pregnant women belonging to P and C groups. 
Figure 1.4 shows the cytokines and chemokines whose concentration significantly changed in 
P and C groups during the study period (P < 0.05). In group C, significant reductions at W37 were 
found for 5 mediators, 4 cytokines [IL-4 (mean 
value, W33: 2.8 × 10
-2
 ± 1.5 × 10
-2
; W37: 1.3 × 
10
-2
 ± 6.9 × 10
-3
), IL-7 (mean value, W33: 1.2 × 
10
-1
 ± 8.6 × 10
-2
; W37: 6.1 × 10
-2
 ± 3.5 × 10
-2
), 
IL-9 (mean value, W33: 1.1 ± 5.6 × 10
-1
; W37: 
3.7 × 10
-1
 ± 1.5 × 10
-1
) and IL-10 (mean value, 
W33: 1.5 × 10
-1
 ± 1.1 × 10
-1
; W37: 9.4 × 10
-2
 ± 
5.4 × 10
-2
)] and 1 chemokine [RANTES (mean 
value, W33: 4.3 ± 2.9; W37: 1.3 ± 3.9 × 10
-1
)]. 
Both IL-4 and IL-10 are produced by Th2 cells 
 
Figure 1.4. Cytokines and chemokines whose 
concentration significantly changed during the study 
period (P < 0.05). P, probiotic group; C, control group; 
W33, 33
rd
 gestational week; W37, 37
th
 gestational 
week. Cytokine or chemokine names are reported in x-
axis. 
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and exert a regulatory role in the immune response. IL-7 and IL-9 are hematopoietic growth factors 
that control proliferation and homeostasis of a variety of hematopoietic cells. RANTES is a pro-
inflammatory chemokine which attracts monocytes, lymphocytes, basophils and eosinophils in the 
inflammatory response. In P group a significant variation was registered only for the chemokine 
Eotaxin, which decreased after the probiotic treatment (mean value, W33: 5.3 ± 8.8; W37: 2.0 ± 
2.1). Eotaxin exerts a pro-inflammatory activity 
by recruiting eosinophils during allergic 
responses. 
Figure 1.5 shows the women, belonging to 
P and C groups, who registered significant 
variations in total levels of immune-mediators 
during the study period (P < 0.05). Significant 
changes were found for women N. 18, 19, 20, 21, 
23, 24, 25 and 27 (8/12; 67%) of C group and 
women N. 1, 2, 3, 10, 11 (5/15; 33%) of P group. 
 
Figure 1.5. Women registering significant variations 
in total levels of immune-mediators. P, probiotic 
group; C, control group; W33, 33
rd
 gestational week; 
W37, 37
th
 gestational week. The identification 
numbers of the women registering significant 
variations are reported in x-axis. 
 
Discussion 
To our knowledge, this is the first study describing the effect of a probiotic mixture, orally 
consumed during the last trimester of pregnancy, on the vaginal microbiota and immune response. 
Although several health-promoting activities of probiotics have been described in relation to the gut 
homeostasis (Hart et al, 2004; Reid et al, 2005), less information is available regarding the 
interactions between orally administered probiotic bacteria and the vaginal microbial habitat. 
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The first step in ascertaining the influence of the dietary supplementation with the probiotic 
VSL#3 on the vaginal ecosystem of pregnant women was the characterization of vaginal bacterial 
communities by using an integrated approach based on PCR-DGGE and qPCR. 
DGGE population profiling, conducted with universal primers for bacteria and Lactobacillus-
specific primers, allowed to investigate the variations of the predominant vaginal bacterial 
communities and lactobacilli species occurring both physiologically in the last trimester of 
pregnancy and potentially associated with VSL#3 intake. The influence of the probiotic intake in 
modulating the predominant bacterial populations and lactobacilli species could be hypothesized 
since significant differences between DGGE profiles at W33 and W37 were found only in women 
belonging to P group. Notably, the lower percentage of women belonging to P group who displayed 
significant differences in Lactobacillus-specific DGGE profiles between W33 and W37, compared 
to the universal bacterial DGGE patterns, suggested a major stability of lactobacilli population and 
a more extended impact of the probiotic VSL#3 on total bacteria than lactobacilli. However, no 
significant changes in single species abundances were found between W33- and W37-related 
universal DGGE profiles. Differently, the statistical analysis of the peak heights of the 
Lactobacillus-specific DGGE densitometric curves allowed to identify a band, corresponding to L. 
helveticus, which significantly decreased after the probiotic treatment. Strains belonging to L. 
helveticus are used as starter cultures in the manufacturing of a variety of fermented dairy products, 
to modulate flavor. The presence of L. helveticus in vagina, likely due to the migration from the gut, 
can be related to a diet rich in yogurt and cheese. This work is not the first describing L. helveticus 
in vaginal samples. Stoyancheva et al identified this species among several Lactobacillus isolates 
from vaginal fluids of healthy Bulgarian women in childbearing age by using three different 
molecular techniques, amplified ribosomal DNA restriction analysis, ribotyping and PCR with 
species-specific primers (Stoyancheva et al, 2006). The decrease of L. helveticus observed in our 
study could be due to a competition between the Lactobacillus strains present in VSL#3 formula 
and dairy L. helveticus strains in colonizing vaginal environment. 
Cluster analysis of universal and Lactobacillus-specific DGGE profiles confirmed the 
stability of the vaginal microbiota in the last trimester of pregnancy since the DGGE profiles related 
to the time points W33 and W37 of the control women were closely related. Also the DGGE 
patterns of the majority of the women administered with VSL#3 grouped according to the subject 
and not to the time point, revealing that the inter-individual variability was higher than variability 
induced by the probiotic supplementation. Thus, the DGGE population profiling suggested the 
ability of the probiotic VSL#3 to modulate the vaginal microbiota, without compromising the inter-
individual species variability. 
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The hypothesis of a positive action of VSL#3 on the vaginal microbiota of pregnant women 
was further supported by qPCR results, which suggested a role of the probiotic product in 
counteracting the decrease of the health-promoting Bifidobacterium genus and the increase of the 
BV-related Atopobium genus, that physiologically occur in late pregnancy. 
The second step of the present research was the investigation of the vaginal immunological 
profiles of the pregnant women in order to search for correlations between the VSL#3 intake and 
changes in vaginal immune response. Pregnancy has been referred to as a state of relative immune 
compromise. This notion has been related to both demonstration of depression of certain aspects of 
cell-mediated immunity and clinical observations of an increased severity of numerous infectious 
conditions in pregnant women (Beigi et al, 2007). On the other hand, preterm cervical ripening can 
be likened to an inflammatory process with cytokines as important mediators (Törnblom et al, 
2005). 
Bioplex immunoassay was used in the present work to measure levels of 27 cytokines, 
chemokines and growth factors in the vaginal samples of the pregnant women belonging to P and C 
groups. In group C a significant reduction at W37 was found for IL-4, IL-7, IL-9, IL-10 and 
RANTES. IL-4 is a key regulator in humoral and adaptive immunity. It has many biological roles, 
including the stimulation of activated B-cells and T-cell proliferation, and the differentiation of 
CD4+ T-cells into Th2 cells. A regulatory role is also exerted by IL-10. In relation to pregnancy, IL-
10 decreases the production of pro-inflammatory cytokines, such as IL-8, IL-6, TNFα, IL-1β and 
prostaglandin E2 in lipopolysaccharide-stimulated fetal membranes (Brown et al, 2000; Fortunato 
et al, 1997). Both IL-4 and IL-10 are produced by Th2 cells. IL-7 and IL-9 are hematopoietic 
growth factors that act as regulators of cell survival, proliferation and homeostasis of a variety of 
hematopoietic cells. RANTES is a potent and versatile chemokine, capable of attracting monocytes, 
lymphocytes, basophils and eosinophils. This cytokine has been implicated in the regulation of the 
inflammatory response and recruitment of macrophages to the implantation site in early pregnancy 
(Athayde et al, 1999). However, no variations in RANTES levels have been associated with 
preterm cervical ripening and labor (Törnblom et al, 2005). Immunological profiles related to the 
women belonging to C group indicated that some fluctuations in vaginal immune-modulators 
occurred physiologically during the last trimester of pregnancy. In particular, it is noteworthy the 
decrease of IL-10 and IL-4, important regulatory cytokines controlling the inflammatory reaction 
responsible for uterine contractions and cervical ripening at the labor time (Dubicke et al, 2010). In 
P group a significant variation was registered only for the chemokine Eotaxin, which decreased 
after the probiotic treatment. Eotaxin selectively recruits eosinophils, and for this reason is 
implicated in allergic responses (Garcia-Zepeda et al, 1996). By comparing the data related to the 
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two study groups, the following hypotheses could be formulated regarding the possible impact of 
the probiotic intake on the cytokine secretion during late pregnancy: probiotics counteracted the 
decrease of anti-inflammatory cytokine levels occurring in C group; probiotics induced the decrease 
of a pro-inflammatory cytokine in P group, showing a global anti-inflammatory effect on the 
vaginal immunity. In addition, a stabilization effect on the vaginal immunity during late pregnancy 
could be attributed to the probiotic intake, since the percentage of women with modified amounts of 
immune-mediators decreased from 67% to 31% in relation to the dietary supplementation. 
The impact of the oral intake of the probiotic VSL#3 on the vaginal microbiota and immune 
response of pregnant women was investigated by molecular fingerprinting techniques (PCR-DGGE 
and qPCR) and Luminex® immunoassay. The major findings of this study are the following: the 
VSL#3 intake seems to be associated with a modulation of the predominant vaginal bacterial 
communities, without compromising the inter-individual species variability; VSL#3 modulation of 
lactobacilli population appears to be related to variations of L. helveticus species; a potential role of 
the probiotic product in counteracting the physiological decrease of Bifidobacterium and increase of 
Atopobium could be hypothesized; the probiotic treatment can be associated with a global anti-
inflammatory effect on the vaginal immunity, with potential implications in preventing preterm 
birth. 
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Background 
Bacterial vaginosis (BV), a common vaginal syndrome affecting pre- and post-menopausal, 
non-pregnant as well as pregnant women, is a complex, polymicrobial disorder associated with an 
increase of the taxonomic richness and diversity of the vaginal microbiota (Ling et al, 2010; Oakley 
et al, 2008). It is characterized by an overgrowth of Gardnerella vaginalis, anaerobic Gram-
negative rods, anaerobic Gram-positive cocci, Mycoplasma hominis, and Mobiluncus spp., and a 
reduction in lactobacilli, particularly those producing hydrogen peroxide (Ling et al, 2010; Ling et 
al, 2011; Turovskiy et al, 2011). The clinical consequences of BV could be important. Indeed, 40% 
of the cases of spontaneous preterm labor and preterm birth are thought to be associated with BV or 
other types of lactobacilli devoid flora (Donders et al, 2011; Pretorius et al, 2007). Furthermore, in 
this state of diminished colonization resistance, BV renders women particularly vulnerable to the 
acquisition of HIV and other sexually transmitted diseases, such as Chlamydia trachomatis, 
Neisseria gonorrhoeae and Herpes simplex virus type-2 infection (Cherpes et al, 2003; Martin et al, 
1999; Wiesenfeld et al, 2003). The diagnosis of BV is based on Amsel’s criteria (Amsel et al, 1983) 
or Nugent score (Nugent et al, 1991) determinations. Current therapy of BV involves effective oral 
or intra-vaginal administration of metronidazole or clindamycin, but long-term follow-up suggests 
recurrence rates as high as 58% one year after treatment (Bradshaw et al, 2006-a). These high 
recurrence rates resulting in repeated exposure to antibiotics and the emergence of drug-resistant 
strains suggest a need for alternative therapeutic tools. 
Rifaximin is a semisynthetic rifamycin derivative, with a broad antimicrobial spectrum 
(Rivkin and Gim, 2011; Scarpignato and Pelosini, 2005) and a good safety profile because of its 
negligible grade of systemic absorption. Thanks to its antibacterial activity covering G. vaginalis 
and other pathogens responsible for urogenital infections (Hoover et al, 1993), rifaximin could be a 
suitable alternative for the local treatment of BV. 
The aim of the study was to evaluate the impact of two doses of rifaximin vaginal tablets (100 
mg and 25 mg) administered for different periods (2 days and 5 days) on the vaginal microbiota of 
women affected by BV. Bacterial DNA extracted from standardized vaginal rinsings was analyzed 
using the culture-independent techniques PCR-DGGE and real-time quantitative PCR (qPCR).  
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Material and methods 
Study population 
The present molecular study was performed on the vaginal fluids collected from 102 patients 
enrolled in a multicentre, double-blind, randomized, placebo-controlled study (EudraCT: 2009-
011826-32). Diagnosis of BV was made using both Amsel’s criteria and Nugent scoring at the 
screening visit (V1). Patients with Nugent score > 3 and positive for at least 3 of 4 Amsel’s criteria 
were included. At the randomization visit (V2), the patients were distributed into 4 treatment 
groups: group A received rifaximin 100 mg vaginal tablet once daily for 5 days, group B received 
rifaximin 25 mg vaginal tablet once daily for 5 days, group C received rifaximin 100 mg vaginal 
tablet once daily for the first 2 days and placebo vaginal tablet for the remaining 3 days, group D 
received placebo vaginal tablet once daily for 5 days. Study medication was administered intra-
vaginally at bedtime. At 7 days after the end of the therapy the first follow-up visit (V3) was 
performed. Patients showing remission according to Amsel’s criteria and Gram stain Nugent score 
attended the second follow-up visit (V4) 28 days after the end of the treatment. Table 2.1 shows the 
distribution of the selected 102 patients into the four treatment groups according to the geographic 
origin and the rate of remission. Rifaximin and placebo vaginal tablets were purchased by Alfa 
Wassermann S.p.A., Bologna, Italy. 
Standardized vaginal rinsings with 2 ml of saline were collected for molecular studies at V1, 
V3 and V4, by flushing and re-aspirating the fluid through a 22 Gauge needle in the left, central and 
right upper vaginal vaults as described elsewhere (Donders et al, 2009). The vaginal rinsings were 
subsequently stored at -80°C until use. 
Extraction of bacterial DNA from vaginal rinsings. 
One ml of vaginal rinsings was centrifuged at 9,500 × g for 15 min, and the pellets washed 
three times in saline at 40°C. Each pellet was resuspended in 180 µl of Enzymatic Lysis Buffer (20 
mM Tris-HCl pH 8, 2 mM EDTA, 1.2% Triton X-100, 20 mg/ml lysozyme) and incubated at 37°C 
for 30 min. Glass beads (200 mg) were added and the sample was mixed by vortexing for 1 min. 
Total DNA was extracted by using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) 
following the protocol “Pretreatment for Gram-positive bacteria”. A slight modification was 
introduced: a centrifugation step (6,000 × g for 5 min) was carried out after the incubation with 
proteinase K to remove glass beads. DNA amounts were quantified by using NanoDrop 1000 
(Thermo Scientific, Wilmington, DE). 
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Table 2.1. Distribution of the patients into the treatment groups (A, B, C and D) according to the 
geographic origin and the rate of remission 
 Treatment groups 
 A B C D 
 
(100 mg/5d) (25 mg/5d) (100 mg/2d) (PBO) 
Total (N:) 27 25 25 25 
Italy (N:) 7 2 1 2 
Germany (N:) 9 11 13 12 
Belgium (N:) 11 12 11 11 
Remission at V3 (N:) 6 12 9 4 
Remission at V3 (%) 22 48 36 16 
 
Real-time quantitative PCR 
Quantitative PCR was performed in a LightCycler instrument (Roche, Mannheim, Germany) 
and SYBR Green I fluorophore was used to correlate the amount of PCR product with the 
fluorescence signal. Each DNA sample was amplified with different genus- or species-specific 
primer sets targeted to 16S rRNA gene or 16S-23S rRNA spacer region: Bact-0011f/Lab-0677r 
(Heilig et al, 2002) for Lactobacillus, F-GV1/R-GV3 (Zariffard et al, 2002) for G. vaginalis, c-
Atopo-f/c-Atopo-r (Matsuki et al, 2004) for Atopobium, g-Prevo-f/g-Prevo-r (Matsuki et al, 2002) 
for Prevotella, VeilloF/VeilloR (Rinttilä et al, 2004) for Veillonella, MycF/MycR (Wiesenfeld et al, 
2003) for M. hominis and Mob-s/Mob-as (Tiveljung et al, 1996) for Mobiluncus. Amplifications 
were carried out in a final volume of 20 μl containing 0.5 μM of each primer, 4 μl of LightCycler-
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FastStart DNA Master SYBR Green I (Roche) and either 2 μl of template or water (no-template 
control). The thermal cycling conditions were as follows: an initial denaturation step at 95°C for 10 
min followed by 30 (Lactobacillus, Atopobium, G. vaginalis, Veillonella, Mobiluncus), 35 
(Prevotella) or 40 (M. hominis) cycles of denaturation at 95°C for 15 s; primer annealing at 63°C 
(Lactobacillus, Mobiluncus), 62°C (Veillonella, M. hominis), or 60°C (Atopobium, Prevotella, G. 
vaginalis) for 20 s; extension at 72°C for 45 s (Lactobacillus, Atopobium, Prevotella, G. vaginalis, 
Veillonella) or 30 s (M. hominis, Mobiluncus) and a fluorescence acquisition step at 82°C (M. 
hominis), 85°C (Lactobacillus, Atopobium, G. vaginalis, Veillonella), 87°C (Prevotella) or 88°C 
(Mobiluncus) for 5 s. DNAs extracted from Lactobacillus acidophilus NCFM, Gardnerella 
vaginalis ATCC 14018, Prevotella bivia ATCC 29303, Veillonella parvula ATCC 10790, 
Atopobium vaginae ATCC BAA-55, Mycoplasma hominis DSM 19104 and Mobiluncus curtisii 
ATCC 43063 were used as standards for PCR quantification. DNAs extracted from vaginal samples 
were amplified in triplicate for each primer set. Data were expressed as ng of DNA of the targeted 
genus or species per μg of total DNA extracted from the vaginal sample. 
PCR-DGGE analysis 
Amplification of the V2-V3 region of the bacterial 16S rRNA gene was carried out using the 
universal eubacterial primers GCclamp-HDA1 and HDA2 (Walter et al, 2000), supplied by M-
Medical, Milan, Italy. The amplification reactions were performed in a Biometra Thermal Cycler T 
Gradient (Biometra, Göttingen, Germany). GoTaq Flexi DNA Polymerase (Promega, Madison, WI) 
was used as thermostable DNA polymerase. The reaction mixture contained 0.5 μM of each primer, 
200 µM of each dNTP, 2 mM MgCl2 solution, 1.25 U of GoTaq Flexi DNA Polymerase, 5 μl of 
Green GoTaq Flexi buffer 5×, and 30 ng of the bacterial DNA template in a final volume of 25 μl. 
The thermocycle program consisted of the following time and temperature profile: 95°C for 5 min; 
30 cycles of 95°C for 30 s, 56°C for 30 s, 72°C for 60 s; and 72°C for 8 min. Samples (5 µl) of the 
amplified products (200 bp) were subjected to gel electrophoresis in 1.5% agarose gels and 
visualized by ethidium bromide staining. 
DGGE analysis was performed using the D-Code Universal Mutation System Apparatus (Bio-
Rad, Hercules, CA) with 20-cm by 20-cm by 0.75-mm gels. The sequence-specific separation of the 
PCR fragments was obtained in 8% (w/v) polyacrylamide (acrylamide-N,N’bisacrylamide, 40:3 
w/v) gels in 0.5× TAE buffer (20 mM Tris, 10 mM glacial acetic acid and 0.5 mM EDTA pH 8). 
The denaturing gels contained a 30% to 50% gradient of urea and formamide increasing in the 
direction of electrophoresis. A 100% denaturing solution contained 40% (v/v) formamide and 7 M 
urea. A stacking gel containing 8% (w/v) polyacrylamide was applied onto the denaturing gel. A 
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volume of 8 µl of PCR samples was loaded onto the stacking gel. Electrophoresis was conducted at 
an initial voltage of 150 V for 5 minutes and then at a constant voltage of 90 V and temperature of 
60°C for 16 h. Following electrophoresis, the gel was silver stained (Bassam et al, 1991) and 
scanned using a Molecular Imager Gel Doc XR System (Bio-Rad). Cluster analysis of the DGGE 
patterns was performed using the FPQuest software version 4.5 (Bio-Rad) with the Ward clustering 
algorithm. The Similarity Indexes (SIs) of profiles were calculated on the basis of the Pearson 
correlation coefficient. SI indicates the % of similarity among 2 or more DGGE profiles belonging 
to the same woman, taking into account the presence/absence and intensity of the bands. The 
Richness Indexes (RIs), of the profiles were also calculated from the densitometric curves, using 
FPQuest. RI indicates the number of bands of each DGGE profile. 
Statistical analysis 
Statistical analysis was performed using SigmaStat (Systat Software, Point Richmond, CA). 
Differences in the amounts of the bacterial genera and species determined by qPCR were analyzed 
using Wilcoxon Signed Rank Test. Kluskal-Wallis One Way Analysis of Variance (ANOVA) on 
Ranks test was applied to compare the SIs of the DGGE profiles related to V1-V3 for all women, 
and V1-V3 and V3-V4 for women who were in remission at V3. Subsequently, Dunn’s test was 
used to make all pairwise comparisons. Differences in the SI values for different dosages and 
duration of treatment were evaluated by a Two Way ANOVA test. Wilcoxon Signed Rank Test was 
used to compare the RIs of the DGGE profiles related to V1-V3 for all women, and V1-V3 and V3-
V4 for women who were in remission at V3. Finally, a Friedman Repeated Measures ANOVA on 
Ranks test was used to compare the RIs of the DGGE profiles related to V1, V3 and V4 for women 
who were in remission at V3, and Tukey’s test was then used to make all pairwise comparisons. A 
P value below 0.05 was considered significant in all statistical tests. 
 
Results 
Variations of lactobacilli and BV-related bacterial populations 
qPCR was performed to quantify Lactobacillus, G. vaginalis, Atopobium, Prevotella, 
Veillonella, M. hominis and Mobiluncus, that are the principal bacterial groups which change in 
presence of BV (Biagi et al, 2009; Lamont et al, 2011; Vitali et al, 2007). Efficiency of qPCR for  
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V1   V3 V1   V3 V1   V3 V1   V3 V1   V3 V1   V3 V1   V3
Lactobacillus G. vaginalis Atopobium VeillonellaPrevotella M. hominis Mobiluncus
A
D
C
B
*
* * ** **
** ** **
* ****
 
Figure 2.1. qPCR evaluation of Lactobacillus, G. vaginalis, Atopobium, Prevotella, Veillonella, M. hominis 
and Mobiluncus at time points V1 and V3 for the treatment groups A (100 mg/day for 5 days), B (25 mg/day 
for 5 days), C (100 mg/day for 2 days) and D (placebo). Data are related to the total number of women 
analyzed (N: 102). The scatter plots show the distributions of quantification data, with the horizontal bars 
representing the median values. *P < 0.05; **P < 0.01. 
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all assays was between 90% and 110% and correlation coefficients for genomic DNA 
standards were > 0.99. 
At the baseline (V1) the percentages of women harboring Lactobacillus, G. vaginalis, 
Atopobium, Prevotella, Veillonella, M. hominis and Mobiluncus were 95%, 89%, 99%, 98%, 30%, 
78% and 20%, respectively. These data show the high frequency of occurrence of G. vaginalis, 
Atopobium, Prevotella and M. hominis in the vaginal ecosystem of women affected by BV, 
differently from Veillonella and Mobiluncus, which were detected in less than 50% of the patients. 
Quantitative variations of lactobacilli and BV-related bacterial groups were visualized in 
scatter plots showing the distributions of qPCR data expressed as log of ng of DNA of the target 
genus or species per µg of total bacterial DNA extracted from the vaginal sample, with the 
horizontal bars representing the log median values (Figure 2.1 and 2.2). 
Figure 2.1 shows the qPCR results at V1 and V3 related to all the women analyzed (N: 102), 
randomized into the four treatment groups (A, B, C, D). Treatment with rifaximin 100 mg/day for 5 
days (group A), induced a slight increase in the amount of Lactobacillus and a decrease in G. 
vaginalis and Atopobium, with a significant reduction only for Atopobium genus [V1: 1.73 log 
ng/µg; V3: 0.93 log ng/µg; (P = 0.02)]. At V3 the log median value of this genus was similar to that 
of lactobacilli. Concentrations of the other BV-related groups did not change after the treatment. In 
response to the administration with rifaximin 25 mg/day for 5 days (group B), Lactobacillus 
significantly increased [V1: 0.75 log ng/µg; V3: 1.28 log ng/µg; (P = 0.03)] and G. vaginalis [V1: 
1.67 log ng/µg; V3: -3.40 log ng/µg; (P = 0.01)], Atopobium [V1: 1.96 log ng/µg; V3: 0.64 log 
ng/µg; (P = 0.005)] and Prevotella [V1: 0.72 log ng/µg; V3: -0.99 log ng/µg; (P = 0.004)] 
significantly decreased at V3. A slight decrease at V3 was also observed for M. hominis. Comparing 
all the bacterial concentrations at V3, Lactobacillus log median value was the highest one. These 
data indicate the efficacy of the treatment with rifaximin 25 mg/day for 5 days. Treatment with 
rifaximin 100 mg/day for 2 days (group C) resulted in a significant reduction of G. vaginalis [V1: 
1.65 log ng/µg; V3: 1.16 log ng/µg; (P = 0.01)], Atopobium [V1: 2.12 log ng/µg; V3: 1.11 log 
ng/µg; (P = 0.003)], Prevotella [V1: 1.18 log ng/µg; V3: -0.52 log ng/µg; (P = 0.003)] and M. 
hominis [V1: -1.13 log ng/µg; V3: -2.12 log ng/µg; (P = 0.01)], together with a slight reduction of 
Lactobacillus genus. Differently from the group B, in the group C the log median values of G. 
vaginalis and Atopobium at V3 were higher than that of lactobacilli, suggesting that rifaximin 100 
mg/day for 2 days was less effective against BV than rifaximin 25 mg/day for 5 days. In the placebo 
group (group D), a reduction in the amounts of all the bacterial groups was observed, with statistical 
significance for Lactobacillus [V1: 0.76 log ng/µg; V3: 0.38 log ng/µg; (P = 0.007)], G. vaginalis 
[V1: 1.92 log ng/µg; V3: 1.55 log ng/µg; (P = 0.04)] and Atopobium [V1: 1.83 log ng/µg; V3: 1.49 
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log ng/µg; (P = 0.005)]. However, the log median values of G. vaginalis and Atopobium remained 
higher than that of lactobacilli at V3. In general, no variations were observed for Veillonella and 
Mobiluncus, being these genera found in a low percentage of women, as described above, and at 
low concentrations (< -0.47 log ng/µg and < 1.56 log ng/µg, respectively). However, a decrease in 
the percentage of women who harbored Veillonella and Mobiluncus was observed in all the 
treatment groups after the antibiotic administration [Veillonella (A, V1: 11.1% vs V3: 7.4%; B, V1: 
24.0% vs V3: 8.0%; C, V1: 28.0% vs V3: 12.0%; D, V1: 28.0% vs V3: 24.0%); Mobiluncus (A, V1: 
4.0% vs V3: 0%; B, V1: 8.0% vs V3: 0%; C, V1: 20.0% vs V3: 4.0%; D, V1: 16.0% vs V3: 
12.0%)]. 
Figure 2.2 shows the qPCR results at V1, V3 and V4 related to the women who were in 
remission at V3 and who performed the last study visit V4 (N: 31), divided into the four treatment 
groups. Treatment with rifaximin 100 mg/day for 5 days (group A) did not significantly affect any 
bacterial group, even though a reduction trend was observed for the BV-related bacteria, and 
Lactobacillus log median concentration after the treatment was higher than that of the other genera 
and species. Treatment with rifaximin 25 mg/day for 5 days (group B) caused an increase of 
Lactobacillus at V3 and V4, which was significant at V4 [V1: 0.72 log ng/µg; V4: 1.57 log ng/µg; 
(P = 0.04)]. A significant decrease at V3 and V4 compared to V1 was observed for G. vaginalis 
[V1: 1.73 log ng/µg; V3: -3.40 log ng/µg; V4: -3.40 log ng/µg; (P = 0.004, V3 vs V1), (P = 0.004, 
V4 vs V1)], Atopobium [V1: 2.02 log ng/µg; V3: 0.52 log ng/µg; V4: 0.56 log ng/µg; (P = 0.004, 
V3 vs V1), (P = 0.02, V4 vs V1)] and M. hominis [V1: -2.32 log ng/µg; V3: -2.81 log ng/µg; V4: -
3.40 log ng/µg; (P = 0.02, V3 vs V1), (P = 0.04, V4 vs V1)]. Prevotella decreased at V3 and V4, 
with a significant variation at V3 only [V1: 0.95 log ng/µg; V3: -1.27 log ng/µg; (P = 0.002)]. 
Treatment with rifaximin 100 mg/day for 2 days (group C) showed a relapse at V4, with 
Lactobacillus concentration increasing at V3 and significantly decreasing at V4 compared to V3 
[V3: 1.80 log ng/µg; V4: 0.33 log ng/µg; (P = 0.03)], and BV-related bacterial groups decreasing at 
V3 and increasing again at V4, with significance for G. vaginalis [V1: 1.91 log ng/µg; V3: -3.40 log 
ng/µg; V4: 1.96 log ng/µg; (P = 0.005, V3 vs V1), (P = 0.05, V4 vs V3)], Atopobium [V1: 2.09 log 
ng/µg; V3: 0.98 log ng/µg; V4: 2.17 log ng/µg; (P = 0.003, V3 vs V1), (P = 0.005, V4 vs V3)] and 
Prevotella [V1: 1.18 log ng/µg; V3: -1.06 log ng/µg; V4: 1.79 log ng/µg; (P = 0.008, V3 vs V1), (P 
= 0.03, V4 vs V3)]. Despite of the absence of significant variations in the placebo group (group D), 
Lactobacillus gradually decreased at V3 and V4 while Prevotella decreased at V3 and increased 
again at V4. Notably, Lactobacillus log median concentration was lower than that of G. vaginalis 
and Atopobium after the treatment. Similarly to the analysis of V1 and V3 for the total number of 
women, no variations were observed for Veillonella and Mobiluncus, due to the low concentrations  
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Lactobacillus G. vaginalis Atopobium VeillonellaPrevotella M. hominis Mobiluncus
V1 V3 V4 V1 V3 V4 V1 V3 V4 V1 V3 V4 V1 V3 V4 V1 V3 V4
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Figure 2.2. qPCR analysis of Lactobacillus, G. vaginalis, Atopobium, Prevotella, Veillonella, M. hominis 
and Mobiluncus at time points V1, V3 and V4 for the treatment groups A (100 mg/day for 5 days), B (25 
mg/day for 5 days), C (100 mg/day for 2 days) and D (placebo). Data are related to the women who were in 
remission at V3 and performed the last study visit V4 (N: 31). The scatter plots show the distributions of 
quantification data, with the horizontal bars representing the median values. *P < 0.05; **P < 0.01, related to 
V1; °P < 0.05; °°P < 0.01 related to V3. 
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(< -0.77 log ng/µg and < 1.01 log ng/µg, respectively) and the low frequency of occurrence of these 
genera. 
Bacterial population profiling with PCR-DGGE 
PCR-DGGE analysis with universal primers for bacteria (HDA1-GC/HDA2) was carried out 
on the vaginal samples collected at V1, V3 and V4 to evaluate the impact of rifaximin on the 
composition of BV microbiota. 
Cluster analyses were performed on DGGE profiles grouped on the basis of the treatment. 
Figure 2.3 represent the cluster for the treatment groups A (100 mg/day for 5 days), B (25 mg/day 
for 5 days), C (100 mg/day for 2 days) and D (placebo). The percentages of women with V1 and V3 
profiles clustering together were 37%, 24%, 28% and 56% for the treatment groups A, B, C and D, 
respectively. This result highlights the ability of rifaximin to modulate the vaginal microbiota  
 
Table 2.2. Mean values of Similarity Indexes [SIs (%)] of DGGE profiles related to the treatment groups A 
(100 mg/day for 5 days), B (25 mg/day for 5 days), C (100 mg/day for 2 days) and D (placebo).  
Treatment group Mean SI (%) 
 Total (N: 102)
1
 Remission (N: 31)
2
 
 V1-V3 V1-V3 V3-V4 
Group A  61.6 53.3 66.8 
Group B  48.4 45.3 62.1 
Group C  54.0 40.4 42.8 
Group D  75.4 83.9 58.7 
 
1
 SIs for V1-V3 were calculated for the total number of women (N: 102). 
2
 SIs for V1-V3 and V3-V4 were calculated for the women who were in remission at V3 and performed the 
last study visit V4 (N: 31). 
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composition exerting the strongest impact at the dosage of 25 mg/day for 5 days. By 
considering the women who were in remission at V3 and performed the last study visit (V4), the 
percentages of V1, V3 and V4 DGGE profiles clustering together were 0% for A and B treatment 
groups, 11% for C group and 50% for D group, further confirming the impact of rifaximin on the 
vaginal communities. 
Table 2.2 reports the mean values of Similarity Indexes (SIs) of the DGGE profiles related to 
V1-V3 for total women analyzed, and V1-V3 and V3-V4 for the women in remission, according to 
the different treatment groups. Considering the total number of women, the highest SI mean value 
of V1-V3 was found for the group D, administered with placebo (75.4%). Among the groups 
administered with rifaximin, the highest SI mean value was found for the treatment group A 
(61.6%), followed by C (54.0%) and B (48.4%). Considering the women who were in remission at 
V3, a similar trend was observed for SI mean values of V1-V3. The placebo group presented the 
highest value (83.9%), followed by the treatment groups A (53.3%), B (45.3%) and C (40.4%). The 
lower SI mean values of V1-V3 for the groups administered with rifaximin compared to the placebo 
group support the previously formulated hypothesis that the antibiotic treatment induces changes in 
the structure of BV microbiota. By considering the SI mean values of V3-V4 for the women in 
remission, maintenance of the antibiotic effect on the vaginal communities was deduced for the 
treatment groups A and B, on the basis of their high SIs (66.8% and 62.1%, respectively). On the 
contrary, the SI mean value for group C was the lowest one (42.8%), indicating that the changes 
induced at V3 by rifaximin 100 mg/day for 2 days were not preserved until the last time point V4. 
SI values were compared using the Kluskall-Wallis One Way ANOVA on Ranks test. SIs of 
V1-V3 related to the total number of women were significantly different by comparing all the 
treatment groups (P < 0.001). In particular, Dunn’s test revealed significant differences for A vs D, 
B vs D, and C vs D (P < 0.05). Also for the women in remission at V3, SIs of V1-V3 resulted 
significantly different by comparing all the treatment groups (P < 0.05); a pairwise comparison by 
Dunn’s test revealed significant differences for B vs D and C vs D (P < 0.05). 
A Two Way ANOVA test was used to compare the influence of the two variables, dosage 
(100 mg vs 25 mg) and duration (5 days vs 2 days) of treatment, on SIs of DGGE profiles related to 
V1-V3. A significant difference was found for women who received different doses of antibiotic (P 
< 0.05), while no difference was observed for women treated for a different number of days (P > 
0.05). This result indicates that the dosage exerts the major influence on the vaginal microbiota 
composition. 
Table 2.3 shows the mean values of Richness Indexes (RIs) for DGGE profiles related to V1 
and V3 for total women, and to V1, V3 and V4 for the women who were in remission at V3,  
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Figure 2.3. Cluster of DGGE profiles of vaginal samples collected from women belonging to 
treatment groups A (100 mg/day for 5 days), B (25 mg/day for 5 days), C (100 mg/day for 2 days) and D 
(placebo). ID indicates the patient identification number, V indicates the visit number, G indicates the group 
of treatment. Similarity values are indicated at each node. 
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Pearson correlation (Opt:2.00%) [0.0%-100.0%]
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Pearson correlation (Opt:2.00%) [0.0%-100.0%]
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Pearson correlation (Opt:2.00%) [0.0%-100.0%]
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according to each group of treatment. Considering the total number of women, a reduction of the RI 
mean values at V3 was observed in the groups administered with rifaximin, A (V1: 13.5 vs V3: 
10.9), B (V1: 14.0 vsV3: 10.7) and C (V1: 15.4 vs V3: 12.2). Similar RI mean values at V1 and V3 
were found for the placebo group (V1: 13.3 vs V3: 13.9). The RI mean values for the women in  
remission decreased at V3 compared to V1 in all the groups treated with the antibiotic (A, V1: 12.5  
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vs V3: 9.8; B, V1: 13.6 vs V3: 8.2; C, V1: 16.2 vs V3: 10.4). The general decrease of RI at V3 
indicates the capability of the antibiotic to reduce the complexity of the vaginal microbiota, 
complexity that is a typical feature of BV. RI mean values at V4 were similar to those calculated at 
V3 for the groups A (10.2) and B (9.0), indicating a maintenance of the antibiotic effect. 
Differently, the RI mean value for the group C (14.6), after the decrease at V3, approximated the 
baseline value at V4, reflecting a restoration of the complexity of the BV microbiota. 
 
Table 2.3. Mean values of Richness Indexes (RIs) for the treatment groups A (100 mg/day for 5 days), B 
(25 mg/day for 5 days), C (100 mg/day for 2 days) and D (placebo). 
Treatment group Mean RI 
 Total (N: 102)
1
  Remission (N: 31)
2
 
 
V1 V3  V1 V3 V4 
Group A  13.5 10.9  12.5 9.8 10.2 
Group B  14.0 10.7  13.6 8.2 9.0 
Group C  15.4 12.2  16.2 10.4 14.6 
Group D  13.3 13.9  11.3 10.8 9.5 
 
1
 RIs for V1 and V3 were calculated for the total number of women (N: 102). 
2
 RIs for V1, V3 and V4 were calculated for the women who were in remission at V3 and performed the last 
study visit V4 (N: 31). 
 
Wilcoxon Signed Rank test revealed significant differences of RIs between V1 and V3 for the 
groups A (P < 0.05), B (P < 0.05) and C (P < 0.001), considering the total number of women, and 
for the groups B (P < 0.001) and C (P < 0.001), considering the women in remission. Friedman 
Repeated Measures ANOVA on Ranks test showed a significant difference of RIs among V1, V3 
and V4 in the groups B (P < 0.05) and C (P < 0.001); a further pairwise analysis with the Tukey’s 
test revealed significant differences for V1 vs V3 and V1 vs V4 in the group B, V1 vs V3 and V3 vs 
V4 in the group C (P < 0.05). These results stress again the efficacy of rifaximin 25 mg/day for 5 
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days in the follow-up period, and the risk of relapse associated to the treatment with rifaximin 100 
mg/day for 2 days. 
In conclusion, DGGE results are in strong agreement with qPCR data, confirming and 
reinforcing them. This integrated molecular analysis allowed us to identify the best treatment 
regimen for the cure of BV, which is rifaximin 25 mg/day for 5 days. 
Discussion 
Symbiosis between the vaginal microbiota and the human host is crucial for the reproductive 
tract health. The importance of this relationship is reflected by the fact that BV has serious 
gynecological and obstetric complications, and it creates a permissive environment for acquiring 
sexually transmitted infections (Turovskiy et al, 2011). Conventional treatment of BV with 
metronidazole and clindamycin does not eradicate all BV-associated bacteria, as evidenced by a BV 
recurrence rate of 58% (Bradshaw et al, 2006-a). Moreover, these treatments play a significant role 
in the expansion of drug resistance in G. vaginalis and Prevotella spp. (Bryskier, 2001; Liebetrau et 
al, 2003). The failure of conventional antibiotics in BV cure and eradication raises the question for 
alternative therapeutic tools. 
Rifaximin is a non-absorbable broad spectrum antibiotic that is associated with a low risk of 
bacterial resistance. While several studies report the efficacy of rifaximin in the treatment of 
gastrointestinal disorders (Rivkin and Gim, 2011; Scarpignato and Pelosini, 2005), the use of this 
antibiotic in genital tract infections has not been explored until now. The purpose of the present 
study was to evaluate the efficacy of different doses of rifaximin vaginal tablets (100 mg/day for 5 
days, 25 mg/day for 5 days, 100 mg/day for 2 days) in BV cure and remission maintenance of 102 
European patients. A combination of two molecular techniques, PCR-DGGE and qPCR, was used 
to achieve a detailed overview of the bacterial composition of the vaginal environment related to the 
BV condition and to the effects of the antibiotic intake. 
Consistent with data from previous studies (Fredricks et al, 2009; Ling et al, 2010), our qPCR 
results showed that BV-associated microbiota is dominated by several anaerobic bacterial species 
which coexist with lactobacilli. In particular, at the screening visit (V1) Atopobium and G. vaginalis 
were the predominant bacteria, found at higher amounts than lactobacilli. Prevotella showed a 
baseline concentration similar to that of Lactobacillus, while Veillonella and Mobiluncus genera, 
which have been previously associated to BV infection (Biagi et al, 2009; Holst et al, 1987; Vitali 
et al, 2009), were detected only in few women and in low amounts. Remarkably, M. hominis was 
recovered in high amounts and was present in 78% of patients, while not more than 35% of patients 
have been found infected with M. hominis by using culture-based methods, highlighting the power 
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of the molecular techniques for ecological studies. Mobiluncus, on the other hand, was only 
recovered in 20% of BV positive women. Still, according to the morphology as recognized in Gram 
stains, Mobiluncus was suspected in 26% of patients, as their Nugent score was 9 or 10, indicating a 
mismatch between microscopic findings and the molecular data. In a previous study (Marconi et al, 
in press), the concentration of A. vaginae was found to correlate extremely well with the Nugent 
scores, with the highest A. vaginae concentration in patients with Nugent scores 9 and 10. This 
leads us to the suggestion that Atopobium should be seen as one of the most important markers of 
severity of the microbial disturbance encountered in BV. Furthermore, as A. vaginae was also 
recovered in less amounts in vaginal fluid expressing intermediate Nugent scores 4-6, and 
Mobiluncus is only represented in score 9 or 10, the role of the latter seems to have been overrated 
in the past and its importance in the diagnosis of BV should be re-appraised. 
By comparing the qPCR data related to the follow-up visits (V3 and V4) and the screening 
visit (V1), we sought to determine whether changes in quantities of vaginal bacteria, as reflected by 
bacterial DNA concentrations, are associated with the cure of BV after rifaximin therapy. In 
particular, we aimed at identifying the most efficient treatment able to reduce the concentrations of 
BV-related bacteria and to allow Lactobacillus spp. to recolonize the vaginal environment, reaching 
the highest abundance in the community. We demonstrated that the treatment with the highest 
dosage of rifaximin (100 mg/day for 5 days, group A) was less effective, as only Atopobium genus 
significantly decreased after the antibiotic intake and lactobacilli did not succeed in recolonizing the 
vaginal mucosa. The intake of rifaximin 100 mg/day for 2 days (group C) gave a better response at 
the first follow-up visit (V3). All the BV-associated bacteria significantly decreased in terms of 
concentration (Atopobium, G. vaginalis, Prevotella and M. hominis) or percentage of presence 
(Veillonella and Mobiluncus), while Lactobacillus significantly increased up to a higher amount 
than all the other groups in the women who were in remission at V3. However, bacterial 
concentrations at the second follow-up visit (V4) were similar to the baseline, indicating a relapse 
that was probably due to the short duration of the antibiotic intake. Rifaximin 25 mg/day for 5 days 
(group B) was found to be the most effective treatment, giving a good response at V3 and 
maintaining the effect until V4. Indeed, a significant increase of Lactobacillus genus together with a 
significant decline of bacteria associated with BV was observed at both the time points V3 and V4. 
The lack of in vivo rifaximin susceptibility of lactobacilli is not surprising. This peculiar feature had 
already been pointed by previous studies reporting that rifaximin did not affect the intestinal 
amounts of several health-promoting microbial groups, such as Lactobacillus spp., Bifidobacterium 
spp., Atopobium/Collinsella spp. (Maccaferri et al, 2010). Our hypothesis that rifaximin 25 mg/day 
for 5 days (group B) represents the most effective treatment against BV is in accordance with the 
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rates of remission at V3 assessed by both Amsel and Nugent criteria. The highest percentage of 
remission was found in group B (48%), while lower percentages were calculated for the other 
treated groups (A: 22% and C: 36%). The lowest rate of remission was registered in the placebo 
group (16%), demonstrating that spontaneous remission could be possible at low rates, as reported 
in the literature (Schwebke, 2000; Voorspoels et al, 2002). 
Information derived from qPCR assays related to specific targeted bacteria were integrated 
with the PCR-DGGE data, which provided an overall picture of the diversity and richness of the 
global bacterial microbiota. Cluster analyses of DGGE profiles revealed a higher intra-individual 
variability in the women treated with the antibiotic compared to the women administered with 
placebo, highlighting the ability of rifaximin to modulate the vaginal microbiota composition. This 
assumption was made by considering that the treatment groups A, B and C presented lower 
percentages of women with V1 and V3 profiles clustering together and lower similarity indexes 
(SIs) for V1-V3 profiles, compared to the placebo group. In particular, the lowest SI values were 
found for V1-V3 profiles of women belonging to the groups B and C, when considering the total 
number of women or the women who were in remission at V3, respectively. A maintenance of the 
antibiotic effect on the vaginal bacterial communities was demonstrated for the treatment groups A 
and B on the basis of their highest SI values of V3-V4 profiles related to the women who were in 
remission at V3. The lowest SI value of the group C suggested that the treatment with rifaximin 100 
mg/day for 2 days did not avoid relapse. In general, these results confirm the hypothesis suggested 
by qPCR data that the treatment with rifaximin 25 mg/day for 5 days is the most effective. In fact, 
the low similarity of V1-V3 DGGE profiles of the group B demonstrates that the antibiotic intake 
induced a variation in the overall composition of the vaginal microbiota, while the high similarity of 
V3-V4 DGGE profiles for the women in remission indicates the maintenance of the effect. The 
identification of rifaximin 25 mg/day for 5 days as the best treatment for the cure of BV was further 
supported by the finding that the variable “dosage” exerted a major influence on the diversity of the 
vaginal microbiota compared to the variable “duration” of the treatment. 
Previous PCR-DGGE studies indicated that the level of complexity of the vaginal microbiota 
was higher in BV infection than in healthy status (Ling et al, 2011; Vitali et al, 2007). Here, the 
complexity of the vaginal communities was evaluated by calculating the richness indexes (RIs) of 
DGGE profiles. The significant decrease of RI values after the antibiotic intake in all the treated 
groups indicates the rifaximin effectiveness in reducing the complexity of the vaginal ecology, and 
restoring a community structure similar to a healthy microbiota. Considering the RI values at V4, 
the maintenance of remission in women treated with rifaximin 25 mg/day for 5 days and the relapse 
occurring in women treated with rifaximin 100 mg/day for 2 days were further confirmed. 
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In conclusion, our results suggest that rifaximin is a potential good candidate for the treatment 
of BV. In particular, the treatment with rifaximin 25 mg/day for 5 days is active against the pool of 
bacteria recognized to cause BV, while it does not affect the normal population of lactobacilli. 
Based on these encouraging results, further clinical studies will be undertaken in order to confirm 
the real advantage of this antibiotic in comparison to standard BV treatments. 
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Concluding remarks 
In the present study the impact of two different therapeutic approaches on the composition of 
the vaginal ecosystem has been studied by using an integrated molecular fingerprinting approach 
based on PCR-DGGE and real-time PCR. 
The oral administration of the probiotic mixture VSL#3 in the last trimester of pregnancy of 
healthy women was analyzed to evaluate the beneficial effects on the vaginal microbiota 
composition and immune response. The microbiological analyses showed only a blind modulation 
of the bacterial population composition in women who consumed the probiotic mixture, without 
significant differences induced by the intake. The DGGE population profiling suggested the ability 
of the probiotic VSL#3 to modulate the vaginal microbiota, without compromising the inter-
individual species variability. Real-time PCR results suggested a role of the probiotic product in 
counteracting the decrease of the health-promoting Bifidobacterium genus and the increase of the 
BV-related Atopobium genus, that physiologically occur in late pregnancy. 
As regards the investigation of the vaginal immunological profiles of the pregnant women, the 
probiotic intake counteracted the decrease of anti-inflammatory cytokine levels occurring in the 
control group, and induced the decrease of a pro-inflammatory cytokine in the group treated with 
VSL#3, showing a global anti-inflammatory effect on the vaginal immunity, with potential 
implications in preventing preterm birth. 
A combination of the two molecular techniques, PCR-DGGE and qPCR, was also used to 
achieve a detailed overview of the bacterial composition of the vaginal environment related to the 
BV condition and to the effects of the antibiotic therapy with rifaximin. In particular, the aim was to 
identify the most efficient treatment able to reduce the concentrations of BV-related bacteria and to 
allow Lactobacillus spp. to recolonize the vaginal environment, reaching the highest abundance in 
the community. The results suggested that rifaximin is a potential good candidate for the treatment 
of BV. In particular, the treatment with rifaximin 25 mg/day for 5 days is active against the pool of 
bacteria recognized to cause BV, while it does not affect the normal population of lactobacilli. A 
modulation in the global composition of the bacterial community is demonstrated by the low 
similarity among DGGE profiles of the same woman before and after antibiotic intake. Patients 
treated with this antibiotic regimen (rifaximin 25 mg/day for 5 days) showed the highest rate of 
remission at follow-up visit after one month from the end of the treatment. 
Based on these encouraging results, an oral probiotic therapy can be suggested for the 
preventive modulation of the vaginal microbial community composition and immune response of 
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the host, in order to maintain the right balance among the vaginal microorganisms and to elicit the 
right physiological immune response, especially during pregnancy. 
Rifaximin has been demonstrated to represent a valid alternative candidate for the cure of BV. 
Further clinical studies will be undertaken in order to confirm the real advantage of this antibiotic in 
comparison to standard BV treatments. 
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